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Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease, causing 
inflammation in one or more joints. About 0,5 – 1.0% of the western population suffers 
from this debilitating disease. The etiology is multifactorial and not fully known yet, but 
there are some factors recognized that are linked to RA, like genetics [1] or smoking 
[2]. RA has a strong genetic association with MHC class II alleles such as HLA-DRB1. 
This predisposition together with smoking causes a higher risk on production of auto-
antibodies and subsequently RA [3]. But many more genes are associated with RA, like 
PTPN22, CTLA4 and TRAF1-C5[4]. Comorbidities such as cardiovascular diseases, 
asthma or infections may shorten the life-span of a patient with RA [5].
The joint (figure 1) is covered by a thin layer of cells, called the synovium. This synovium 
forms a barrier around the joint and the main function of the synovium is the production 
of synovial fluid. Synovial fluid is necessary to lubricate the joint and facilitate smooth 
movement of the joint. The synovium also filters the synovial fluid from unwanted 
debris that causes joint damage [6]. Fibroblast-like synoviocytes and macrophage-like 
synoviocytes are the two main cell types building up the synovium [7, 8].
Cartilage is a layer of connective tissue at the articulating surfaces of the bones and 
is therefore important in absorbing the shocks generated during walking or running. 
Articular cartilage consists of a highly organized structure of extracellular matrix 
composed of collagen fibres and aggregating proteoglycans [9]. In between this 
organized structure are the chondrocytes that are responsible for maintaining the 
normal function and structure of the cartilage, by synthesis and turnover of extracellular 
matrix[10].
Pathogenesis
RA is classified as a multifactorial autoimmune disease, meaning this disease is the 
result of an interplay of factors that causes the immune system to turn against itself 
(=auto). Therefore, autoantibodies are found in the serum of RA patients indicating 
a role of the B lymphocytes, or B cells [11]. These cells, that originate from the bone 
marrow, are able to make antibodies against antigens and in the case of RA against 
autoantigens. Two important autoantigens are rheumatoid factor, an autoantibody 
to the Fc portion of IgG and anti-citrullinated protein antibodies, directed against 
proteins that are citrullinated [12, 13]. B cells are also found in the synovium and can 
interact with a variety of other cells, like the T cells [14]. T cells, that originate from the 
thymus, exist in different forms, such as the CD4+ T helper cells. T cells are activated 
upon encounter with an antigen presenting cell and thereafter start to produce and 
initiate the production of pro- and anti-inflammatory cytokines. 
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Figure 1. Overview of the knee joint. On the left side a healthy joint, on the right side an arthritic joint with 
synovitis, pannus formation, cartilage destruction and bone erosion and deformation. The synovial lining 
is normally only a couple of cell layers thick, but is now invaded by immune cells, resulting in synovitis. 
This activated synovial lining now starts to produce pro and anti-inflammatory mediators, such as TNFα, 
IL-1 and IL-10. The invading pannus tissue starts to break down cartilage and bone, causing irreversible 
cartilage and bone damage and bone deformations.
Well known pro-inflammatory cytokines important in RA are tumor necrosis factor-
alpha (TNF-a) and interleukin-1 beta  (IL-1b) [15, 16]. Suppressive cytokines like 
IL-1 receptor antagonist (IL-1ra) and interleukin-10 (IL-10) play a role as well. The 
importance of B and T cells during RA is underlined by the effective treatment of RA 
using anti-B and anti-T cell therapies [17, 18].
Chronic joint inflammation comprises synovial hyperplasia and inflammation; 
thickening of the synovial lining caused by an increased division in synoviocytes 
and by infiltration of a variety of cells such as monocytes, macrophages, neutrophils, 
dendritic cells and T- and B-cells [19, 20]. Attraction and infiltration of these cells is 
caused by the local production of chemoattractants, such as the CXC-chemokines 
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[21]. Neoangiogenesis, the formation of new blood vessels frequently seen during 
RA, facilitates this infiltration of cells, but also supplies the inflamed synovium with 
extra nutrients [22]. It still remains a question if angiogenesis is a result or a cause of 
RA [23]. 
Synovial inflammation and hyperplasia can result in pannus formation, a crucial 
event in the pathogenesis of cartilage and bone destruction [24]. Cartilage collagen 
and proteoglycan degrading enzymes (proteases) and destructive cytokines are 
produced by the inflamed synovium. The most common proteases are the matrix 
metallo-proteinases (MMP) that mostly degrade collagen [25], and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS) that are regarded as the 
principal aggrecan degrading enzymes[26]. These enzymes cause a breakdown 
of the collagen type II network in the cartilage. A diminished proteoglycan content, 
together with diminished function of the chondrocytes result in irreversible cartilage 
damage [27]. IL-1 has a big influence on cartilage damage as Joosten et al. [28] 
showed. The main effect of IL-1 is inhibition of extracellular matrix synthesis, but it 
can also stimulate synovial fibroblasts in the pannus region to release MMPs and IL-1 
can also act upon chondrocytes to release nitric oxide [29].   
Bone damage is another important hallmark of RA. During synovial inflammation, 
hematopoietic stem cells are directed towards differentiation into osteoclasts. 
This differentiation is regulated by a variety of cytokines, especially RANKL [30]. 
Osteoclasts are capable of breaking down mineralized tissue. Here as well, IL-1 
seems to have a big influence on bone damage [28, 29]. 
All in all, RA is a complex disease, where the etiology is still not fully known. Both 
innate and adaptive immunity play a role in the diverse destructive processes going 
on in the joint. To pave the way to a cure for RA, still a lot of fundamental research 
has to be done using, for instance, animal models. 
Animal models of RA
To study RA, different experimental mouse models are available. The models used 
for this thesis are described below. Although it is difficult to exactly mimic human RA, 
these models approach the disease as good as possible by all emphasizing different 
aspects of the disease. Arthritis can be induced by immunization or local injections 
in the joint. 
Collagen-induced arthritis (CIA) is the best known RA model in mice and resembles 
both immunological as well as pathological features with human RA. In this model, 
mice are immunized against collagen type II from a different animal, such as bovine 
collagen. Autoantibodies against collagen type II are produced in response and cause 
the activation of the complement cascade resulting in polyarticular inflammation, and 
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cartilage and bone damage [31, 32]. Susceptibility of CIA depends on the presence of 
specific MHC class II molecules [33]. The CIA model is dependent on T cell activation, 
but also B cells play a role[ 34]. The collagen type II specific T cell response was first 
identified as a Th1 response, explained by the presence of the Th1 cytokines IFN-γ 
and IL-12[35], but later complemented with the discovery of Th17 and associated 
cytokines IL-17 and IL-23 [36]. The autoimmune response against collagen type II 
exists and worsens until all the cartilage is gone. Hence, the CIA model is regarded as 
a chronic arthritis model. This model reflects many important pathways in the arthritic 
process, such as the T and B cell pathway, and is dependent on some well known 
cytokines, such as IL-1β [28]. It is known that a variety of MMPs and cathepsins are 
present during the inflammatory process, making this model an interesting tool for 
imaging of protease activities [37]. For imaging purposes it is also an advantage 
that the disease expresses systemically and eventually also symmetrically in synovial 
joints, including knee joints, toes and the paws. At the paws scattering of light is 
minimized, because there is less hair present, giving a more reliable imaging signal. 
The downside of this model is the limited and non-synchronized incidence of the 
arthritis.
Another well known model is the antigen-induced arthritis model (AIA). In this model 
mice are immunized with methylated bovine serum albumin (mBSA) dissolved in 
freunds complete adjuvant and arthritis is induced by intra-articular injection with 
mBSA. One intra-articular injection gives an acute arthritis, with synovitis, and 
cartilage and bone destruction. A flare-up of the model can be induced by a second 
injection of a low dose of mBSA, that results in a chronic arthritis [30]. The acute 
phase of this model is mainly T cell driven[38] and B cell activation does not seem 
to be important [39]. However, B and T cells may both become important during the 
flair-up of the model. IL-1α and β are shown to be important in the local process of 
AIA, while IL-6 and TNFα do not seem to be important [40]. Because induction is 
local and limited to the injected knee joint, this model is unilateral, leaving one knee 
joint that can serve as an internal control. This is an important asset when using this 
model for imaging purposes.
The acute streptococcal cell wall (SCW) model is a local transient model of joint 
inflammation. Heat inactivated streptococcal cell wall fragments are injected intra-
articularly into the knee joint. This provokes a toll-like receptor (TLR)-2 dependent 
acute inflammation, caused by activation of the complement cascade [41]. First, 
influx of polymorphonuclear cells in the joint cavity is seen, followed by synovitis 
and proteoglycan depletion [42]. If no further injection is given, the inflammation and 
proteoglycan depletion recovers. However, when injections are repeated, a chronic 
arthritis model is induced with T and B cell involvement [43]. A shift is seen from a 
TLR-2 dependent reaction after a single SCW injection, towards a TLR-4 dependent 
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SCW model after 4 injections [44]. Both TNFα and IL-1 are important regulators in 
this model and a combined treatment using anti-TNFα and anti-IL-1 was found to be 
most effective in suppressing acute SCW arthritis [42]. IL-10 also plays a regulatory 
role during SCW arthritis as was shown by Lubberts et al. [45], where treatment using 
IL-10 resulted in a diminished influx of inflammatory cells and a diminished cartilage 
proteoglycan depletion. The SCW model is therefore a fast model that can be 
manipulated using a variety of cytokine treatments. Because the different processes 
like influx of polymorphonuclear cells or proteoglycan depletion occur at different, but 
fixed time points after induction, the SCW model is a highly predictable model.
Diagnosis and treatment
The different animal models are a good starting point to give us insight into some 
mechanisms of the disease. Understanding the underlying mechanisms and actions 
of the important cytokines and proteases can lead to a more reliable diagnosis and, 
even more important, new therapeutic interventions. There is no single test to diagnose 
RA, but a couple of different methods are used in the clinics nowadays, besides 
examining the physical discomforts. Measurement of rheumatoid factor in the blood 
is used already for a long time, but is not conclusive [12]. Just like measuring anti-
citrullinated protein antibodies, or C-reactive protein [13]. Early diagnosis, however, is 
still difficult. Therefore, classification criteria were set up, aiming for early identification 
of patients at risk to develop persistent and erosive RA [46]. After a first diagnosis, 
it is possible to investigate the degree of damage already done by the disease. To 
visualize cartilage damage, bone damage, or even synovial inflammation in the joint, 
several imaging techniques, for instance x-ray [47], MRI [48], SPECT [49], can be 
used. 
To treat RA, a widely used concept is the use of biologicals also called biological 
disease-modifying anti-rheumatic drugs (DMARDS); medication in the form of, for 
instance, antibodies or peptides isolated from natural resources. The most familiar 
therapy is neutralisation of TNFα [50, 51], but also B- or T-cell suppression is conducted 
[52]. The course of the disease and the outcome of a treatment is not the same for 
every patient. For instance, some patients suffer from massive cartilage destruction 
already in the early phase of the disease, while others develop destruction later on. 
In addition, the disease can follow an intermittent course with exacerbations but also 
remissions. Regarding the treatment options, some patients respond very well to anti-
TNFα treatment, while others do not [53]. Taken this into account, a personalized 
treatment option would be the best. Because a lot of the regular treatments come 
with side effects, treating the patient only when it is necessary during exacerbation, 
is desirable. To monitor the patient in a personalized way, non-invasive imaging 
techniques can be used.
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Pre-clinical imaging
Imaging is a common technique used nowadays in the clinic. There is a range of 
different modalities that are used to diagnose a disease or to follow-up the efficacy of 
a treatment. Examples are an ultrasound machine where sound waves are used to 
visualize body structures, a CT scanner where 3D images are made using x-ray, an 
MRI device where strong magnetic fields are used to visualize body structures, or a 
SPECT scanner where a gamma-emitting radioisotope is used.
To study experimental RA in rodents, pre-clinical imaging devices that are adopted to 
the small bodies of rodents are used. Amongst them are the MRI scanner and devices 
for optical imaging. With an MRI scanner, images of the anatomy and function of the 
body can be made. There is no need to use reporters or probes in an MRI scanner, but 
often a contrast agent is used to improve the visibility of the tissue that is investigated 
[54, 55]. Contrast agents used and investigated nowadays are, amongst others, iron 
oxide nanoparticles [56, 57]. Optical imaging uses fluorescence or bioluminescence 
to visualize enzyme activity, gene expression or tumor growth. A variety of different 
tools can be used, like activatable fluorescence probes [58], targeted antibodies 
coupled to a fluorescent label[59] or overexpression of luciferase using a transgene 
[60]. The main advantages of optical imaging are the short acquisition times, and the 
absence of radioactive tracers.
Superparamagnetic Iron Oxide Nanoparticles
One of the tools that can be used for imaging in MRI are Superparamagnetic Iron 
Oxide Nanoparticles (SPION). SPION are nanoparticles with an iron core and a shell 
of polymer (figure 2). SPION are present in different forms, but Fe2O3 (maghemite) and 
Fe3O4 (magnetite) are particularly important to the health sector. Magnetite has an 
improved biocompatibility, since the iron is totally oxidized and therefore the formation 
of reactive molecules that could damage cells is prevented. The size of SPION vary 
from 5 nm up to 150 nm, depending on the manufacturing protocol and coating[61]. 
Size affects the distribution of the particles through the body. 
Small particles (40-150nm) are phagocytosed or endocytosed by the monocytes and 
macrophages of the reticuloendothelial system and therefore primarily end up in the 
liver [62, 63]. On the other hand, ultrasmall particles (20-40nm) have a longer blood 
half-life compared to the small particles, making them suitable blood pool contrast 
agents [64].
The shell of polymer prevents agglomeration caused by magnetic interactions that 
could eventually lead to thrombosis. Researchers have used different natural or 
synthetic polymers, but also inorganic materials such as silica or gold for coating. 
The most prominent coatings of SPION are dextran [65], polyethylene glycol [66] and 
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polyvinyl alcohol [67]. Polymer coating also gives the potential to attach antibodies 
or therapeutic molecules, creating a SPION for targeted delivery of treatments [68]. 
Because SPION exhibit superparamagnetic properties, they can be used for imaging 
in MRI scanners [69]. It was recently shown that SPION can help to determine 
dexamethasone treatment efficacy in vivo in arthritic rats by MR-imaging [56]. SPION 
can also be used to label and track specific cells. A recent study showed that SPION 
are suitable for in vivo monitoring of human mesenchymal stromal cell tracking[70]. 
Figure 2. Build-up of a SPION, comprising an iron oxide core, a polymer coating and attachment of an 
antibody and a therapeutic agent. Because of the iron oxide core, these particles can be visualized using 
MRI. The polymer coating creates stability by preventing agglomeration, but also creates a possibility to 
attach an antibody for targeted delivery and/or a therapeutic agent for treatment of a disease. SPION can 
also be modified by adding a functional group that can affect, amongst others, cell uptake.
Targeted SPION can be used to detect certain disease processes and in combination 
with a therapeutic molecule treat the disease at the same time. This is called 
‘theranostics’: a combination of a diagnostic tool and a therapeutic agent at the same 
time. Although the fabrication and use of these theranostic agents is still a challenge, 
multiple studies using targeting or therapeutic SPION are published. Hsieh and co-
workers [71] developed a VEGF-targeted SPION for in vivo colon tumor targeting. 
Accumulation of targeted nanoparticles in colon cancer tissue in mice was detected 
by MRI, whereas no accumulation of control nanoparticles was seen. Targeted SPION 
using VCAM antibodies were also used in a mouse model of vascular inflammation 
to specifically target atherosclerotic lesions [66]. Reddy and co-workers [72] were 
able to produce a theranostic agent that is light-activated to treat and image brain 
tumors. Particles were targeted to the tumor using a targeted peptide, and upon near-
infrared light exposure became toxic to the tumor cells, therefore killing the tumor. 
Using MR-imaging, it was possible to visualize the particles, hence degradation of 
the tumor could be followed. Microparticle, as described by Butoescu et al. [73] are 
multiple SPION encapsulated in a PLGA matrix, containing dexamethasone. These 
microparticles were kept in an arthritic joint by a magnet and were slowly releasing 
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the dexamethasone to treat arthritis for a prolonged time, compared to intra-articular 
injections of dexamethasone only. 
A variety of studies were done using SPION in mice and rats, but also some clinical 
trials were conducted. Even in 1996, two intravenous formulation of iron oxide 
nanoparticle-based contrast agents were clinically approved for in vivo imaging and 
they were used to image liver lesions [74, 75]. But in 2008 and 2009 these agents 
were taken of the market,  because the manufacturers discontinued the production of 
these particles. Nowadays, no SPION based products are on the market, but lots of 
research and clinical trials are ongoing. 
Activatable fluorescence probes
Activatable probes can be used to image enzyme activity in vivo during animal 
experimentation. These probes are normally quenched and become activated and 
fluorescent by enzymatic cleavage of one or more specific enzymes (figure 3). In RA 
several proteases, like cathepsins and MMPs, are important during disease activity 
and are therefore interesting targets for optical fluorescence imaging [58]. 
Figure 3. Schematic representation of the activation of a fluorescent probe by a variety of MMPs or 
cathepsins. Normally the fluorophores are quenched by proximity, but when cleaved by MMPs or cathepsins 
the fluorophores are released and become fluorescent.
Cathepsin S is known to be important in antigen processing and presentation, but also 
in extracellular matrix degradation during arthritis [76]. In vivo imaging of cathepsin 
S activity in mice was proven to be possible using the activatable probe AW-091 
[77]. Inflammation was induced by intra-plantar injection of zymosan, causing a rapid 
influx of mononuclear cells, synovial hypertrophy and pannus formation. Imaging of 
cathepsin S activity showed a higher fluorescent signal in the zymosan injected paw, 
compared to the contralateral paw. Fluorescent probe signal could be diminished 
using dexamethasone, an anti-inflammatory agent. 
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MMPs are involved in irreversible cartilage damage, and therefore a interesting target 
for imaging. Using an activatable probe, MMP-3 activity can be visualized early in 
the RA process, even before any histological changes were seen [78]. An MMP-3 
activatable probe is also useful to monitor treatment efficacy in the CIA model, as Lee 
et al. [79] showed. They showed a significant decrease in MMP-3 fluorescent signal 
in vivo as well as in the serum of methotrexate and infliximab treated animals.
Fluorescence imaging, using the non-activatable indocyanine green, has already 
found its way to the clinic to visualize and assess synovitis in patients with RA [80, 81]. 
This method is relatively quick and it is possible to quantify the amount of synovitis, 
making it an objective method.
Antibodies and peptides
Antibodies and peptides, in the form of DMARDS, can be used to treat a disease, but 
they also have the potency to be used for imaging purposes. This can be either in 
vivo or ex vivo, or eventually coupled to a therapeutic molecule or SPION to exploit 
the targeting characteristics of the antibodies or peptides. 
For instance, single-chain variable fragment, coupled to a fluorescent label and 
specific to damaged cartilage can be used to detect cartilage damage caused by RA 
or OA [59]. Selective accumulation in an arthritic joint with cartilage damage can be 
visualized using in vivo fluorescence imaging. Subsequently, this fragment can be 
coupled to a therapeutic molecule to treat the arthritis[82]. Schwager et al. [83] fused 
an antibody directed against a splice isoform of fibronectin (F8) to IL-10. The F8-IL10 
complex was then used to treat CIA. A reduced arthritis score and reduced cytokine 
levels were found. Some ex vivo research has been done with damaged cartilage and 
antibodies targeted against collagen type II [84, 85]. On the other hand it still remains 
a challenge to identify a good biological marker for cartilage degradation.
Another possibility is imaging of the presence of specific cell types during disease 
progression. Macrophages, known to be highly involved in the arthritis process, express 
F4/80 antigen on their surface. During arthritis, these macrophages accumulate at 
the place of inflammation and are therefore a readout for disease activity. By using 
fluorescently labeled monoclonal antibodies against F4/80, macrophages can be 
visualized during inflammatory changes in experimental arthritis [86].
Imaging of gene expression
Genetic factors play an important role in the susceptibility to develop RA. Many genes 
have been identified as genetic risk factors related to RA [1, 87]. Hence, studying 
the expression of certain genes is an intriguing field for research. As shown in this 
thesis, imaging of gene expression can also assist in the selection of an efficient gene 
therapeutic approach. Also, investigating gene expression profiles of, for instance, 
Introduction and outline ׀ 21
1
20 ׀ Chapter 1 
cytokines, chemokines or MMPs important during RA can give more insight in the 
disease process. Combining gene expression analysis with imaging can benefit 
this research. Gene expression is elicited upon activation of the promoter by a 
set of transcription factors. These transcription factors are made after activation of 
a receptor by its ligand, that subsequently activates a whole cascade of kinases. 
The transcription factor then binds to the transcription factor binding site to up- or 
downregulate the transcription of a gene. Well known transcription factors important 
during RA are NF-κB and AP-1 [88, 89].
To study gene expression, the gene of interest can be replaced by a luciferase 
gene. When the transcription factors bind to the transcription factor binding sites, 
the promoter is activated and the luciferase gene is transcribed, eventually leading 
to the production of the luciferase protein (figure 4). Luciferase can convert the 
injected substrate luciferin into visible light. By using an optical imaging system, gene 
expression can be visualized and quantified [90, 91].
Figure 4. Schematic figure of a disease-inducible expression system. During inflammation several 
transcription factors travel to the nucleus where they bind to the transcription factor binding site. This can 
activate the promoter whereupon the transgene is transcribed. On the other hand, when inflammation is 
absent, no transcription factors are present, resulting in an inactive promoter and no transcription of the 
transgene.
Gene therapy 
Treatments used nowadays, like TNF-a inhibitors, can diminish disease activity, but 
some patients experience side effects. Because of the continuous systemic suppression 
of the immune system, infections elsewhere in the body can flourish [51]. A local, long-
lasting therapy, like gene therapy, can be the solution to circumvent the side effects 
of the conventional way of treatment. The US Food and Drug Administration defines 
gene therapy as “products that mediate their effects by transcription and/or translation 
of transferred genetic material and/or by integrating into the host genome and that 
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are administered as nucleic acids, viruses, or genetically engineered microorganisms. 
The products may be used to modify cells in vivo or transferred to cells ex vivo prior to 
administration to the recipient”. Already in the ‘60s experiments were done using gene 
therapy [92] and up to date more than 1800 clinical trials were conducted worldwide [93]. 
Gene therapy in rheumatoid arthritis seems to be promising, but challenging. The joint, 
which is a semi-enclosed environment, can be used as target for gene therapy, mainly 
because the cells of the synovial lining are relatively easy to transduce [94, 95]. Some 
gene therapeutic work has already been done using experimental arthritis models in 
mice. Bakker and collegues from our group[96] showed the feasibility of gene transfer as 
a therapeutic approach to modulate arthritis. Intra-articular injection of transduced cells 
expressing hIL-1Ra prevented the onset of CIA. Zhang et al. [97] used osteoprotegerin, 
injected periarticularly to an arthritic joint, as a transgene to treat CIA. Osteoprotegerin 
can bind and inactivate RANKL, which is an important factor in the differentiation and 
activation of osteoclasts. Indeed protection against subchondral bone and cartilage 
erosions was found, as well as a decrease in mean macroscopic scores of arthritis. 
Recently, Shields et al. [98] demonstrated the use of binding immunoglobulin protein 
as a transgene for systemic gene therapy in the CIA model. Decreased macroscopic 
and histological scores were seen, together with a suppression of IL-17, confirming the 
immunoregulatory properties of the binding immunoglobulin protein. 
Disease-inducible expression systems
Rheumatoid arthritis is known for its intermittent disease course, with exacerbations or 
flares and remissions. Ideally, the therapeutic protein is only expressed during a flare of 
the disease, whereas during remission no treatment is necessary. Varley and co-workers 
[99] were the first to implement an expression system that responded to inflammatory 
stimuli. They used the murine complement factor 3 promoter to regulate the expression 
of a transactivator of transcription (tat). This tat protein then stimulated the expression 
of a transgene inserted downstream. Bakker et al. [100] thereafter showed feasibility 
of this inducible expression system in the CIA model, with IL-1ra as the therapeutic 
transgene. IL-1ra had already proven to be a good candidate to ameliorate the effects 
of IL-1 on cartilage damage and to prevent the onset of CIA [96]. 
Subsequently, a variety of different disease-responsive proximal promoters were 
developed using a computational analysis of genes differentially regulated during 
arthritis [89]. These disease-responsive proximal promoters have binding sites where 
transcription factors, released during the disease-process, can bind and subsequently 
can regulate the transcription of a gene. Efficacy of this method was demonstrated by 
our group [101]. A hybrid of the IL-1 enhancer and IL-6 proximal promoter was used to 
express IL-4 in a CIA model. Cartilage erosion was prevented and side effects, caused 
by the overexpression of IL-4, were diminished. 
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Outline of this thesis
With respect to the already existing imaging tools, techniques and treatments 
for arthritis, there is clearly still a need for improvement. It remains a challenge 
to adequately diagnose and treat a patient, minimizing the risks of side effects. 
Therefore the aim of this thesis was to explore new imaging tools and implement 
them into experimental arthritis mouse models, and simultaneously use some of 
these techniques to optimize personalized (gene)therapy.
In chapter 2 and chapter 3 imaging of inflammation using SPION is discussed. SPION 
are very versatile and can be used for diagnostic imaging purposes or for targeted 
therapy using antibodies as described in chapter 4. SPION are therefore an interesting 
tool to use in the personalized medicine approach. The different possibilities of using 
SPION in arthritis research are discussed in the review in chapter 2. They can be 
used to detect arthritis by imaging of inflammation using MRI, but they can also be 
used for cell tracking or for monitoring the effects of different treatments. Drug-loaded 
nanoparticles can also be used as a therapeutic tool. To be able to use SPION in the 
clinic, safety issues have to be addressed. In chapter 3 we investigated the effects 
SPION have on the course of arthritis. We found that, when using a clinically relevant 
dose, the SPION do not change the course of arthritis, nor do they provoke an 
inflammatory effect in naive mice. Only after administration of a high dose of SPION, 
a short lasting inflammatory response was found.
In chapter 4 and chapter 5 antibodies and fluorescent probes were used to detect 
destruction in experimental arthritis. In chapter 4 we investigated a panel of antibodies 
directed against cartilage collagen type II, to select an antibody that can be used as a 
diagnostic antibody. Trypsin treated bovine cartilage explants were used to investigate 
the binding capacity of each antibody to damaged cartilage. Eventually, one candidate 
antibody was choosen and we were able to detect cartilage damage in the AIA model 
by SPECT CT imaging. This antibody can also be coupled to a SPION to allow MRI 
imaging. In chapter 5 we used activatable fluorescent probes to detect cathepsin and 
MMP activity in mouse models of rheumatoid arthritis and osteoarthritis. We found 
correlations between enzyme activity and pathological changes such as cartilage 
damage and proteoglycan depletion. Using an anti-IL-1αβ treatment, we showed that 
these fluorescent probes were able to reflect treatment efficacy.
To investigate another imaging tool and the feasibility to also use this tool for gene 
therapy, gene expression profiles were imaged during arthritis, using disease-
inducible promoter reporters. This is described in chapter 6, 7 and 8. The disease-
inducible promoter Saa3 is evaluated in chapter 6. Here we showed that this promoter 
is a feasible tool to assess inflammation in vivo in the SCW model, and ex vivo in 
Introduction and outline ׀ 25
1
24 ׀ Chapter 1 
synovial fibroblasts and with the use of serum of RA patients. In chapter 7, six different 
disease-inducible promoters were used and tested in vivo in the SCW model, using 
bioluminescence imaging. Two promoters that showed different activation profiles, the 
Saa3 and the MMP13 promoter, were chosen to perform local gene therapy. Using 
IL-10 as a transgene, we were able to diminish synovitis and cartilage proteoglycan 
depletion, by upregulating IL-1RA and SOCS3 gene expression. Systemic gene 
therapy, using a constitutive promoter, is described in chapter 8. Bioluminescence 
imaging was used to optimize the route of administration and a dose escalating 
study was done to find the optimal dose of lentivirus. An inactive mutant of TAK1 
was overexpressed during the CIA model and a reduction in macroscopic scoring, 
proinflammatory cytokine gene expression and Th17 positive cells in the spleen was 
seen. We concluded that overexpression of TAK1 disrupts progression of arthritis and 
impairs T-helper cell development and can therefore be a useful tool in personalized 
gene therapy.
The results described in this thesis are summarized and discussed in chapter 9 and 
the future perspectives are given.
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Superparamagnetic Iron Oxide Nanoparticles (SPION) are used for magnetic 
resonance imaging (MRI) of cellular processes or anatomical changes in different 
diseases. Many possible products and technologies have now reached their cutting 
edge to be transferred to a pre-clinical or clinical level. In this review SPION and 
their applications in different diseases and especially in inflammatory and arthritic 
diseases are discussed. SPION need to be delivered to a certain spot where disease 
activity is high. The use of antibodies or peptides for targeted delivery is addressed. 
Interesting can be the use of cartilage specific antibodies for early detection of 
cartilage damage in rheumatoid arthritis or osteoarthritis, or combining SPION 
with gene therapy. SPION as a therapeutic and diagnostic (theranostic) agent is an 
intriguing way to treat arthritic or other inflammatory diseases.
Superparamagnetic Iron Oxide Nanoparticles (SPION) are particles with an iron oxide 
core and a total particle size in the range of 5 – 150 nm [1]. The size of SPION depends 
on the manufacturing protocol and coating. Size affects the distribution of the particles 
through the body. Small particles (40-150nm) are phagocytosed or endocytosed by the 
monocytes and macrophages of the reticuloendothelial system and therefore primarily 
end up in the liver [2, 3]. On the other hand, ultrasmall particles (5-40nm) have a longer 
blood half-life compared to the small particles, making them suitable blood pool contrast 
agents [4]. SPION are present in different forms, but Fe2O3 (maghemite) and Fe3O4 
(magnetite) are particularly important to the health sector. Magnetite has an improved 
biocompatibility, since the iron is totally oxidized and therefore the formation of reactive 
molecules that could damage cells is prevented. SPION can be visualised by magnetic 
resonance imaging (MRI), due to their unique magnetic properties. Under the influence of 
a magnetic field, SPION become magnetized and when the magnetic field is deactivated, 
the magnetization of the SPION is lost[5]. During MRI, SPION can induce a signal loss 
on the image which is not specific, as hypointense signal intensity can also be created 
by other tissues. In addition, SPION effects based on signal loss or negative contrast 
are difficult to quantify due to saturation effect. Therefore, MR sequences for positive 
contrast have been the subject of intense research but there is no standard method 
for positive contrast yet. As a very promising approach, ultrashort echo time (UTE) has 
been proposed as a technique to visualize and quantify SPION in vivo using positive 
contrast[6].  
Due to the magnetic force and high surface energy, SPION tend to agglomerate. To 
prevent this agglomeration, SPION need to be coated. The most prominent coatings 
of SPION are dextran, polyethylene glycol (PEG) and polyvinyl alcohol (PVA), but also 
silica or gold[7]. The advantage of a coating, is the possibility of attaching molecules to 
the surface of the SPION. This can be a targeting molecule, like an antibody, as well as 
a therapeutic molecule. Nanoparticles are recognized by the reticuloendothelial system 
(RES) and are taken up by the cells of this system, the monocytes and macrophages 
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[3]. SPION that are released from the cells because of cell death are taken up and 
metabolized by nearby macrophages, or enter the bloodstream and are taken up and 
metabolized by macrophages in the liver and spleen[3]. Intravenous (i.v.) administration 
of the SPION gives the opportunity to visualize different organs, like liver [8], spleen [5] 
or lymph nodes [9]. Passive targeting of the SPION can be modified by changing the 
particle size or the type of coating [10]. Many variables exist for the manufacturing of 
SPION. Important variables are the size of the particle, the type of coating and the charge 
of the particle. There is no clear consensus regarding these characteristics, it depends 
on the goal of the research.
A major concern nowadays is the toxicity of these nanoparticles. Many SPION products 
are on the border of experimental and clinical use. The safety aspects now start to be an 
important issue. Many studies about the effects of SPION on cell viability and function 
are done using in vitro assay [11]. These particles are then tested in healthy animals. 
The effects of these particles on the course of a disease is studied much less. But this 
is equally important, especially when the SPION are used in the clinics. Some SPION 
formulations are already proven to be biocompatible, using these nanoparticles is an 
intriguing way to detect and treat a disease.  
Detection of inflammatory diseases using SPION
SPION are mainly used pre-clinically and sometimes clinically to detect inflammatory 
processes. Macrophages play a important role during inflammation and are abundantly 
present at the site of inflammation [12]. Because SPION are incorporated into macrophages 
by endocytosis, they form the perfect marker to detect inflammatory processes (table 1).
Multiple sclerosis (MS) is a debilitating disease, comprising demyelination of neurons 
and influx of inflammatory cells into the central nervous system, during exacerbations 
of the disease [20]. The use of MRI in the diagnosis of the disease was a big step 
forward in early detection, but advances can be made in predicting and affecting the 
course of the disease. The use of SPION can be a promising tool to unravel the disease 
processes. In rats, abnormalities in the brain caused by the experimental autoimmune 
encephalomyelitis model, were seen on MRI 24 hours after i.v. injection of AMI-227, a 
ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle [13]. USPIO MR-imaging 
compared to gadolinium contrast agent MR-imaging of brain lesions in patients with MS 
showed different signal profiles [21, 22]. A contrast agent such as gadolinium stays in 
the circulation and is eventually secreted by the kidneys, on the other hand, USPIO are 
taken up by cells. Gadolinium showed blood-brain-barrier disruptions, characterizing one 
feature of MS, whereas USPIO visualized the cellular component of the disease. This 
USPIO based technique made it possible to show inflammatory cell influx into the 
brain.
The use of SPION in inflammatory diseases ׀ 35
2
34 ׀ Chapter 2
Table 1. The use of iron oxide nanoparticles to detect a variety of inflammatory diseases. 
Disease Species SPION 
characteristics
Coating material Remarks
Multiple Sclerosis
[13]
Rat 20-40 nm Dextran SPION can cross the blood-brain-
barrier and are thus useful in brain 
imaging
CNS inflammatory 
disease
[14]
Human 17-30 nm 
Ferumoxytol
Polyglucose sorbitol 
carboxymethylether
Useful in the diagnosis of CNS 
inflammatory disorders. However, 
a long lifetime in CNS may result in 
confusion for haemorrhage on MRI
Vascular 
inflammation
[15]
Mouse 26 nm PEG + 
VCAM-1 peptide
Targeted SPION were able to bind 
to atherosclerotic regions and were 
visualised by ex vivo MRI
Heart disease
[16, 17]
Human 17-31 nm
Ferumoxytol
Polyglucose sorbitol 
carboxymethylether
Approval for treatment of iron 
deficiency anemia, tested for 
angiography and myocardial infarct
Arthritis
[18]
Rat 120-180 nm 
Endorem
Dextran Nanoparticles were found on MRI only 
in macrophages of the synovium after 
i.v. injection in arthritic knee joints and 
not in contralateral knee joints
Arthritis
[19]
Mouse <50 nm 
Combidex
Dextran Nanoparticles were found in the 
synovial lining of arthritic knees, 
however MRI on mouse knee joints 
is still challenging.
Atherosclerosis is thickening of an artery wall, caused by inflammation of the 
endothelium, these sites are called atherosclerotic lesions or plaque [23]. Visualization 
of these lesions is possible by passive targeting using USPIO, as was demonstrated 
by Sigovan and co-workers [24] using New Zealand white rabbits. At the place of the 
lesion, a signal loss was detected by MRI, indicating the presence of nanoparticles at 
these sites of inflammation. It is known that vascular cell adhesion molecule (VCAM)-
1 attribute to the pathogenesis of the disease [25]. Therefore, visualizing VCAM-1 
can assist in an early detection of plaque formation. Active targeting, using USPIO 
conjugated with VCAM-1 peptide, showed specific accumulation at the sites with 
atherosclerotic plaques [15]. The presence of the nanoparticles at these sites was 
confirmed by histology and microscopy.
During an acute myocardial infarct inflammation occurs and can have a negative 
effect on the healing [26]. By using nanoparticles, influx of inflammatory cells can be 
assessed. Magnetic nanoparticles made for dual imaging by MRI and fluorescence 
tomography were found to be useful in detection of myocardial macrophage infiltration 
in rodents [27, 28]. Recently, two pilot studies investigated the potential of Ferumoxytol 
to assess myocardial infarct in patients in the acute phase. Alam and collegues [17] 
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observed that Ferumoxytol injection was associated to a decrease MR signal in the 
area of an infarcted myocardium in 10 patients, in comparison to a control group 
of 6 patients that did not receive iron oxide contrast media. Yilmaz and co-workers 
[16] studied 14 patients with an acute ST-elevation, an abnormal electrocardiogram 
reflecting a damaged or inflamed cardiac muscle, with Ferumoxytol enhanced MRI 
and observed a substantial drop in MR signal in the infarct core and peri-infarct 
zone. These authors also followed the MR signal evolution over four days after the 
SPION injection. The signal drop induced by the SPION was already present after 6h 
and began to disappear after 96h. There was no evolution of the signal between 6h 
and 48h. Interestingly, both studies also measured a signal decrease in the remote 
‘healthy’ myocardium suggesting that it could be possible to measure the macrophage 
response in the normal myocardium at distance from the infarct. 
All these studies are of significant clinical interest. SPION enhanced MRI of MS, 
atherosclerosis or myocardial infarct and the ability to detect and visualize macrophage 
infiltration and activity may open new possibilities for risk prediction and therapy 
monitoring.
SPION for cell labeling and tracking
SPION are taken up easily by cells of the RES and also mesenchymal stem cells 
(MSC) can phagocytose nanoparticles. Schulze and collegues [29] demonstrated by 
transmission electron microscopy that PVA coated SPION were taken up by MSC and 
were stored in intracellular vesicles. By labeling cells ex vivo with SPION a traceable 
cell is created that can be visualized by MRI. MSC are able to have an anti-inflammatory 
and neuroprotective effect [30]. It is important to emphasize that incubation of MSC with 
SPION does not give a toxic effect. Several studies indeed showed no adverse effects 
of SPION internalization into cells, when looking at proliferation and mitochondrial 
activity [29, 31, 32]. Moraes et al. [33] used these characteristics to study the effect on 
Huntington’s disease, a neurodegenerative disorder, while tracking the SPION labeled 
cells with MRI in rats. Labeled MSC were injected into a specific part of the brain, 
the striatum, subsequently MR-imaging was performed on multiple days, up to 60 
days after MSC injection. Labeled MSC were still present in the striatum at that time. 
Neuroprotective effects caused by the MSC were seen even nine months after MSC 
injection. Rats injected with MSC showed less dilation of the ventricles in the brain, 
compared to saline injected control rats.
MSC are also known for their protective effects on cartilage and bone damage in 
experimental arthritis. Kehoe and co-workers[34] demonstrated that intra-articular 
injection of MSC in the AIA model at the peak of inflammation prevented the occurrence 
of severe cartilage damage and also reduced joint inflammation. To investigate 
whether MSC are traveling to the joint after intravenous injection, Markides et al. [35] 
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used SPION labeled MSC and injected them into mice with AIA. Indeed, a signal loss, 
explaining the presence of labeled MSC was visible using MRI.
A recent discovery is the ability to load exosomes with SPION. Exosomes are small 
cell derived vesicles present in extracellular fluids. Melanoma exosomes play a role in 
the formation of premetastatic niches in lymph nodes, therefore promoting metastasis. 
These exosomes can be loaded with SPION using electroporation [36]. In this way, the 
exosomes can be followed using MRI. Hu and collegues [37] were able to visualize 
exosomes that travelled to nearby lymph nodes after injection of SPION labeled 
exosomes in the footpad of mice. This gives rise to a new method for delivery of 
nanomedicine.   
Labeling and tracking of MSC and exosomes using SPION can give more insight into 
the cellular processes during an inflammatory disease. Because MSC are versatile 
cells, their therapeutic characteristics can be exploited in cell-based therapies.
SPION used to detect arthritis
Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease, causing 
inflammation in one or more joints. The joint is covered by a thin layer of cells, called 
the synovium. Fibroblast-like synoviocytes and macrophage-like synoviocytes are 
the two main cell types building up the synovium. Cartilage is a layer of connective 
tissue at the articulating surfaces of the bones. Articular cartilage consists of a highly 
organized structure of extracellular matrix composed of collagen fibres and aggregating 
proteoglycans [38]. Because macrophage-like synoviocytes are part of the synovium, 
SPION can be incorporated into the joint. During inflammation, massive influx of 
inflammatory cells, like neutrophils and macrophages, is seen in the joint cavity and 
synovial tissue. Irreversible cartilage damage is also one of the hallmarks of RA [39] 
and osteoarthritis (OA) and might therefore be an important target for diagnosis and 
early treatment.
Already in 2001, Dardzinski and colleagues [19] proved the efficacy of the use of USPIO, 
with a diameter of 30-50 nm, to detect collagen-induced arthritis (CIA) in mice by MRI. 
Using a low dose USPIO of 105 µg administered i.v., only the popliteal lymph nodes 
of arthritic mice became visible. However, after injection of 1.05 mg a slight signal loss 
was also visible around the joint, indicating incorporation of USPIO in synovial tissue. 
After intra-articular (i.a.) injection, a dramatic signal loss was observed and uptake of 
USPIO by neutrophils was confirmed by histology. They concluded however that from a 
clinical point of view, i.v. administration would be preferable.
Beckmann et al. [18] used a somewhat larger SPIO contrast agent, with a diameter 
of 150 nm, to detect antigen-induced arthritis (AIA) in rats. Signal attenuation after 
i.v. injection of the SPIO was found in the arthritic joint compared to the contralateral 
The use of SPION in inflammatory diseases ׀ 37
2
36 ׀ Chapter 2
non-arthritic joint. Comparison was made with the study of Dardzinski and co-workers 
[19], where a slight signal loss was seen in the arthritic joint, whereas Beckmann and 
colleagues [18] found a significant signal loss. This can be caused by the difference 
in SPION size. Beckmann et al. [18] used bigger particles compared to Dardzinski et 
al. [19]. These bigger particles are taken up more easily by cells of the RES, whereas 
smaller particles stay in the circulation for a longer time and are therefore more difficult 
to visualize in the joint.  Also, the difference between the experimental models and 
timing of the imaging procedure can cause different results. 
Simon and collegues [40] made a comparison between three different types of USPIO 
that were already used for clinical trials; Sinerem, Ferumoxytol and Resovist. Focus 
was on the diagnostic potential of these USPIO in the AIA model after i.v. injection. All 
three USPIO showed the potential to visualize synovitis on MRI and were therefore, 
despite their different physicochemical properties, regarded as equals.
Gramoun and co-workers [41] elegantly demonstrated the feasibility of MRI tracking 
of in vivo SPION-labeled macrophages to assess RA treatment effects as well as 
monitor minute cellular behavior in a non-invasive approach. Monocytes were in vivo 
loaded with SPION by i.v. administration and the effects of Dexamethasone (DXM) 
treatment on joint inflammation was imaged by 3T MRI and subsequently confirmed by 
histological analysis. Interestingly, SPION demonstrated to be more accurate than the 
currently widely applied contrast agent gadolinium chelate in illustrating the treatment 
effects of DXM, especially at later time points. In addition, the commercially available 
contrast agent Ferumoxyl showed similar results as SPION in rat arthritis, suggesting 
the great potential of SPION for in vivo detection in patients, not only in RA but in other 
inflammatory disease models as well [42, 18].
Theranostics: Targeted SPION for drug delivery
In their review, Liu et al. [43] explained the various requirements for a nanoparticulated 
drug strategy. They distinguished nano-drugs into actively and passively targeted drugs, 
whereby the passive targeting to tissues or organs is due to the enhanced permeability 
of barriers, as is described in multiple examples above. On the other hand, using active 
targeting means that the nano-drug can travel to and is released at the targeted site 
(figure 1). Targeting ligands like antibodies, which can identify specific cell types or 
tissue receptors, can enhance the active targeting. Targeted drug-loaded nanoparticles 
are very specific and can have high affinities for specific cells or tissues. SPION are 
interesting nanoparticles that might not only be used for in vivo imaging or cell tracking, 
but they should also be considered as potential ‘theranostic’: a combination of a 
diagnostic tool and a therapeutic agent at the same time. 
The use of SPION in inflammatory diseases ׀ 39
2
38 ׀ Chapter 2
Figure 1. Schematic representation of different targeting methods. 
SPION can be delivered either intra-articularly or intravenously. Upon injection SPION can be taken up by 
macrophages. Targeting SPION can be used to, for instance, detect cartilage damage. If the SPION also 
carries a therapeutic cargo, a treatment can be given at the same time. Because SPION are paramagnetic, 
an external magnet can be used to hold the SPION at the site of inflammation.
Aptamers are single-stranded oligonucleotides (DNA or RNA) that recognize and 
bind to a wide range of targets with high affinity and specificity. These aptamers, 
because of their low immunogenic potential, have now been identified as excellent 
tools for diagnostics purposes, scientific research, and targeted therapy [44]. Kanwar 
and colleagues [45] developed an LNA-aptamer, which was loaded on the surface 
of SPION. This complex was used to deliver the specific aptamers in tumor cells in a 
co-culture model of normal and cancer cells. The surface of these SPION was also 
loaded with iron-saturated bovine lactoferrin, which exhibits anti-tumor activity and 
caused massive tumor cell death in the in vitro co-culture experiment. 
Reddy et al. [46] developed a theranostic agent that was light-activated, to treat and 
image brain tumors. This nanoparticle was utilized with a targeting peptide and with a 
photosensitizer called Photofrin. The particles are therefore targeted to the tumor and 
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upon near-infrared light exposure become toxic to the tumorcells, killing the tumor. 
Because these particles were visible using MRI, the degradation of the tumor could 
be followed. Rats that received the targeting particles showed a longer survival time. 
Zolata and collegues [47] showed, using another SPION based theranostic agent, 
that tumor volume was decreased after injection of the theranostic SPION in mice. 
This agent was functionalized with a HER2 antibody, making the SPION specific for 
HER2 overexpression tumor cell, and conjugated to doxorubicin, a chemotherapeutic 
agent. The SPION were also labelled with Indium111, making it therefore possible to 
visualize the tumor with both MRI and SPECT techniques.
Another way of delivering medication to the targeted site is using a combination of 
SPION and gene delivery/therapy. The advantage of using SPION for gene delivery, 
is the ability to visualize and monitor the gene delivery real-time by MRI. Some hurdles 
have to be taken, like loading the SPION with DNA, without losing the characteristics of 
the SPION and protecting the DNA from external molecules like nucleases. However, 
Kievit et al. [48] showed some promising results using SPION coated with chitosan, 
PEG and polyethylenimin, coupled to a plasmid containing green fluorescent protein 
(GFP) under the control of a constitutive promoter. In vivo fluorescence imaging 
showed a GFP signal in the targeted tumor, meaning the nanoparticles travelled to 
the tumor and the tumor tissue was effectively transfected with GFP. 
Using SPION as a theranostic agent is an emerging concept, especially in the cancer 
research field. SPION can be conjugated with a variety of different therapeutic 
molecules, from a chemotherapeutic agent to a plasmid for gene delivery. Some 
promising results are published using these theranostic SPION.
Drug delivery using (targeted) SPION in arthritis
Targeting drugs to the required site of action will not only improve the therapeutic 
efficacy but also reduce the risk of side-effects. In RA the affected joints are the 
potential drug delivery sites to effectively target inflammation and the connective tissue 
destructive processes. However, the poly-articular nature of RA makes it impractical 
to inject all affected joints in a patient. SPION can travel to an inflamed joint after i.v. 
injection. Therefore they are delivered systemically, but release their drug locally. 
Small synthetic drugs can be delivered locally and to limit their off side action these 
drugs can be loaded onto nanoparticles. However, when delivered systemically these 
nanoparticles have to be surface-modified to prevent being scavenged by the RES. 
SPION can be coated with antibodies or peptides specific for arthritic processes. 
When these antibodies or peptides recognize specific epitopes present in the affected 
joint these modified nanoparticles can be used for local drug targeting.
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Mohammadi-Samani and co-workers [49] produced magnetite nanoparticles with 
methotrexate bound to a chitosan coating. Although the size of the particle was 
much bigger with the drug coating and the magnetic properties were diminished, the 
particle still looked promising for delivering methotrexate to a site of inflammation. 
In vitro assays showed that methotrexate was released slowly from the particle, 
allowing higher concentrations at the site of inflammation and thereby reducing the 
drug adverse reaction in other healthy tissues. Because methotrexate is widely used 
in arthritis patients, this particle can be interesting to treat arthritis patients.
Targeted delivery of siRNA using SPION is also a promising strategy to treat certain 
diseases. Chen et al. [50] showed that using siRNA against CD44v6 coupled to 
SPION caused a decrease of CD44v6 protein in a in vitro model. Furthermore they 
showed targeting of these SPION to a gastric tumor. Satake and collegues [51] used 
this approach to treat B cell leukaemia. SPION were functionalized with an antibody 
that targets B cells and with siRNA against a protein important in the leukaemia 
process. They found a reduced number of B cells, while other cells numbers were 
not affected.
Local retention to the joint or another place in the body can be improved by applying 
an external magnet, like Pisciotti et al. [52] showed, using an external magnet to attract 
SPION to the tumour site. An increase of amount of SPION up to 160% was seen 
when using an external magnet. Also cellular uptake of SPION is increased when 
using a magnetic field [53]. Butoescu et al. [54] used a subcutaneously implanted 
magnet near the knee to study the retention of paramagnetic microparticles in an 
arthritic knee joint. A significant increase in amount of microparticles was observed in 
knee joints with a subcutaneously implanted magnet.
Local retention to the joint can also be improved by introducing specific ligands, 
receptors or antibodies to the outer surface of SPION. A small sized and excellent 
candidate would be an aminoacids arginine, glycine and aspartic acid (RGD) peptide 
that has been used to target tumors specifically [55]. RGD peptide binds to the αvβ3 
integrin on newly synthesized blood vessels. As angiogenesis is also an hallmark of 
rheumatoid arthritis this property of RGD can be used to target SPION to the arthritic 
joint when delivered systemically. 
Another target could be the extracellular matrix (ECM). Local inflammatory processes 
can cause destruction of extracellular matrix components leading to neo-eptitopes and 
elicit the synthesis of new ECM components. Also, OA patients suffer from cartilage 
and bone damage. This makes these ECM components interesting targets for selective 
deposition of biologicals to achieve higher therapeutic efficacy. The study presented 
by Schwager and co-workers[56] showed that targeted delivery of interleukin-10 
(IL-10) is efficacious in experimental arthritis. By using side-by-side comparison of 
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immunohistochemical staining of synovial tissue using several antibodies directed 
against different ECM antigens, they identified the extra-domain A, a splice variant 
of fibronectin as the best candidate. This antibody was fused to human IL-10 and 
injected into mice with CIA. Arthritis scores were significantly reduced using the 
antibody IL-10 complex. When using a combination of the complex and methotrexate 
the arthritis scores were even lower. Hughes et al. [57], also used IL-10 to treat AIA 
in mice. They selected a single-chain variable fragment specific to collagen type II in 
cartilage that was affected by reactive oxygen species. This fragment was coupled 
to the IL-10 with an matrix-metalloproteinase (MMP) sensitive cleavage site and, as 
shown by histology, was targeted to damaged cartilage. Therefore, the IL-10 was 
targeted to damaged cartilage and released after cleavage by MMPs. Joint swelling 
was significantly inhibited by the IL-10 and serum cytokine levels were as low as the 
healthy control. The combination of an antibody specific to damaged cartilage, fused 
with an MMP cleavage site to IL-10, as a therapeutic molecule could be a promising 
combination for coupling to SPION, which makes it then possible to diagnose and 
treat for instance osteoarthritis.
Clodronate (dichloromethylene bisphosphonate) encapsulates liposomes are taken 
up by macrophages and induce apoptosis [58]. Clodronate liposomes injected 
systemically to inactivate the RES by inducing apoptosis of macrophages, or injected 
locally to deplete the macrophages in the synovium, have both a profound effect on 
experimental models of RA [59-61]. Liposome-mediated delivery of corticosteroids is 
also more effective on suppressing arthritis at lower dosages than free corticosteroids 
and thereby safer to use with lesser side effects [62-64]. Both liposomes and SPION 
are known to travel to an inflamed joint. This makes SPION an interesting alternative 
delivery vehicle for corticosteroids as well. By using Poly(D,L-lactide-co-glycolide acid) 
(PLGA) coating of SPION, DXM, a corticosteroid, could be embedded onto the bead 
and could be internalized by the synovial cells [65, 66]. Butoescu and colleagues [54] 
injected DXM containing PLGA coated SPION i.a. and showed that these particles 
were suitable delivery vectors for DXM to ameliorate AIA. The rapid clearance of free 
DXM from the joint could be overcome by co-encapsulation on SPION. Retention could 
be further increased by applying an external magnetic field. Using this technique the 
particles were still present in the joint 3 months after injection. Joints treated with the 
DXM particles showed significantly less inflammation on histology, meaning the DXM 
was released from the particle and reached the glucocorticoid receptors. 
More and more research is done to the theranostic properties of SPION in the arthritis 
field, but it still remains a challenge to produce and successfully use such an agent. 
Especially combining a good targeting molecule together with an effective therapeutic 
molecule seems to be challenging. However, big steps are made towards bringing 
the two together to effectively treat (osteo)arthritis.
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Conclusions
In conclusion SPION can, among others, be used for diagnostic imaging, follow-up 
and evaluation of treatment efficacy, or targeted therapy with a variety of antibodies, 
peptides and therapeutic molecules. SPION can be used to detect all kinds of 
inflammatory diseases, as well as arthritis, and to track labelled cells in vivo. This 
is because of the underlying mechanism that comprises the uptake of SPION by 
monocytes and macrophages, that are phagocytosing cells known to be highly 
involved in inflammation. The SPION are therefore transported to, or taken up at 
the site of inflammation, where they can be detected using MRI technology. Using 
SPION for drug delivery is a promising tool, that still needs some optimization and 
further research. The ability of nanoparticles to both diagnose and treat diseases, 
so use as a theranostics, is an emerging but challenging concept. Drug that showed 
systemic toxicity can now be re-evaluated and coupled to a targeted particle. In that 
case, less drug is needed, followed by less side-effects for the patients. In the same 
time, the diseased region is targeted efficiently and therefore the drug can have an 
optimal effect. Combining SPION with a therapeutic molecule that is released only 
in arthritic conditions, by for instance an MMP sensitive cleavage site, can ensure 
local treatment without systemic side-effects. Combining a targeted SPION with 
gene therapy can also give an effective long-lasting treatment option for patients with 
osteo(arthritis). Shortly, SPION are very versatile and can be used to diagnose and 
treat different inflammatory diseases, but still some research needs to be done.
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Abstract 
Background
Superparamagnetic Iron Oxide Nanoparticles (SPION) are used in diagnostic imaging 
of a variety of different diseases. For such in vivo application, an additional coating 
with a polymer, for example polyvinyl alcohol (PVA), is needed to stabilize the SPION 
and prevent aggregation. As the particles are foreign to the body, reaction against the 
SPION could occur. In this study we investigated the effects that SPION may have on 
experimental arthritis after intra-articular (i.a.) or intravenous (i.v.) injection.
Methods 
PVA-coated SPION were injected either i.a. (6 or 24 µg iron) or i.v. (100 µg or 1 mg 
iron) into naïve Toll-like receptor-4 deficient (TLR4-/-) or wild-type C57Bl/6 mice, or 
C57Bl/6 mice with antigen-induced arthritis. As control, some mice were injected with 
PVA or PBS. MR imaging was performed at 1 and 7 days after injection. Mice were 
sacrificed 2 hours and 1, 2, 7, 10 and 14 days after injection of the SPION, and RNA 
from synovium and liver was isolated for pro-inflammatory gene expression analysis. 
Serum cytokine measurements and whole knee joint histology were also performed.
Results 
Injection of a high dose of SPION or PVA into naïve knee joints resulted in an immediate 
upregulation of pro-inflammatory gene expression in the synovium. A similar gene 
expression profile was observed after SPION or PVA injection into knee joints of 
TLR4-/- mice, indicating that this effect is not due to LPS contamination. Histological 
analysis of the knee joints also revealed synovial inflammation after SPION injection. 
Two hours after i.v. injection of SPION or PVA into naïve mice, an upregulation of 
pro-inflammatory gene expression was detected in the liver. Administration of SPION 
or PVA into arthritic mice via i.a. injection did not result in an upregulation of gene 
expression and also no additional effects were observed on histology. MR imaging 
and histology showed long-term retention of SPION in the inflamed joint. However, 
14 days after the injections no long-term effects were evident for gene expression, 
histology or serum cytokine concentrations. 
Conclusions
Injection of SPION, either locally or systemically, gives an acute inflammatory 
response. In the long term, up to 14 days after the injection, while the SPION reside 
in the joint, no further activating effects of SPION were observed. Hence, we conclude 
that SPION do not aggravate arthritis and can therefore be used safely to detect joint 
inflammation by MR imaging.
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Introduction
Superparamagnetic iron oxide nanoparticles (SPION) are used for imaging of 
anatomical, cellular and molecular changes in different diseases. Being very small 
particles (10-100 nm), they are taken up quickly by the mononuclear phagocyte 
system and can therefore travel easily to inflammatory lesions [1, 2]. Due to their 
unique paramagnetic properties, SPION can be visualized by Magnetic Resonance 
Imaging (MRI) [3-5]. SPION are already used in pre-clinical and occasionally clinical 
studies to detect arthritis [6, 7], as well as inflammatory bowel disease [8], central 
nervous system inflammatory diseases [9] and atherosclerotic lesions [10]. However, 
toxicity and safety profiles are still not complete and not much is known about the 
response to in vivo injected nanoparticles.
SPION need an additional coating with polymer to allow a longer residence time in 
the blood circulation and to prevent the formation of aggregates [5, 11]. Moreover, 
naked SPION are known to affect cell viability caused by toxic effects [12]. In case 
of polyvinyl alcohol (PVA)-coated particles, biocompatible PVA functionalized with 
amino- or carboxyl-groups are used. These groups serve for charge regulation as well 
as anchor points for further attachment of peptides and proteins, including antibodies, 
fluorescent dyes or a drug [13]. 
Rheumatoid arthritis is a disease characterized by chronic inflammation of articular 
joints, which causes irreversible cartilage and bone damage. During joint inflammation, 
nanoparticles will be taken up by monocytes or macrophages and then migrate 
through the body and to the site of inflammation. It is known that a large proportion 
of the nanoparticles injected intravenously (i.v.) are taken up by Kupffer cells, the 
macrophages in the liver [1]. However, part of the SPION will reach the target organ, 
the arthritic joint. The synovial lining in the joints consists of fibroblasts as well as 
macrophages and is therefore also capable of capturing these nanoparticles.
Several in vitro and some in vivo studies have shown the reaction of cells and 
tissues after the uptake of nanoparticles. For example, Murray et al. [14] reported 
elevated levels of the pro-inflammatory cytokines Interleukin (IL)-6 and IL-8 in the 
supernatant of HEK cells that were incubated with nanoparticles. Cho et al. [15] found 
lung inflammation, explained by an increase in polymorphonuclear leukocytes and 
lymphocytes, 24 hours after intratracheal instillation of nanoparticles. These studies 
showed pro-inflammatory effects after nanoparticle exposure, but were performed 
under healthy conditions. The question therefore arises if nanoparticles aggravate 
disease activity. The in vivo effects that nanoparticles have on the course of a disease 
have been studied to a lesser extent [15, 16]. Consequently, it is important to further 
explore the effects that nanoparticles have under disease conditions. Hence, in this 
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study we set out to determine the effects of PVA-SPION injection, either locally or 
systemically, on the course of experimental arthritis. We investigated the reaction of 
the target organ, the synovial tissue, as well as the main systemic organ, the liver, after 
SPION injection in both arthritic and non-arthritic animals. Gene expression profiles, 
blood serum cytokine levels and histological joint inflammation were studied. We 
showed that injection of SPION resulted in an acute and short-lasting inflammatory 
response in naïve mice, but no adverse effects were observed on the course of 
chronic antigen-induced arthritis.
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Materials and Methods
SPION production and characterization
SPION production
SPION were synthesized following a co-precipitation method in order to obtain 
a maghemite phase (γ-Fe2O3) suspension [17]. Briefly, a 1:2 molar ratio of 1.5 L 
Fe2+:Fe3+ solution (0.064 moles from FeCl2 and 0.128 moles from FeCl3) were mixed 
with 120 ml of ammonia solution (NH4OH at 25%). 10 minutes after reaction, the 
black suspension obtained was magnetically washed with deionized water until the 
pH reached 7. The SPION were then oxidized from magnetite (Fe3O4) to maghemite 
phase (γ-Fe2O3) by redispersion in 160 ml of nitric acid (HNO3 at 2 M) and 240 ml 
of ferric nitrate (Fe(NO3)3 at 0.35 M) under reflux for 90 minutes. The suspension 
was sedimented onto a magnet to remove the excess of reactant, was redispersed 
in DI water and dialyzed (MWCO 12-14 kDa cellulose membrane tubing) against 
HNO3 (0.01 M) for 3 days, changing the solution every 12 hours. The suspension 
was finally centrifuged 15 minutes at 30,000 g keeping only the supernatant. The 
final suspension, called naked SPION, was at 10 mgFe.ml-1 and at approximately pH 
2. The naked SPION were surface modified using a mixture of PVA-OH and amino 
functionalized PVA as described previously [13, 18]. A mixture of 10 volumes of 
naked SPION at 10 mgFe.ml-1, 9 volumes of PVA-OH at 100 mg.ml-1 (Mowiol 3-85 
from Kuraray Europe GmbH) and 1 volume of amino-PVA at 20 mg.ml-1 (M12 from 
Erkol) was prepared. The suspension of PVA-SPION was stored at 4°C at least one 
week before further use.
SPION characterizations
The crystallite’s mean diameter (dTEM) was measured by counting and averaging 400 
crystallite diameters observed on Transmission Electron Microscopy (TEM CM12: 
FEI Co. Philips Electron Optics, Zürich, Switzerland at 125.000 X magnification and 
120 kV). Hydrodynamic diameter (dH) as well as Zeta potential were measured on 
PCS apparatus (Zeta-Pals from Brookhaven: Laborchemie GES.M.B.H., Vienna, 
Austria) at pH 4.5 for naked SPION and 5.7 for PVA-SPION and with a refractive index 
of 2.42. SPION concentrations (cFe in mgFe.ml1) were measured using a magneto-
susceptometer MS3 from Bartington, using the  method described elsewhere [18]. 
The mass concentration of PVA versus iron (mgPVA/mgFe) was calculated using the 
loss of mass (%TGA) measured by thermogravimetric analyses (Mettler Toledo 851e) 
from 30 to 800°C at 10°C.min-1 under 30 ml.min-1 of air and the cFe measured above. 
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Ethics statement
All in vivo studies complied with national legislation and were approved by local 
authorities (Animal Ethics Committee, Radboud University Nijmegen, Permit 
numbers: 2013-035, 2013-162 and 2013-193) for the care and use of animals with 
related codes of practice.
Animals
Female, 12 week old C57Bl/6J mice were obtained from Janvier (Le Genest Saint 
Isle, France). Male and female, 8-16 week old TLR4-/- mice in C57Bl/6J background 
were bred in house. All mice were housed in filter-top cages with food and water 
supplied ad libitum. The mice were provided with an in house shelter of a specially 
designed transparent igloo and were offered cotton wool as nesting material. Mice 
were i.a. injected with either 6 µg Fe/knee  (low dose) or 24 µg Fe/knee (high dose) 
in 6 µl total volume. Mice injected i.v. received either 3.3 mg Fe/kg (low dose) or 33.3 
mg Fe/kg (high dose) in 200 µl. Control injections (i.a. and i.v.) were performed with 
equal volumes of PBS. Mice were euthanized by cervical dislocation at different time 
points after injection of the SPION. 
Induction of experimental arthritis
Mice were immunized with 100 μg of mBSA (Sigma), emulsified in 100 μl Freund’s 
complete adjuvant (Difco Laboratories, Detroit, MI). Injections were divided over both 
flanks. Heat-inactivated Bordetella pertussis (RIVM, Bilthoven, The Netherlands) was 
administered intraperitoneally as an additional adjuvant. Two subcutaneous booster 
injections in the neck region with (in total) 50 μg mBSA/Freund’s complete adjuvant 
were given 1 week after the initial immunization. Three weeks after these injections, 
primary AIA was induced by injecting 60 μg of mBSA in 6 μl of PBS into the right knee 
joint, resulting in chronic arthritis.
RNA isolation and quantitative PCR analysis
Single synovial tissue biopsies were isolated from the lateral and medial side of the 
knee joint using a 3 mm biopsy punch (Stiefel, Wachtersbach, Germany) and pooled 
as one sample. Total RNA was extracted from the tissue homogenates using TRI 
reagent (Sigma) according to manufacturer’s protocol. Isolated RNA was treated with 
DNAse followed by reverse transcription of 1µg RNA into cDNA using Moloney murine 
leukemia virus reverse transcriptase 0.5µg/µl oligo(dT) primers, and 12.5mM dNTPs 
(Invitrogen). Quantitative real-time PCR was performed using the StepOnePlus 
sequence detection system (Applied biosystems). PCR was performed in a total 
reaction volume of 12.5 µl consisting of appropriate cDNA, 5 µM forward and reverse 
primer and SYBR green PCR master mix (Applied biosystems). The PCR protocol 
consisted of 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 sec at 
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95°C and 1 min at 60°C. The cycle threshold value (Ct) of genes of interest was 
compared to the Ct of reference gene glyceraldehyde-3-phophate dehydrogenase 
(GAPDH) (delta Ct).
Serum cytokine measurements
Keratinocyte chemoattractant (KC) and IL-6 levels in the blood serum were 
determined on a Luminex-100 system (Luminex Corp) using a bead-based multiplex 
immunoassay (Milliplex, Merck Millipore). Data analysis was performed with Bio-Plex 
Manager software (Bio-Rad Laboratories).
MR-imaging
MR imaging was carried out on a Siemens 3T Tim Trio clinical scanner, with 42 
samples per group scanned in a single acquisition arranged in the manufacturer’s 
wrist coil.  A T1-weighted gradient echo sequence was used to acquire these ex vivo 
images of the mouse knees. Coronal slices were aligned with the knee joint from a 3D 
isotropic resolution acquisition of 310µm, with parameters TR/TE 14.3/5.9ms and flip 
angle 12°. Hypo-intense signal regions were identified as resulting from accumulation 
of SPION particles.
Histology
Knee joints were isolated, fixed in phosphate buffered 4% formaldehyde, decalcified 
with 5% formic acid, dehydrated and embedded in paraffin. Serial sections of 7µm 
were cut and stained with Haematoxylin/Eosin to study inflammatory cell influx. These 
histopathological changes were scored on an arbitrary scale ranging from 0-3 per 
joint. Inflammation was graded from 0 to 3 as follows: 0 = no inflammatory cells in joint 
cavity and a healthy, un-inflamed appearance of the synovium, 1 = a few inflammatory 
cells in joint cavity and synovium, 2 = joint cavity and synovium partly filled with 
inflammatory cells, 3 = joint cavity and synovium totally filled with inflammatory cells. 
Proteoglycan depletion was graded 0 to 3 as follows: 0 = no loss of safranin-O red 
staining of glycosaminoglycans in the cartilage, 1 = some loss of red staining, 2 = 
moderate loss of red staining, 3 = total loss of red staining in the upper metabolically 
active layers of the cartilage (above the tidemark of the deeper calcified cartilage 
layer).
Statistics
Statistical differences between experimental groups were tested using the Mann-
Whitney U-test, unless stated otherwise (Graphpad Prism V4.0). P values less than 
0.05 were considered significant. Results are expressed as the mean ± SEM.
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Results
SPION characterization
The crystallite size of the SPION used in our studies is around 8 nm (fig. 1). The 
hydrodynamic diameter of the naked SPION is 14 nm and increases to 45nm when 
covered with a PVA layer, proving the effective adsorption of PVA onto naked SPION 
surface and a small aggregation of the naked SPION in a PVA-hydrogel cluster [17]. 
The PVA coating was also shown by the loss of mass observed in thermogravimetric 
analyses (TGA) (PVA/Fe ratio, table 1). The Zeta potentials were positive for naked 
and PVA coated particles at +26 mV and +17 mV, respectively. The PVA-SPION 
concentrations are at 4.7 mgFe.ml-1. 
Figure 1. Transmission Electron 
Microscopy of SPION. 
(A) magnification 45000x and 
(B) magnification 125000x.
Table 1. Characterization of naked SPION and PVA coated SPION.
Nanoparticles dTEM (nm)
dH 
(nm) [pH]
Zeta potential 
(mV) [pH]
PVA/Fe ratio 
(mgPVA/mgFe)
cFe 
(mgFe.ml-1)
Naked-SPION 7.8 ± 2 14 ± 2 [4.5] +26 ± 2 [4.5] 0 9.4
PVA-SPION 7.8 ± 2 45 ± 3 [5.7] +17 ± 2 [5.7] 9 4.7
dTEM: crystallite’s diameter; dH: hydrodynamic diameter; cFe: concentration of nanoparticles in mgFe.ml-1 
measured in TGA.
SPION migrate to, and reside in, articular joints after i.v. or i.a. injection
After i.v. injection SPION are distributed to the synovial tissue of the inflamed, arthritic 
joint, but not to a non-inflamed joint, as was visualized using MR imaging (figs. 2a-c). No 
MRI signal was detected in an AIA joint without SPION (fig. 2a). SPION however were 
also taken up in the bone marrow of the femur and tibia of both arthritic and non-arthritic 
joints (figs. 2b,c). The i.v. injected SPION resided in the inflamed synovial tissue for at 
least 7 days, evidenced by MR imaging (fig. 2c). After i.a. injection, SPION remained 
in the joint where they were taken up by cells from the synovial lining (fig. 2d). SPION 
resided for at least 14 days in the joint, in either an inflammatory or a non-inflammatory 
environment. This was shown using the Prussian blue staining (fig. 2e), where blue-
coloured cells were still visible in the synovial lining 14 days after SPION injection.
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Figure 2. MR-imaging and Prussian blue histology visualizes SPION content in knee joints of mice. 
Coronal MR images of knee joints ex vivo. T1-weighted gradient echo sequence, 3D isotropic resolution of 
310µm, TR/TE 14.3/5.9ms and flip angle 12°.  Blue arrows indicate hypointense signal in the region of SPION 
uptake in synovial tissue. (A) Control knee joint with AIA and no SPION. (B) Control knee joint without AIA 
and with i.v. injected SPION; signal from SPION detected in bone marrow, but not in synovium. (C) AIA knee 
joint i.v. injected with SPION; signal from SPION detected in bone marrow and synovial tissue. (D) AIA knee 
joint injected i.a. with SPION; signal from SPION detected in synovial tissue. (E) Prussian blue staining of 
histological slide of AIA knee joint with SPION injected i.a. Blue arrow indicates Prussian blue staining of 
SPION taken up by cells of the synovium. Magnification 100x.
SPION provoke an  inflammatory response in naïve knee joints
After local (i.a.) and systemic (i.v.) administration, a difference between high or a low 
dose injections of SPION or PVA was found; the high dose elicited an inflammatory 
response whereas the low dose mostly showed no significant differences. Therefore, 
further results are only described for the high doses of SPION or PVA. SPION injected 
locally into naïve knee joints of C57Bl/6 mice caused a significant upregulation of 
the pro-inflammatory genes IL-1β, IL-6 and KC 2 hours after SPION injection, when 
compared to knee joints injected with PBS (table 2). Injection of PVA alone also provoked 
an inflammatory response. After i.v. or i.a. injections of SPION in Toll-like receptor-4 
knockout (TLR4-/-) mice a similar upregulation of pro-inflammatory genes was seen 
compared to C57Bl/6,. Hence, upregulation of pro-inflammatory genes after SPION 
injection was not due to Lipopolysaccharide (LPS) contamination (table 2). Histological 
analysis demonstrated that inflammatory cell influx was significantly higher one day 
after injection of SPION, in both C57Bl/6 and TLR4-/- mice, compared to PBS control 
group (fig. 3) In contrast, inflammatory cell influx was not significantly raised after PVA 
injections. However, differences between C57Bl/6, TLR4-/- and the PBS control group 
were no longer seen two days after SPION injection (data not shown). Proteoglycan 
depletion in the cartilage was absent at all time points. When SPION were injected 
systemically, an upregulation of the IL-1β gene in the synovium was detected (table 
2), but no signs of joint pathology were observed on histology (data not shown). When 
studying the effects on gene expressions in the liver, a significant upregulation of the 
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pro-inflammatory genes IL-1β and Tumor Necrosis Factor-α (TNFα), and of the acute 
phase protein Serum amyloid a-1 (Saa1) was found after i.v. injection of SPION or 
PVA alone (table 3). Local injections of nanoparticles or its coating did not provoke 
such an inflammatory response.
Figure 3. Histological analysis shows more inflammation in knee joints 1 day after i.a. injection of 
SPION. Histological scoring of inflammation in knee joints of naïve C57Bl/6 mice (A) or naïve TLR4-/- mice 
(D), 1 day after i.a. injection of SPION. Significantly more inflammation is seen in knee joints injected with 
the high concentration of SPION in both C57Bl/6 mice (B) and TLR4-/- mice (E) compared to PBS injected 
knee joints of C57Bl/6 mice (C) or TLR4-/- mice (F). Magnification 50x. F=femur, P=patella, S=synovium. 
n=4 mice per group, * p<0.05, ** p<0.01 when using a one-way ANOVA. 
Table 2. Gene expression in synovial tissue of naïve mice two hours after SPION or PVA injection.
C57Bl/6 TLR4-/-
High dose 
PVA-SPION
Low dose 
PVA-SPION
High dose 
PVA
Low dose 
PVA
High dose 
PVA-SPION
TNFα i.a. 1.6 ± 0.5 0.2 ± 1.0 3.5 ± 0.2** 1.0 ± 0.3 1.2 ± 0.4 i.v. 1.4 ± 0.4 0.2 ± 0.6 3.0 ± 0.3* 0.1 ± 0.1 1.9 ± 0.4
IL-1β i.a. 5.1 ± 0.9* 1.9 ± 1.9 5.2 ± 0.6* 2.7 ± 0.4 3.4 ± 0.9*i.v. 4.3 ± 0.3* 2.6 ± 1.4 4.5 ± 0.2** 1.5 ± 0.6 4.3 ± 0.6
IL-6 i.a. 6.4 ± 0.7* 3.3 ± 1.3 7.3 ± 0.6** 2.7 ± 0.3 4.2 ± 1.0*i.v. 3.6 ± 0.6 0.6 ± 0.6 6.8 ± 0.1** 0.3 ± 0.3 0.0 ± 0.3
KC i.a. 5.1 ± 0.7* 2.6 ± 1.4 5.9 ± 1.0** 2.1 ± 2.1 3.7 ± 0.8*i.v. 4.4 ± 0.7 0.6 ± 1.1 7.4 ± 0.2* -0.6 ± 0.3 3.0 ± 0.4
Gene expression in synovial tissue of naïve C57Bl/6 and TLR4-/- mice, 2 hours after injection of PVA-
SPIONs or PVA alone. Depicted as mean ± SEM, ddCt corrected for PBS injections and GAPDH. n=4 
mice per group, * = p<0.05, ** = p<0.01 when using a one-way ANOVA (C57Bl/6) or Mann-Whitney U test 
(TLR4-/-) compared to PBS injected. 
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Table 3. Gene expression in the liver of naïve mice two hours after SPION or PVA injection.
High dose 
PVA-SPION
Low dose 
PVA-SPION
High dose 
PVA
Low dose 
PVA
TNFα i.a. -0.1 ± 0.4 0.3 ± 1.7 0.3 ± 0.6 -0.2 ± 0.0i.v. 5.5 ± 0.7** 1.0 ± 0.1 6.1 ± 0.3** 1.3 ± 0.9
IL-1β i.a. 0.0 ± 0.4 0.7 ± 0.5 0.3 ± 0.2 -0.6 ± 0.7i.v. 5.1 ± 0.5** 1.1 ± 0.6 5.9 ± 0.7** 1.9 ± 0.7
Saa1 i.a. 1.4 ± 0.5 0.2 ± 0.1 1.0 ± 0.5 1.0 ± 0.2i.v. 6.1 ± 0.8*** 1.1 ± 0.1 6.6 ± 0.2*** 1.3 ± 0.1
Gene expression in the liver of naïve C57Bl/6 mice, 2 hours after injection of PVA-SPIONs or PVA alone. 
Depicted as mean ± SEM, ddCt corrected for PBS injections and GAPDH. n=3 mice per group, ** = 
p<0.01, *** = p<0.0001 when using a one-way ANOVA compared to PBS injected. 
Injection of SPION does not aggravate arthritis 
Intra-articular injection of SPION during experimental arthritis caused a minor upregulation 
of TNFα and IL-1β gene expression in the synovium at 2 days after injection, which was 
on the 5th day of the AIA model (table 4). No differences were found in serum protein 
concentrations of IL-6 nor KC at all days, nor was any increase of inflammatory cell influx 
or cartilage proteoglycan depletion observed on histology (data not shown). Local injection 
of PVA into the arthritic joint gave no inflammatory response at all. Almost the same results 
were seen after i.v. SPION or PVA injection in arthritic mice; i.e. no upregulation of pro-
inflammatory genes in the synovium and no enhanced joint pathology on histology. In the 
liver, on the other hand, i.v. injected SPION or PVA induced a significant upregulation of 
TNFα and IL-1β gene expression after two hours, on day 3 of the AIA model. (table 5). After 
i.a. injection of SPION or PVA alone no effects were observed on gene expressions in the 
liver. Acute phase protein gene expression of Saa1 showed a trend toward upregulation. 
In the serum, IL-6 and KC protein concentrations showed a trend to be higher 2 hours 
after i.v. SPION injection, but only PVA alone caused a significant upregulation (fig. 4). 
This effect was completely absent at 1 and 2 days after SPION injections, corresponding 
to day 4 and 5 of the AIA model (data not shown). 
Table 4. Gene expression in synovial tissue of arthritic mice two days after SPION or PVA injection.
High dose 
PVA-SPION
Low dose
 PVA-SPION
High dose 
PVA
Low dose 
PVA
TNFα i.a. 2.2 ± 0.2* 2.0 ± 0.2* 0.5 ± 0.5 0.6 ± 0.3i.v. 0.6 ± 0.7 1.1 ± 0.3 0.0 ± 0.6 -0.2 ± 0.5
IL-1β i.a. 2.9 ± 0.4* 2.5 ± 0.1* 1.1 ± 0.5 1.0 ± 0.5i.v. -0.3 ± 0.6 0.8 ± 0.1 -0.1 ± 0.4 -0.7 ± 0.8
IL-6 i.a. 1.8 ± 0.5 2.2 ± 0.3 1.0 ± 0.8 0.5 ± 0.7i.v. 0.0 ± 0.5 1.9 ± 0.4 0.3 ± 0.7 -0.3 ± 1.0
KC i.a. 1.7 ± 0.5 1.3 ± 0.4 1.0 ± 0.6 0.6 ± 0.5i.v. -0.4 ± 0.5 1.1 ± 0.2 0.3 ± 0.6 -0.6 ± 0.8
Gene expression in synovial tissue of arthritic C57Bl/6 mice at day 5 of the AIA model, 2 days after injection 
of PVA-SPIONs or PVA alone. Depicted as mean ± SEM, ddCt corrected for PBS injections and GAPDH. 
n=4 mice per group, * = p<0.05when using a one-way ANOVA compared to PBS injected.   
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Table 5. Gene expression in the liver of arthritic mice two hours after SPION or PVA injection.
High dose 
PVA-SPION
Low dose 
PVA-SPION
High dose 
PVA
Low dose 
PVA
TNFα i.a. 0.1 ± 0.4 0.4 ± 1.6 0.8 ± 0.2 -0.1 ± 0.5i.v. 4.8 ± 0.2*** 0.6 ± 0.7 4.4 ± 0.3*** 2.1 ± 0.1*
IL-1β i.a. 0.0 ± 0.4 1.1 ± 0.1 0.3 ± 0.2 0.5 ± 0.8i.v. 3.8 ± 0.5*** 0.2 ± 0.3 4.2 ± 0.3*** 1.5 ± 0.5
Saa1 i.a. 0.3 ± 0.5 1.8 ± 0.4 0.5 ± 0.1 -1.5 ± 1.6i.v. 2.4 ± 0.3 0.7 ± 0.5 2.7 ± 0.8 2.7 ± 0.5
Gene expression in the liver of arthritic C57Bl/6 mice at day 3 of the AIA model, 2 hours after injection of 
PVA-SPIONs or PVA alone. Depicted as mean ± SEM, ddCt corrected for PBS injections and GAPDH. n= 
3 mice per group, * = p<0.05, *** = p<0.0001 when using a one-way ANOVA compared to PBS injected. 
Figure 4. Serum cytokine concentrations are significantly elevated after i.v. injection of a high 
concentration of PVA. Serum cytokine concentration of IL-6 (A) and KC (B), 2 hours after i.v. injection 
of SPION or PVA in arthritic mice. The high concentration of PVA alone provoked a significant higher 
concentration of IL-6 and KC, injection of SPION gave a trend towards a higher concentration compared to 
PBS injections. n=3 mice per group, * p<0.05 when using a one-way ANOVA.
Long-term effects, up to 14 days after injection of SPION or PVA, were also investigated 
using the high dose. After i.a. injection of SPION no adverse consequences were 
observed on gene expression profiles in the synovium (data not shown). Concomitantly, 
histology (fig. 5) and serum cytokine concentrations did not show signs towards a 
change in inflammation. However, when looking at gene expression profiles in the 
liver, a downregulation of IL-1β was seen at day 7, 10 and 14, but only after i.a. 
injections (fig. 6). Intravenous injections did not elicit either a pro or anti-inflammatory 
response in the synovium (fig. 5) or the liver.
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Figure 5. Histological analysis shows no aggravation in joint pathology 14 days after SPION 
injection. Histological scoring of inflammation in knee joints of arthritic mice, 14 days after i.a. (A) or i.v. 
(D) injection of a high dose of SPION or PVA. No differences in synovial inflammation are seen between 
the i.a. SPION (B), the i.v. SPION (E) injected groups and the control i.a. PBS (C) and i.v. PBS (F) injected 
groups. Magnification 50x. F=femur, P=patella, S=synovium. n=8 mice per group, one-way ANOVA used.
Figure 6. Downregulation of IL-1β gene expression 7, 10 and 14 days after i.a. SPION injection. 
Gene expression of IL-1β in the liver of arthritic mice, 7 (A), 10 (B) and 14 (C) days after SPION injection 
(high dose) show a significant downregulation, but only after i.a. injecting of SPION. n=5 mice per group, * 
p<0.05, ** p<0.01, ***p<0.05 when using a one-way ANOVA.
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Discussion 
The implications of injecting nanoparticles on the severity and course of arthritis 
has never been studied in vivo, although some in vitro studies point towards an 
inflammatory effect. Therefore, in this study we investigated the effects SPION may 
have on arthritis. We have shown that local or systemic injection of SPION causes a 
short-lasting inflammatory response within 2 days after SPION injection, but 14 days 
after injection no long-term adverse effects on the course of experimental arthritis 
were observed.
It was reported previously that PVA-coated SPION can accumulate at sites of 
inflammation in rat [19]. By using MR imaging, we showed that, when injected i.v., 
part of the SPION will migrate to the joint, but only when joint inflammation is present. 
This was also shown previously by Beckmann and co-workers in a study [20], where 
nanoparticles coated with dextran were injected i.v. in rats with antigen-induced 
arthritis. Significantly less nanoparticles accumulated in the joints of dexamethasone-
treated rats. 
We observed that SPION injected i.a. stay in the joint for at least 14 days after injection, 
in both an inflammatory as well as a non-inflammatory environment. Because SPION 
apparently reside in the joint for quite some time, it is important to examine any 
potential inflammatory reactions to these foreign particles. Two different dosages of 
nanoparticles were used, chosen from a clinical point of view. The low dose did not 
show any pro-inflammatory effects in naïve as well as arthritic mice. The high dose 
provoked some short-lasting inflammatory signs, which are discussed below. 
In non-arthritic mice, we found a short-lasting pro-inflammatory response of the 
synovial tissue two hours after the SPION were injected i.a. and also a short-lasting 
pro-inflammatory response of the liver two hours after the particles were injected i.v. 
However, this response to the nanoparticles was only transient, since two days after 
the injection, no inflammatory effect was observed anymore. It is known that SPION 
can cause oxidative stress in cells [21], which can lead to activation of AP-1 and 
NFκB and eventually lead to the release of pro-inflammatory cytokines. We indeed 
found upregulated gene expressions of IL-6 and other pro-inflammatory cytokines, but 
not of TNFα. Remarkably, gene expression of IL-1β was also significantly elevated in 
the synovium after i.v. injection, but no signs of inflammation were seen on histology. 
This increased IL-1β expression can be caused by a mild inflammation of the blood 
vessel walls in the synovium. Synovial tissue is highly vascularized and nanoparticles 
may cause an activation of endothelial cells in the blood vessels [22]. An in vitro 
indication of the pro-inflammatory effects of SPION came from Laskar et al. [23]; they 
incubated M2 macrophages, which are known as the anti-inflammatory subtype, with 
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SPION and found a shift of M2 macrophages towards the more pro-inflammatory 
macrophage subtype, the M1. Kodali and co-workers [24] also found an impaired 
ability of macrophages, incubated with  SPION , in shifting from M1 to M2.
Whereas different research groups found activation of a variety of cell types after 
SPION incubation [14, 25], meanwhile other groups found no adverse effects. For 
instance, Cengelli et al. [26] used SPION to explore the option of these particles to 
be phagocytosed by specific cells in brain-derived structures. Inflammatory activation 
via nitric oxide of endothelial cells incubated with SPION was investigated, but they 
did not find higher nitric oxide levels, indicating no inflammatory activation of these 
cells. Also, when injecting these particles in naïve C57Bl/6 mice no side effects were 
observed, demonstrating in vivo biocompatibility. This indicates that effects can vary 
between different sizes and types of SPION and coating, but also between different 
cell types from different organs.
Although PVA is accepted as a safe polymer to use in humans, most studies are 
carried out with hydrogel implants coated with PVA [27, 28] and not with PVA in 
solution. We found, after injection of PVA alone, a short-term inflammatory effect that 
lasted one day, which was even more severe than the injection of SPION. From this 
we can conclude that PVA alone causes substantial inflammation, but when PVA is 
coupled to a nanoparticle it becomes less inflammatory. 
Since it is difficult to detect LPS contamination in vitro in nanoparticle samples [29], 
we used TLR4-/- mice to test for LPS contamination in our experimental in vivo setup. 
LPS can bind to TLR4, causing a release of pro-inflammatory cytokines as TNFα 
and IL-1β [30-32]. Upon SPION injection into TLR4-/- mice, similar inflammatory 
responses were found as in C57BL/6 mice; hence this signaling was not mediated 
through TLR4, eliminating the possibility of LPS contamination. 
Because SPION provoke a pro-inflammatory response in naïve mice, it is also 
important to know if these nanoparticles aggravate existing inflammation, in this case, 
arthritis. Therefore, SPION were injected into a highly inflamed knee joint, which again 
caused a pro-inflammatory response in the synovium two days after SPION injection. 
However, this response was only detectable on gene expression, and was clearly less 
severe compared to SPION injection into a naïve knee joint. A similar response was 
observed in the liver upon systemic administration of nanoparticles: two hours after 
i.v. injection of SPION in arthritic mice, the liver responded by upregulating TNFα 
and IL-1β gene expression, but again this was less severe compared to naïve mice. 
Of clinical importance, these effects were no longer detected at day 7, 10 or 14 after 
SPION injection and were therefore regarded as transient and short-lasting. 
Effects of SPION on experimental arthritis ׀ 65
3
64 ׀ Chapter 3
There are also indications that SPION can cause a downregulation of pro-inflammatory 
genes [24, 33], and a subsequent diminishing of inflammation might therefore be 
expected. At the later time points of our animal study, we indeed reported lower gene 
expression levels of IL-1β, but not of TNFα, in the liver after i.v. injection of SPION 
into arthritic mice. Wu et al. [34] also reported a suppressed production of IL-1β, but 
not TNFα, in LPS stimulated microglia cells, that were subsequently incubated with 
SPION. However, we did not observe a decrease nor increase in the course of arthritis 
between SPION injected and PBS-control injected animals at these time points. In 
addition, no effect was observed on histology or serum cytokine concentrations, even 
though the SPION were shown to be still present in the arthritic joint as seen on MRI 
and confirmed by Prussian blue stained histological sections. 
Conclusions
Injection of a high dose of SPION for the MR imaging of joint inflammation causes an 
inflammatory response that is more pronounced in naïve mice compared to arthritic 
mice, while the low dose of SPION did not elicit a response. In the long term, up to 14 
days after the injections, no adverse effects appear and the injection of SPION does 
not influence the course of arthritis. Therefore, we conclude that PVA-coated SPION 
can be used safely to detect joint inflammation by in vivo MR imaging.
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Abstract
Introduction
Erosion of cartilage occurs within the first two years of rheumatoid arthritis and is 
highly variable within and between patients, which makes a patient-tailored treatment 
difficult but necessary. Molecular imaging using collagen type II antibodies may be 
a valuable tool to detect early cartilage destruction. For this purpose we developed, 
and selected an antibody from a panel of anti-collagen type II monoclonal antibodies 
based on its binding to damaged cartilage explants.
Material and Methods
A panel of different monoclonal antibodies directed against bovine collagen type II 
were developed using the hybridoma technology. Bovine cartilage explants were 
treated with various concentrations of trypsin (from 0% to 2.5%) to induce different 
degrees of cartilage destruction. From these experiments one candidate antibody 
was selected and used for further investigation. Bovine cartilage explants as well as 
explants from human pathologic cartilage were used for in vitro binding and blocking 
studies. 
Results
Bovine cartilage explants treated with various concentrations of trypsin showed that 
2,5% trypsin induced maximum proteoglycan (PG) depletion and strong staining of 
DIPEN neo-epitope in aggrecan, but no erosions. Anti-collagen type II antibody 7 
(CIIAb7) strongly bound to trypsin treated cartilage when compared to non-damaged 
cartilage and isotype matched control IgGs. CIIAb7 also strongly bound to human PG 
depleted cartilage. 
Conclusion
CIIAb7 binds to damaged bovine and human cartilage. Therefore, CIIAb7 might  be 
a promising antibody for molecular imaging of proteoglycan loss and/or targeted 
delivery in the early stages of rheumatoid arthritis.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory and autoimmune disease 
characterized by synovial inflammation and destruction of cartilage. Cartilage erosion 
develops in many RA patients within the first two years of the disease [1]. During 
the first phase of RA, cartilage proteoglycans are depleted. This early cartilage 
damage is reversible and is caused by a combination of a diminished proteoglycan 
content and a deregulation in the function of chondrocytes [2]. Abnormal proliferation 
of the synovium, known as pannus formation, is a crucial event in the development 
of cartilage damage [3]. The inflamed synovium produces proteoglycan degrading 
enzymes (proteases) and destructive cytokines. Matrix-metalloproteinases (MMP) 
can also degrade collagen type II, causing irreversible breakdown of the cartilage 
collagen network [4]. Van Meurs et al. [5] showed that interleukin (IL)-1 also causes 
cartilage damage by stimulation of MMP activity in cartilage.
Various studies have shown that initiating effective therapy within the first 2 years of 
clinical symptoms leads to a better long-term disease outcome [6-8]. However, RA is 
a heterogeneous disease with large variations in the pathogenetic processes taking 
place within the individual patients and between patients. Moreover, inflammatory 
and destructive mechanisms may be uncoupled [9]. The onset and course of RA, rate 
of progression of joint damage and response to therapy are different for each patient, 
making patient stratification and a patient-tailored treatment approach desirable. 
One indirect approach for measuring early cartilage destruction is detection of 
inflammatory cells which have been shown to correlate with development of joint 
destruction [3]. Binding proteins like antibodies or nanobodies have been used 
for detecting receptors on macrophages or endothelial cells [10]. A more direct 
approach for imaging cartilage destruction would be the detection of cartilage matrix 
components which become accessible after cartilage damage. The cartilage matrix 
consists of a network of collagen type II in which proteoglycans are embedded. In 
intact cartilage, the collagen network is completely shielded by proteoglycans and not 
available for binding to e.g. antibodies. During early RA, proteoglycans are degraded 
by metalloproteinases and can be targeted by cationic molecules like 99mTc-N-
(triethyl(ammonium)-3-propyl-[15] ani-N5 (NCP) which will visualize cartilage erosion 
[11]. However, detection of even earlier damage would be of more benefit as timing 
of effective treatment is essential for the outcome and for prevention or retardation of 
joint damage. The superficial zone of the cartilage containing the denuded collagen 
fibers exhibit the first signs of severe destruction. This may form an interesting target 
that can be visualized using specific antibodies. 
Various imaging modalities such as radiography, computed tomography (CT), 
ultrasonography and magnetic resonance imaging (MRI) can visualize cartilage 
destruction [12], but those techniques are not very sensitive. For more selective 
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molecular imaging of cartilage, cartilage specific antibodies can be used in combination 
with a specific marker, such as a fluorescent label or a superparamagnetic iron oxide 
nanoparticle (SPION).
In the present study we developed recombinant antibodies against collagen type II 
that specifically bind to the exposed collagen fibers in damaged cartilage of different 
species and that can be used for detection of early cartilage destruction in RA using, 
for instance, MR-imaging. We selected and validated a candidate antibody (CIIAb7) 
using healthy and damaged bovine cartilage as well as damaged human cartilage. 
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Material and Methods
Cartilage specimen
Full thickness bovine articular cartilage explants were aseptically dissected from 
the metacarpophalangeal joint of young bulls (1–2 years) and placed in PBS (Life 
Technologies, Merelbeke, Belgium). Human cartilage was collected from patients with 
severe cartilage destruction undergoing total knee arthroplasty or from patients suffering 
a femoral neck fracture of the hip. After collection, cartilage explants of approximately 
4 x 4 mm were cut and placed in PBS. The Medical Ethics Committee of Radboud 
University Nijmegen Medical Centre approved the study protocol.
Hybridoma derived anti-collagen type II antibodies
Antibodies against bovine collagen type II have been raised in Balb/c mice by 
ModiQuest. In short: At day 52 of the immunization procedure with bovine collagen 
II, serum samples were analyzed for bovine collagen type II reactivity. Spleens of 
responder mice were dissected following a final booster. Splenocytes were harvested 
and fused with a mouse myeloma cell-line (NS-1) using electrofusion. Supernatants of 
the resulting hybridoma cell lines were analyzed for collagen type II reactivity.  A panel 
of primary clones have been selected and subcloned either by the use of limited dilution 
techniques or by ClonePix FL (Molecular Devices) automated subcloning device in 
order to ensure clonality. Resulting anti-collagen type II antibodies were purified from 
the culture medium of the corresponding hybridoma cell lines using AKTA-FPLC 
machines in combination with protein-A agarose packed columns. 
Radiolabeling of antibodies with 125I and 111In
125I labeling: collagen type II antibodies and an isotype control IgG2b antibody were 
radiolabeled using the chloramine-T method. Hypochlorite released from chloramines 
T acts as an effective oxidizing agent for iodine to form iodine monochloride which 
undergoes electrophilic substitution with aromatic rings in amino acid tyrosine. 125I 
protein was separated from free 125I by sephadex G-25 fractionation. The specific 
activity was 3 µCi/µg. 
111In labeling: collagen type II and isotype control antibodies were dissolved in 0.25 M 
ammonium acetate, pH 5.4. For radiolabeling, 70 μg of antibodies was incubated with 
260 Mbq of 111In-oxine (Covidien BV) in 0.1 M 2-(N-morpholino) ethanesulfonic acid 
buffer ,pH 5.4 (twice the volume of 111In), for 15 min at 90oC. After incubation 50 mM 
EDTA was added to a final concentration  of 5 mM. Subsequently , the reaction mixture 
was purified on a PD10 column, eluted with PBS containing 0.5% BSA. 111In collagen 
type II and isotype control antibody was diluted in PBS containing 0.5% lysozyme. 
Labeling efficiency and radiochemical purity were determined with ITLC and HPLC.
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Detection of MMP activity in human cartilage explants
Cartilage explants from damaged human cartilage were cut into pieces. A commercially 
available fluorescent probe MMPsense 680 (Perkin Elmer, Massachusetts, USA) 
was used to image the MMP activity on the surface of the human explants. The 
MMPSense 680 can be activated by various MMPs (2, 3, 12 and 13), known to 
degrade collagen and proteoglycans during arthritis. MMPsense was diluted 70 times 
in PBS and cartilage specimen were incubated for 2 hours at 37oC and additionally 
placed inside the light-tight chamber and imaged with the IVIS Lumina (Caliper Life 
Sciences), using the Cy5.5 filter. The collected data were analyzed and quantified 
using Living Image 3.0 (Caliper Life Sciences).  
In vitro cartilage binding studies 
Bovine and human cartilage explants were cut and placed into PBS in 24-wells 
plates, each well contained 3 randomly picked explants. Bovine cartilage explants 
were treated with various concentrations of trypsin (0%, 0.6%, 1.25% and 2,5%) in 
PBS for 1 hour at 37⁰C. Thereafter, trypsin was inactivated by incubating the explants 
with 1% fetal calf serum in PBS for 15 minutes and were then thoroughly washed. 
Explants were incubated for 3 hours with 5µg/ml of 125I or 111In labelled antibodies at 
37⁰C or with 5µg/ml HRP labelled antibodies overnight at 4⁰C. Thereafter, explants 
were washed in PBS and standard-sized pieces were obtained using a 3 mm 
punch (Stiefel Laboratories, Coral Gables, Florida, USA). This also eliminated the 
unintended binding of antibodies to exposed collagen as a result of the dissection 
of the explants. Explants were then counted for activity in a gamma-counter and 
analyzed using RiaCalc WIZ program 3.6. Explants incubated with HRP labelled 
antibodies were incubated with DAB for 10 minutes and then washed with water. 
Thereafter photographs were taken and the mean staining intensity corrected for total 
area was calculated using ImageJ software.
Histology 
Mice knee joints were isolated, fixed in phosphate buffered 4% formaldehyde, 
decalcified with 5% formic acid, dehydrated and embedded in paraffin. Bovine 
and human cartilage explants were fixed in phosphate buffered 4% formaldehyde, 
dehydrated and embedded in paraffin. Serial sections of 7µm were made and stained 
with Safranin-O to assess cartilage destruction and proteoglycan depletion.
Immunohistochemical DIPEN staining
For DIPEN immunostaining, sections of mouse knee joints and bovine cartilage explants 
were deparaffinized, rehydrated and digested with proteinase-free chondroitinase 
ABC to remove the side chains of the proteoglycans. Subsequently, sections were 
treated with 1% hydrogen peroxide, 1,5% normal goat serum, and affinity purified 
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rabbit anti-DIPEN IgG (Kindly provided by John Mort, Montreal, Canada). Thereafter 
sections were incubated with biotinylated goat anti-rabbit, and avidin-streptavidin-
peroxidase (Elite kit, Vector Labs, Burlingham, CA, USA) staining was performed. 
Counterstaining was done with orange G. 
Statistical analysis
Statistical differences were calculated by one-way ANOVA using GraphPad Prism 
software version 5. P values less than 0.05 were considered significant.
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Results
Selection of collagen type II antibodies on binding to damaged bovine cartilage
A panel of  murine monoclonal antibodies were developed against bovine collagen 
type II. Bovine cartilage explants were damaged using 2.5% trypsin and subsequently 
incubated with a subset of eight different anti-collagen type II antibodies labeled with 
125I. Binding of 3 out of 8 antibodies to the damaged cartilage was significantly higher 
compared to binding of the isotype control antibody, namely antibodies 6 (p<0.01), 7 
(p<0.0001) and 8 (p<0.0001) (figure 1). Because of their high binding affinity, CIIAb7 
and CIIAb8 were selected for further investigation. 
Figure 1: Binding of 8 different 125I labeled 
collagen type II antibodies and an isotype 
control antibody to bovine cartilage 
explants. Well-defined bovine cartilage 
explants were damaged by 2.5% trypsin 
treatment and additionally incubated with 
125I labeled antibody (1 mg/ml). Three out 
of 8 collagen type II antibodies showed 
higher binding to damaged cartilage when 
compared to the isotype control. n=6 per 
group, ** p<0.01, *** p<0.0001 when using 
a one-way ANOVA.
In order to obtain variable stadia of destruction, bovine explants were incubated 
with various concentrations of trypsin (0, 0.6%,1.25% and 2.5%). The damage 
caused by the trypsin was well defined using safranin-O staining (figure 2 A-D) and 
immunohistochemical detection of DIPEN (figure 2 E-H), a neoepitope in the aggrecan 
core protein that is cleaved by different MMPs. Gradually more safranin-O staining 
was lost when using a higher concentration of trypsin, reflecting more depletion of 
proteoglycans and thus cartilage destruction. Complete  depletion of proteoglycans 
was only found after incubation with 2.5% trypsin. Trypsin treatment also induced a 
concentration dependent increase in DIPEN neoepitope staining. DIPEN was detected 
in and around chondrocytes and within the cartilage matrix. Optimal DIPEN staining 
was found after using 2.5% trypsin. Non treated cartilage showed low PG depletion 
and only minor DIPEN staining was observed within the chondrocyte. Next, explants 
of bovine cartilage treated with different concentrations of trypsin were incubated with 
CIIAb7 or CIIAb8, and binding capacity was visualized using antiIgG2b peroxidase 
antibodies and DAB (figure 2 I). As CIIAb7 showed a concentration dependent 
increase and already major binding to 0.6% trypsin damaged cartilage (figure 2 J), 
this antibody was selected for further imaging studies.
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To test the specificity of CIIAb7, a blocking study was performed (figure 3). Co-
incubation with excessive amount of soluble collagen type II protein blocked binding 
of CIIAb7 to cartilage completely. This means that binding to cartilage using this 
antibody is through recognition of collagen type II.
Figure 2: Immunolocalization of the two best binding collagen type II antibodies (CIIAb7 and CIIAb8) to 
cartilage explants varying in matrix damage. A-H: To obtain different stages of damage, explants were 
incubated with different concentrations of trypsin (0%, 0.6%, 1.25% and 2.5%). Note that the increase in loss 
of red staining, reflecting PG depletion, and DIPEN staining is correlated with higher trypsin concentrations. 
Maximal PG depletion and DIPEN staining was observed using 2.5% trypsin. I-J: Immunolocalisation 
showed that CIIAb7 was the best binder, while significant binding was already observed in 0.6% trypsin 
treated cartilage and the binding showed a concentration dependent pattern.  Therefore, this antibody was 
used in further studies. Original magnification 100x.
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CIIAb7 also binds to damaged human cartilage
Next we investigated whether CIIAb7 was also able to bind to damaged human 
cartilage. Explants from human cartilage were incubated with MMPsense, an 
activatable fluorescent probe detecting a range of active MMPs. Analysis was done 
by imaging and quantification of the MMPSense fluorescence signal, using the IVIS 
Lumina. Thereafter, the explants were histologically stained using safranin-O, to 
visualize PG depletion and cartilage damage. We found that the explant which showed 
a strong fluorescent signal was severely damaged, as seen by massive fissuring and 
erosion of the cartilage surface and an increased PG depletion. The two explants that 
showed a low MMPsense signal showed less PG depletion and almost no fissuring or 
erosions (figure 4 A-E). To investigate if CIIAb7 is also able to bind to damaged human 
cartilage, explants were incubated with CIIAb7 or the control antibody labeled with 
111Ind. Binding of the CIIAb7 to damaged cartilage from arthroplasty was significantly 
raised, when compared to the isotype control (figure 4 F). These results indicate that 
CIIAb7 cross reacts with epitopes also present in human collagen type II and apart 
from bovine, also effectively binds to damaged human cartilage as well.
Figure 3: Blocking study of CIIAb7, using free collagen type II. A significant decrease in antibody binding 
was found after incubation of CIIAb7 with an excess of free collagen type II. This applies to explants 
incubated with either 0% or 2.5% trypsin. n=6 per group, *** p<0.0001 using a one-way ANOVA.
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Figure 4: A-E: Human explants from patients with severe cartilage damage (CD) or a femoral neck 
fracture (FNF) were incubated in MMPSense solution. The fluorescence signal, reflecting MMP activity 
and coming from the surface of the cartilage, was measured and quantified using an IVIS Lumina (A and 
E). Additionally PG depletion was analysed using histology (B-D). Note that the high fluorescence signal 
correlated to severe erosions and PG depletion in the cartilage explants. F: CIIAb7 and isotype control 
antibody were labeled with 111Ind and incubated with human cartilage explants. Significantly more binding 
was found using CIIAb7 compared to the control antibody. Binding of CIIAb7 was also significantly higher 
in explants with severe cartilage damage, compared to explants from femoral neck fracture. CD: cartilage 
damage, FNF: femoral neck fracture Mean+/- SEM. n=5 per group, *** p<0.0001 when using a one-way 
ANOVA. Original magnification 100x.
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Discussion
In the present study we demonstrate a technique to select a novel anti-collagen type 
II monoclonal antibody that can be used as a tool for molecular imaging of cartilage 
destruction.  Accurate quantification of disease progression of RA is a decisive factor 
during treatment. Molecular imaging may become a powerful tool in diagnosing 
a disease, screening the efficacy of a therapy and facilitating the development of 
personalized medicine. Current clinical molecular imaging approaches use MRI 
or PET/SPECT based techniques [13-15]. Focus thereby lies on the detection of 
receptors on inflammatory cells which are involved in joint damage during RA, like 
endothelial cells or macrophages. Targeting of E-selectin expressed by endothelial 
cells[16] or F4/80 [17], folate receptors [18] or macrophage mannose receptor [10] 
expressed by macrophages, showed that higher signals were correlated to elevated 
joint inflammation in experimental RA. Macrophages can be tracked using SPION 
and MR-Imaging [19]. Although above markers give a good indication of the severity 
of joint inflammation they are not always correlated to cartilage destruction. 
In the present study we trace lesions in the damaged cartilage matrix by detecting 
the availability of free collagen type II. In healthy cartilage, collagen type II is shielded 
by proteoglycans and not available for binding, but during rheumatic disease activity 
these proteoglycans are depleted and free collagen type II becomes available [20]. 
The bindings capacity of collagen type II antibodies was tested in trypsin treated 
bovine cartilage. This method was already successfully used before [21]. Trypsin 
can be an activator of latent MMPs [22] which may be within the cartilage matrix in a 
latent proform and may explain the abundant PG depletion and DIPEN neoepitopes 
found in and around chondrocytes and in the cartilage matrix. DIPEN staining within 
the chondrocyte is probably a result of internalization by CD44 and has been shown 
to be dependent on hyaluronic acid [23]. DIPEN neoepitopes within the cartilage 
matrix reflect MMP activity which precedes irreversible matrix erosion. Some DIPEN 
staining was also detected in chondrocytes of untreated bovine cartilage suggesting 
that remodeling of PGs did already occur in vivo or was the result of the isolation 
procedure.
From a panel of different anti-collagen II antibodies, CIIAb7 was selected as the 
best molecule to further investigate its potential for molecular imaging of damaged 
cartilage. CIIAb7 showed a concentration dependent binding to trypsin treated bovine 
cartilage. This correlated also to the concentration dependent PG depletion and 
DIPEN staining. To verify the specificity of CIIAb7, a blocking study using an excess 
of free collagen type II was done. Binding of CIIAb7 to the cartilage was completely 
blocked by the free collagen, indicating  specific binding to collagen type II.
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Molecular imaging is increasingly used in the clinics nowadays to diagnose and 
monitor disease activity [24]. Consequently, it is also important that our candidate 
antibody binds to epitopes in human collagen type II. Therefore we investigated 
the binding capacities of CIIAb7 to damaged human cartilage. Because MMPs are 
important in the process of cartilage degradation, we investigated MMP activity in 
the human cartilage explants using an activatable fluorescent probe. Previously we 
showed that this probe significantly correlated to PG depletion and DIPEN staining 
using the collagen-induced arthritis model [25]. Indeed, using damaged human 
cartilage explants, a higher fluorescent signal was found in an explant that has more 
fissures, erosions and PG depletion compared to other explants. Jones et al. [26] used 
the same technique to characterize human osteoarthritic cartilage and compared 
molecular imaging of MMP activity with imaging of actual cartilage damage using 
magnetic resonance imaging. They also found a correlation between PG depletion 
and the presence of active MMPs in human cartilage explants. CIIAb7 was also 
used to detect cartilage damage in human cartilage explants. These explants were 
obtained from patients suffering from severe cartilage damage or a femural neck 
fracture, undergoing joint replacement surgery. Binding of CIIAb7 was in both groups 
significantly higher compared to the control antibody. 
Hughes et al. [27] also showed binding of an antibody to damaged cartilage. They 
used fluorescence imaging to visualize the antibody that was specific for cartilage 
damaged by reactive oxygen species. In further studies Hughes et al. [28] fused viral 
interleuk-10 with a MMP cleavable linker to this antibody to treat AIA. They found 
a reduction in knee thickness and evidence on histology that the antibody targeted 
the cartilage and also released the viral interleukin-10 to diminish arthritis. Another 
promising study was done by Cho and colleagues [21], where immunoliposomes, 
containing a fluorescent marker, were conjugated with an antibody directed against 
collagen type II. These immunoliposomes were injected in older guinea pigs suffering 
from spontaneous osteoarthritis. Fluorescent imaging showed an accumulation of the 
immunoliposomes in the affected joint. Comparison with histological data confirmed 
binding of the immunoliposomes to areas with damaged cartilage. These results are 
promising for patient tailored treatment of arthritis.
Our CIIAb7 binds specifically to damaged and not intact mouse, bovine, and human 
cartilage. This suggests that the collagen type II epitope to which the antibody is 
directed is (structurally) conserved throughout the three species. The advantage 
of our approach is that the antibody can be selected using trypsin treated bovine 
cartilage explants and human cartilage explants and then may further be tested in 
vivo. This antibody can be used in vivo for detection of proteoglycan loss of cartilage 
and potentially for targeted drug delivery to the arthritic joint.  
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Abstract
Rheumatoid arthritis (RA) and Osteoarthritis (OA) are serologically and clinically 
distinctive, but at local level both diseases have many molecular pathways in 
common. In vivo molecular imaging can unravel the local pathological processes 
involved in both diseases. In this study we investigated matrix-metalloproteinases 
(MMP) and cathepsin activity during cartilage destruction, in an RA and OA mouse 
model, using biophotonic imaging of substrate-based probes. Mice with collagen-
induced arthritis (CIA) or destabilization of the medial meniscus (DMM) were imaged 
using near-infrared fluorescent probes, activated by several cathepsins or MMPs. 
Fluorescence signal intensity was compared to synovial gene expressions, histology, 
and a cartilage staining of a neoepitope of aggrecan cleaved by MMPs of the amino 
acids DIPEN. Increased cathepsin and MMP activity was seen during CIA, while the 
DMM model only showed increased MMP activity. DIPEN expression was only seen 
during CIA. A possible explanation can be differences in gene expressions; MMP3 
and -13, known to produce DIPEN neoepitopes, were upregulated in the CIA model, 
while MMP12, known to be involved in elastin degradation and chemokine inhibition, 
was upregulated in the DMM model. Thus, molecular imaging showed no cathepsin 
activity at the time of cartilage damage in the DMM model, while both cathepsins and 
MMPs are active in the CIA model during disease progression.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease which is characterized by 
chronic inflammation and connective tissue destruction of synovial joints, leading 
to loss of function. Inflammatory and immune cells invade the synovial tissue and 
release a variety of mediators as cytokines, proteases, growth factors and radicals 
that attack the cartilage and bone structure [1]. Osteoarthritis (OA), on the other hand, 
is a disease which is mainly characterized by a slow progressive destruction of the 
cartilage [2]. The exact cause of OA is unknown, but a rupture of the meniscus can 
already cause instability and subsequent cartilage damage [3].
Several imaging modalities are available to monitor disease progression in patients; 
acoustics to measure synovitis and cartilage edema, X-ray or MRI to measure bone 
loss and loss of cartilage by joint space narrowing, and MRI to detect soft-tissue 
pathology [4]. Additional techniques to measure molecular processes primarily used 
in preclinal research are SPECT and PET, using radioisotopes, and biophotonic 
imaging, using fluorescent probes [5]. The advantage of the latter is that enzyme 
activities can be assessed using quenched fluorophores that become activated upon 
enzymatic cleavage.
During RA a variety of proteases are upregulated in the inflamed joint, including 
different cathepsins [6,7] and matrix metalloproteinases (MMP) [8]. Cathepsins are 
lysosomal proteases able to degrade collagen. Cathepsin S is secreted by tissue 
macrophages and is involved in extracellular matrix (ECM) degradation. It has been 
shown that mice with cathepsin S deficiency are less susceptible to Collagen Induced 
Arthritis (CIA), indicating an important role for cathepsin S in the development of 
this model [9]. On the other hand, cathepsin L and K are known to be involved in 
osteoclastic bone degradation [10]. Cathepsin B, L, and S are all abundantly found 
in the synovial fluid and the lining tissue of arthritic joints [7,11]. Differences are seen 
between the macrophage-like cells, called type A synoviocytes, and the fibroblast-like 
cells, called type B synoviocytes, in expression of cathepsins. Cathepsin K is mostly 
expressed in type B synoviocytes whereas cathepsin S is mostly expressed in type A 
synoviocytes [12].
Lower cathepsin expressions are seen in OA compared to RA [12,13]. In a study 
of Lai et al., 2004 [14], cathepsin B was used as a marker of collagenase-induced 
OA. They showed that, using a cathepsin B sensitive Near-Infrared (NIR)-fluorescent 
probe, a difference could be measured between osteoarthritic and normal joints. They 
therefore proposed that this method may provide a new strategy for early detection 
of osteoarthritis.
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The MMPs are a large group of zinc dependent enzymes known to degrade the ECM 
during both RA and OA, causing cartilage proteoglycan depletion and breakdown 
of the collagen network, leading to erosion. MMP2 and MMP9 belong to the 
gelatinases, while MMP13 belongs to the collagenases. MMPs are regulated in three 
ways; by transcriptional control, by pro-enzyme activation and by tissue inhibitors of 
metalloproteinases (TIMPs) [11].
During RA, MMPs are produced by chondrocytes and the cells of the synovium. MMPs 
can directly influence the cartilage, because of their ability to cleave components of 
the ECM. Also indirectly can MMPs influence the cartilage homeostasis; they affect 
chondrocyte function and therefore the maintenance of the cartilage. The amino acid 
sequence DIPEN is a neoepitope in the proteoglycan core-protein that is cleaved by 
MMPs, such as MMP13, and remains bound to hyaluronan in the cartilage [15] and 
on chondrocytes [16]. DIPEN can be visualized by immunostaining, and is nowadays 
known to represent MMP activity on histology. Interestingly, Mort et al., 1998 [17] 
showed that cathepsin B can also cleave aggrecan, and therefore produce the DIPEN 
neoepitope as well.
In this study we investigated cathepsin and MMP activity in the process of cartilage 
destruction, in both an RA and an OA model, using fluorescence imaging. CIA, a 
model displaying profound inflammatory cell influx and destruction, resembling RA 
was used. On the other hand, the DMM model, displaying cartilage destruction as an 
effect of the instability of the joint cause by the rupture of the meniscus, but with less 
inflammatory cell influx, was used to resemble OA. Geurts et al. 2011 [18] found no 
differences between human RA and OA synovial fibroblasts, when using hierarchical 
clustering of gene expression profiles. Using fluorescence imaging, we tried to unravel 
the local pathological processes involved in both diseases. The activity of MMPs 
and cathepsins in these two different processes of cartilage damage was monitored, 
using an activatable NIR-fluorescent probe and this may predict the amount of 
inflammation or cartilage damage caused during (osteo)arthritis. The CIA is a model 
that is highly dependent on interleukin-1 (IL-1) [19] and, by treating these mice with 
anti-IL-1 antibodies [20], we can also determine the sensitivity of the different probes 
to determine response to therapy. We showed that, using anti-IL-1 antibodies, the two 
probes are sensitive to treatment response, and that cathepsins are not active at the 
time of cartilage damage in the DMM model, while both cathepsins and MMPs are 
active in the CIA model during disease progression. 
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Materials and methods
Animals
For the CIA model, 12 week old male DBA1/J mice, and for the DMM model, 12 week 
old male C57Bl6/J mice were obtained from Janvier (Le Genest Saint Isle, France). 
All mice were housed in filtertop cages and food and water were supplied ad libitum. 
All in vivo studies complied with national legislation and were approved by the local 
authorities of the Care and Use of Animals.
Induction of experimental arthritis
Bovine type II collagen was dissolved in 0.05 M HAc to a concentration of 2 mg/ml 
and was emulsified in equal volumes of Freund’s complete adjuvant (2 mg/ml of M. 
Tuberculosis strain H37Ra; Difco laboratories, USA). For the imaging experiment 40 
mice were used. 6 non arthritic animals were used as controls. For RNA isolation and 
subsequent microarray, 18 mice were used. Mice were immunized intradermally at 
the base of the tail with 100 µl emulsion (100 µg of bovine collagen type II). After 21 
days an intraperitoneal (i.p.) booster injection with bovine type II collagen dissolved 
in phosphate buffered saline (PBS) was given. Clinical onset and progression was 
monitored by macroscopic scoring of the paws, on a scale of 0 to 2 for each paw, in a 
blinded fashion by two independent observers. Cumulative scoring based on redness, 
swelling, and, in later stages ankylosis was as follows: 0=no changes; 0.25=1-2 
toes red or swollen; 0.5=3-5 toes red or swollen; +0.5=swollen ankle; +0.5=swollen 
footpad; +0.5=severe swelling and ankylosis. Incidence at day 31 was calculated as 
percentage of positive animals from the total amount of animals used. Mean severity 
was calculated as the mean macroscopic score of all paws. At day 31 mice were 
imaged and sacrificed, ankle joints were processed for histology.
Induction of experimental OA
Destabilized medial meniscus OA was induced by transection of the medial anterior 
meniscotibial ligament as described by Glasson et al. [21]. Sham operations were 
included, which served as a control. For the imaging experiment 12 mice were DMM 
operated, together with 4 sham operated mice. For RNA isolation and subsequent 
microarray, 6 mice were DMM operated. At day 56 after surgery, mice were imaged 
and sacrificed, knee joints were processed for histology.
Anti-Interleukin-1α/β treatment
As a treatment, CIA mice were given an i.p injection with rabbit anti-murine IL-1α and 
anti-IL-1β serum (1 mg Ig’s each) at day 22 after immunization. This dose revealed 
to be sufficient to suppress several murine arthritis models [20]. As a control, mice 
received an i.p. injection with normal rabbit serum (2 mg Ig’s).
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Fluorescent agents
Two commercially available fluorescent probes (Perkin Elmer, Massachusetts, USA) 
were used to image the disease activity and efficacy of the treatment. The ProSense 
680 probe becomes activated upon enzymatic cleavage by cathepsins (B, L and S), 
which are collagen degrading lysosomal cysteine proteinases. The MMPSense 680 
can be activated by various MMPs [2, 3, 12 and 13), known to degrade collagen and 
proteoglycans during arthritis. 
Fluorescence imaging
CIA mice received an i.v. injection with either ProSense (n=16) or MMPSense (n=24, 
150 µl, 2nmol) at day 31 of the model. DMM or sham mice received an i.v. injection 
with either ProSense (n=4) or MMPSense (DMM; n=8, sham; n=4, 150 µl, 2nmol ) 
at day 56 of the model. At day 31 of the non-synchronized CIA model, the mice had 
a range of different disease severities, ranging from no clinical signs of arthritis to 
severe arthritis. This allowed to correlate the fluorescent signal intensities to arthritis 
severity. Day 56 of the DMM model was chosen, because this time point represents 
moderate to severe osteoarthritis [21] and at this time point no effects are seen 
anymore from the surgical procedure, while at week 4 sham operated animals also 
showed MMP activity due to wound healing (data not shown). At the time of imaging 
(6 hours post i.v. injection), mice were anesthetized with 2.5% isoflurane/oxygen, 
shaved, placed on their back inside the light-tight chamber and imaged with the 
IVIS Lumina (Caliper Life Sciences), using the Cy5.5 filter. The collected data were 
analyzed using Living Image 3.0 (Caliper Life Sciences). For the CIA model, two-
dimensional regions of interest (ROIs) were drawn around the ankle joints. For the 
DMM model, ROIs were drawn around the knee joints. Fluorescence signal intensity 
was measured and corrected for background and tissue autofluorescence by using 
blue-shifted background filters.
RNA isolation
For the CIA model, one synovial tissue sample from the lateral site and one from 
the medial site was isolated per knee joint, in a standardized manner using a 3 mm 
biopsy punch (Stiefel, Wachtersbach, Germany). Biopsies were taken from 12 non-
diseased and 12 arthritic knee joints, so 24 biopsies per group, in total 48 biopsies. 
Samples from both medial and lateral site were pooled in a randomized fashion to 
generate triplicates for each group, each triplicate consisted of eight biopsies. For 
the DMM model, 2 groups were made: DMM (right knee joints) and contralateral 
(left knee joints). Per knee joint one synovial tissue sample from the lateral site 
and one from the medial site was isolated in a standardized manner using a 3 mm 
biopsy punch. Biopsies were taken from 6 mice. Samples were pooled to generate 
triplicates, each triplicate consisted of four biopsies. Total RNA from the biopsies 
was prepared by TRIzol extraction (Invitrogen Life Technologies), and purified on 
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an affinity resin (RNeasy Kit, Qiagen) according to the manufacturer’s instructions. 
Quantity and purity were assessed by the absorbance at λ = 260 nm (A260nm) and the 
ratio A260nm/A280nm. Integrity of the RNA was confirmed by non-denaturing agarose gel 
electrophoresis. Total RNA was stored at -80 ˚C until further processing.
Oligonucleotide array
One microgram of total RNA was used as a starting material for cDNA preparation. 
Generation of biotinylated cDNA and subsequent hybridization, washing and staining 
of MOE 430_2 oligonucleotide arrays (Affymetrix, Santa Clara, CA) were performed 
according to the Affymetrix Expression Analysis Technical Manual for one-cycle 
amplification. The arrays were then scanned using a laser scanner GeneChip Scanner 
(Affymetrix), and data were analyzed and normalized using Affymetrix Microarray Suite 
(MAS) 5.0 software according to the manufacturer’s instruction. The gene expression 
data were deposited in the Gene Expression Omnibus database under accession 
number GSE13071.
Histology
CIA ankle joints and DMM knee joints were isolated, fixed in phosphate buffered 4% 
formaldehyde, decalcified with 5% formic acid, dehydrated and embedded in paraffin. 
Serial sections of 7µm were made and stained with Heamatoxylin/Eosin (HE) to study 
inflammatory cell influx, chondrocyte death, or stained with safranin-O to assess 
cartilage destruction and proteoglycan depletion. These histopathological changes 
were scored on an arbitrary scale ranging from 0-3 per joint. For the CIA model, 
of each mice both hind paw were examined. Cell influx (predominantly exudates of 
polymorphic neutrophils) was graded from 0 to 3 as follows: 0 = no inflammatory 
cells in joint cavity, 1 = a few inflammatory cells in joint cavity, 2 = joint cavity partly 
filled with inflammatory cells, 3 = joint cavity totally filled with inflammatory cells. 
Synovitis (characterized by monocyte and lymphocyte infiltration) was graded from 0 
to 3 as follows: 0 = healthy, uninflamed appearance of the synovium, 1 = mild influx 
of inflammatory cells into the synovial lining, 2 = substantial influx of inflammatory 
cells into the synovium, 3 = severe influx of inflammatory cells into the synovium. 
Destruction of cartilage was graded 0 to 3 as follows: 0 = normal appearance, 1 = 
minor destruction of the cartilage surface, 2 = clear loss of cartilage, 3 = cartilage 
almost absent. Chondrocyte death was graded 0 to 3 as follows: 0 = no chondrocyte 
death, 1 = some chondrocyte death, evident by empty lacunae in the cartilage, 2 = 
most places of cartilage have empty lacunae, 3 = no chondrocytes present, lots of 
empty lacunae. Proteoglycan depletion was graded 0 to 3 as follows: 0 = no loss of 
safranin-O red staining of glycosaminoglycans in the cartilage, 1 = some loss of red 
staining, 2 = moderate loss of red staining, 3 = total loss of red staining in the upper 
metabolically active layers of the cartilage (above the tidemark of the deeper calcified 
cartilage layer).
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Immunohistochemical DIPEN staining
For immunostaining, sections of CIA ankle joints and DMM knee joints were 
deparaffinized, rehydrated and digested with proteinase-free chondroitinase ABC to 
remove the side chains of the proteoglycans. Subsequently, sections were treated 
with 1% hydrogen peroxide, 1.5% normal goat serum, and affinity purified rabbit anti-
DIPEN IgG (Kindly provided by John Mort, Montreal, Canada). Thereafter sections 
were incubated with biotinylated goat anti-rabbit, and avidin-streptavidin-peroxidase 
(Elite kit, Vector Labs, Burlingham, CA, USA) staining was performed. Counterstaining 
was done with orange G. 
Statistics
Data are presented as mean ± standard error of the mean. Significance analysis was 
done using a two-tailed unpaired Mann-Whitney test when comparing two groups 
(GraphPad Prism, V 4.0).  Statistical correlations were made using the Pearson’s 
correlation coefficient. A p-value of <0.05 was regarded as significant.
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Results
Biophotonic imaging of local cathepsin protease activity in the CIA model
Mice immunized with collagen type II were imaged using the cathepsin-cleavable 
NIR-fluorescent ProSense probe. A strong fluorescent signal was measured from the 
inflamed paws (figure 1). In a separate study, a microarray analysis was performed on 
synovial tissue biopsies obtained from knee joints. The obtained fluorescence signal 
coincided with enhanced expression of the extracellular matrix degrading enzymes 
cathepsin-K (∼9-fold) and cathepsin-S (∼5-fold), as compared to non-diseased knee 
joints (table 1). Histologically, inflammatory cell influx can be seen in the joint space, 
as well as proteoglycan depletion in cartilage, seen as discoloration of the red stained 
cartilage layer. Empty lacunae in the cartilage represent chondrocyte death. (figure 
2). The extent of the fluorescence signal significantly correlated (Pearson r=0.81, 
p<0.001) with the amount of inflammatory cell influx in the ankle joint (table 2). The 
measured fluorescence signal intensity also correlated with other histological changes 
as proteoglycan depletion (r=0.78, p<0.01), but not with chondrocyte death (figure 3A) 
and cartilage erosion. This showed that the cathepsin activity in the arthritic joints, 
detected by the ProSense probe, is strongly correlated with synovial inflammation.
Table 1. Differences in upregulation of genes between the arthritic collagen-induced arthritis model 
and the osteoarthritic destabilization of the medial meniscus model. Gene expressions in synovial 
biopsies from knee joints of CIA at day 10 after booster, and in synovial biopsies from knee joints at day 
56 of the DMM model. MMP12 is the only MMP upregulated in the DMM model, while in the CIA model 
MMP13, -3 and -2 are upregulated. This reflects different processes during cartilage damage in the DMM 
model, compared to the CIA model. Depicted as fold increase compared to joints of non-diseased (CIA) or 
non-operated animals (DMM). 
CIA# day 10 DMM+ day 56
 ProSense 
Cathepsin B 3.3 1.2
Cathepsin S 4.7*** 2.4
Cathepsin L 2.6 1.0
Cathepsin K 9.0** 3.3*
MMPSense 
MMP13 21.9** 1.3
MMP12 <1.2 19.6**
MMP3 12.8** 2.1
MMP2 4.7** 1.3
#: Collagen-induced arthritis model, +: destabilization of the medial meniscus model, ***: p<0.001, **: 
p<0.01, *: p<0.05
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Figure 1. Cathepsin and MMP activity is significantly higher in arthritic animals. A-C: Fluorescent 
signal intensity as measured by IVIS, using ProSense or MMPSense was higher in arthritic versus control 
animals (p<0.05 for both ProSense and MMPSense measurements). This reflects higher cathepsin and 
MMP activity in hind paws of arthritic animals. B-D: Histological staining of ankle joints from arthritic animals 
with corresponding pictures of fluorescent imaging using ProSense or MMPSense. Influx of inflammatory 
cells, chondrocyte death and corresponding fluorescence signal intensity was higher in arthritic joints. 
Histological slides are representative for the corresponding fluorescent images. c: calcaneus, i: influx of 
inflammatory cells, arrowhead: chondrocyte death as presented by empty lacunae.
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Table 2. Correlation of the NIR-fluorescence signal with various histological parameters in the CIA 
model. Correlations between the NIR-fluorescence signal intensity and histological parameters were 
calculated using Pearson’s correlation coefficient. 
Pearson r 
ProSense group
Inflammation 0.81***
Chondrocyte death 0.44
Cartilage erosion 0.47
Proteoglycan depletion 0.78**
DIPEN staining 0.60*
MMPSense group
Inflammation 0.66***
Chondrocyte death 0.72***
Cartilage erosion 0.52**
Proteoglycan depletion 0.61**
DIPEN staining 0.74***
***: p<0.001, **: p<0.01, *: p<0.05
Figure 2. Histological staining of collagen-
induced arthritis in the ankle joint showed 
inflammation, cartilage damage and DIPEN 
expression. Histological staining of a non-
diseased joint (A,C,E) and a joint with CIA (B,D,F). 
A,B: safranin-O staining, more proteoglycan 
depletion can be seen in joints with arthritis. C,D: 
DIPEN neoepitope staining representing MMP 
mediated proteoglycan cleavage, with IgG control 
(insert). A strong DIPEN staining is present in joints 
with arthritis, no DIPEN staining is present in non-
diseased joints. E,F: haematoxylin eosin staining, 
cartilage destruction and chondrocyte death can 
be seen in joints with arthritis. C = calcaneus, CE: 
cartilage erosion, i: influx of inflammatory cells in 
the joint cavity, *: proteoglycan depletion, arrow: 
DIPEN staining, arrowhead: chondrocyte death, #: 
aspecific staining of inflammatory cells in the joint 
cavity.
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Figure 3. Fluorescent signal intensity of MMPSense, but not ProSense, correlated with chondrocyte 
death. A: No correlation can be seen between ProSense and chondrocyte death. B: A strong correlation 
can be seen between MMPSense and chondrocyte death. 
Biophotonic imaging of local cathepsin protease activity in the DMM model. 
Cathepsin activity was measured 56 days after surgical induction of the DMM model at 
time of joint pathology (figure 4A). No difference between contralateral and operated 
knee was seen, indicating no cathepsin activity during the osteoartritic process at 
this stage of the disease. The microarray analysis showed limited upregulation of 
cathepsin B (~1-fold), S (~2 fold) and K (~3 fold), and no upregulation of cathepsin 
L genes (table 1). This confirmed that the lack of fluorescence signal was due 
to low levels of local cathepsin expression. No inflammatory cell influx was seen 
histologically (figure 5), confirming the absence of inflammation seen with ProSense. 
Therefore, these results show that at this stage of the disease, no cathepsin activity 
was present in the knee joints.
Biophotonic imaging of matrix metalloproteinase activity in arthritic CIA joints
Matrix metalloproteinase activity in the arthritic joint was imaged using the MMP-
activatable MMPSense probe (figure 1C). Microarray analysis showed that MMP13 
was highly expressed (~22-fold) in the inflamed synovium, as well as MMP3 (~13-fold); 
also compared to MMP2, which was upregulated 5 times (table 1). The fluorescence 
signal of MMPSense correlated with the extent of cartilage proteoglycan depletion 
(r=0.61, p<0.01), joint inflammation (r=0.66, p<0,001), and cartilage erosion (r=0.52, 
p=0.01) (table 2). In comparison to the ProSense probe used in this study, the 
MMPSense correlated much better (r=0.72, p<0.001) with the histologically observed 
chondrocyte death (figure 3B). This shows that the MMPSense probe reflects MMP 
activity, which was strongly correlated with cartilage destruction.
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Figure 4. Biophotonic imaging of knee joints of the osteoarthritic destabilization of the medial 
meniscus model showed MMP activity, but no cathepsin activity, in osteoarthritic knee joints. 
A: Fluorescence signal intensity of the ProSense probe did not show a difference between DMM and 
control knee joints, indicating no differences in cathepsin activity. B: Fluorescence signal intensity of the 
MMPSense probe was measured in the unilateral DMM model and sham operated animals. The ratio 
between DMM operated and corresponding control knee joints is significantly higher compared to the 
ratio between sham operated and control knee joints. C: Representative fluorescence image of a DMM 
operated mouse, imaged with MMPSense. D: Representative fluorescence image of a sham operated 
mouse, imaged with MMPSense. E: Representative fluorescence image of a DMM operated mouse, 
imaged with ProSense.
Biophotonic imaging of matrix metalloproteinase activity in osteoarthritic DMM joints
MMP activity, in contrast to cathepsin activity, was significantly increased in 
osteoarthritic knee joints, compared to contralateral knee joints (figure 4B). This 
activation was not a result of the surgery itself, because no MMP activity was seen 
in sham operated animals. According to the microarray analysis from synovial tissue 
biopsies, MMP12 was indeed upregulated almost 20 times (table 1). MMPs are 
involved in cartilage damage, therefore histological sections were examined to confirm 
cartilage damage, which was indeed seen as fibrillations, fissures and sometimes 
complete loss of cartilage above the tight mark as shown by the arrows (figure 5).
DIPEN neoepitope formation in arthritic CIA and osteoarthritic DMM joints
Expression of DIPEN, a neoepitope in the proteoglycan core-protein that can be 
cleaved by MMPs, was visualized by immunostaining. More DIPEN staining was seen 
in arthritic joints, compared to non-diseased joints (figure 2). Staining was mostly 
seen in the chondrocytes but also in the damaged superficial cartilage. No differences 
in DIPEN staining were seen between contralateral and DMM knees, while cartilage 
damage was clearly present in DMM knee joints (figure 5). As expected, sham 
operated animals in the DMM model did not show DIPEN staining.
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Figure 5. Histological staining of destabilization of the medial meniscus operated knee joints showed 
cartilage damage, but no inflammation or DIPEN staining. Histological staining of non-operated joint 
(A,D,G), a sham operated joint (B,E,H) and a DMM operated joint (C,F,I). A,B,C: safranin-O staining, no 
differences in proteoglycan depletion can be seen between the different treatments, while cartilage loss is 
visible in the DMM operated knee joint. D,E,F: DIPEN neoepitope staining representing MMP mediated 
proteoglycan cleavage, with IgG control (insert). No difference in DIPEN staining can be seen between the 
different treatments. G,H,I: haematoxylin eosin staining, fissures, fibrillations and loss of cartilage can be 
seen in the DMM knee joint, while no OA features are visible in the control and sham operated joints. F = 
Femur, T = Tibia, arrow: cartilage erosion.
Table 3. Incidence, severity and fluorescence signal of collagen-induced arthritis at day 31 after 
immunization is lower in mice treated with neutralizing rabbit anti-murine IL-1αβ antibodies.
NRS# aIL-1+
ProSense group n=8 n=8
Incidence 63% 38%
Mean severity (0-2) 0.6 0.1*
Mean fluorescent signal IVIS (au) 0.186 0.055*
MMPSense group n=12 n=12
Incidence 83% 0%
Mean severity (0-2) 0.9 0.0***
Mean fluorescent signal IVIS (au) 0.139 0.036***
# Normal Rabbit Serum, + Rabbit anti-murine IL-1αβ antibodies, *: p<0.05, ***: p<0.001
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Anti-IL-1 treatment in the CIA model
Mice immunized with collagen type II were treated with anti-IL-1α/β polyclonal 
antibodies, as previously described [19]. Incidence and severity was suppressed by 
anti-IL-1 treatment (table 3). At day 31 after immunization, mice were imaged using 
the ProSense and MMPSense probe. A strong fluorescence signal was measured 
from the inflamed paws, whereas the signal was significantly lower in the group which 
had received the anti-IL-1 treatment (table 3). Analysis of the paws histologically 
confirmed the anti-inflammatory effect of IL-1 blockade and associated lower 
fluorescence signals in these mice (figure 6). The histological score of inflammation 
was 1.2 in normal rabbit serum (NRS) treated mice and 0.2 in anti-IL-1 treated mice. 
Also on histology, a reduction in chondrocyte death was seen; mice treated with NRS 
had a histological score for chondrocyte death of 1.1, while the anti-IL-1 treated mice 
had a score of 0.25. No DIPEN expression was seen in animals treated with anti-IL-1 
(figure 6). 
Figure 6. Histology and representative 
biophotonic imaging of anti-IL-1 
treated animals. Histological staining and 
representative fluorescent images of joints 
from anti-IL-1 treated animals, imaged with 
either ProSense (A,C,E,G) or MMPSense 
(B,D,F,H). A,B: safranin-O staining, no 
proteoglycan depletion can be seen upon 
anti-IL-1 treatment. C,D: DIPEN neoepitope 
staining representing MMP mediated 
proteoglycan cleavage, with IgG control 
(insert). There is no DIPEN neoepitope 
formation present in joints from anti-IL-1 
treated animals, E,F: haematoxylin eosin 
staining, no inflammation or chondrocyte 
death can be seen. C = calcaneus.
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Discussion
In this study we have shown, using NIR-fluorescence imaging, that MMPs are 
active during the process of irreversible cartilage destruction in both RA and OA 
experimental models. Cathepsin activity was only seen in the RA model. In the CIA 
model, inflammation and destruction are correlated, while the DMM model showed 
MMP activity without notable inflammation, suggesting a role for MMPs, but not for 
cathepsins in the DMM model.
CIA is characterized by a polyarticular chronic inflammation and the inflamed knees 
and paws can be imaged using NIR-fluorescent probes. The ProSense probe is most 
sensitive for cleavage by cathepsin B, an enzyme highly expressed in monocytes 
and dendritic cells and enhanced in the inflamed synovium [7]. On the other hand, 
cathepsin B is also proposed as a diagnostic marker for OA [14]. We found increased 
gene expression and enzyme activity of cathepsins in the inflamed synovial tissue and 
the arthritic joint in the CIA model. The signal intensity of ProSense was correlated 
with cartilage proteoglycan depletion illustrating the potential proteoglycan degrading 
activity as was shown for especially cathepsin L [22]. No cathepsin activity, and 
only a marginal upregulation of cathepsin genes, was found in the DMM model, 
corresponding to a limited role for cathepsins at this stage of the OA model. 
Like cathepsins, MMP levels are also lower during OA as compared to RA [23]. In 
our study, MMP upregulation was seen in both the CIA and the DMM model, on gene 
expression levels, and when using fluorescence imaging. The MMPSense probe is 
activated by a range of MMPs (MMP2, -3, -12, -13) and therefore does not distinguish 
between these different MMPs. Interestingly, when looking at the microarray, different 
MMPs are upregulated in the CIA model (MMP-2, -3 and -13), when compared to 
the DMM model (MMP-12). In the CIA model, the fluorescence signal intensity of 
the MMPSense probe seemed to correlate to chondrocyte death, while in the DMM 
model, the MMPSense signal is also upregulated, but there is no chondrocyte death. 
This can also be caused by the upregulation of different MMPs in the two models.
Aggrecan, a major proteoglycan in cartilage, can be cleaved by MMPs [15] 
or cathepsin B [17] between the first and second globular domain of the core 
protein, leaving a specific neoepitope of the amino acids DIPEN. The amount of 
DIPEN in cartilage is a marker of cartilage proteoglycan degradation, and can be 
immunohistochemically detected in cartilage of experimental models of arthritis [24]. 
Because no DIPEN staining was seen in early stages of CIA with mild proteoglycan 
depletion, as demonstrated with safranin O staining, van Meurs et al. [24] speculated 
about a limited role for MMPs early in disease. In later stages of CIA, with marked 
proteoglycan depletion, a strong DIPEN staining was visible at sites where cartilage 
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erosion was abundant. For this, DIPEN was considered as a marker of irreversible 
cartilage damage. Another group [25] also showed a delayed response of MMPs in 
cartilage explants; only after 12 days of culture the MMPs were activated and started to 
cleave aggrecan. We observed DIPEN expression in the CIA model, which correlated 
with MMP activity, measured by the fluorescent probe. Interestingly, we did not see 
DIPEN staining in the DMM model, while fissures, fibrillations and cartilage loss was 
confirmed histologically. This discrepancy can be caused by the differences between 
the strains of mice used in this study, the DBA1/J for the CIA model and the C57Bl6/N 
for the DMM model [26]. Another explanation can be the lack of cathepsin activity in 
the DMM model. Mort et al., 1998 [17] showed that cathepsins can cleave aggrecan 
by endo- and exopeptidase activity, and leave the DIPEN neoepitope in the cartilage. 
Because we only saw MMP activity and no cathepsin activity in the DMM model, this 
MMP activity may not be enough to activate DIPEN neoepitope formation. On the 
other hand, it is known that MMP-3 and -13 can produce the DIPEN neoepitope [27], 
while MMP-12 is mostly regarded as a MMP that is involved in elastin degradation 
and the inhibition of chemokines [28]. According to our microarray, MMP-3 and -13 
are upregulated in the CIA model, giving DIPEN expression, while only MMP-12 is 
upregulated in the DMM model, giving no DIPEN expression. It is also shown that 
MMP12 is mostly expressed by M2 macrophages [29], while Tsuneyoshi et al., 2012 
[30] showed that there are more M2 macrophages present in synovial tissue of OA 
patients, compared to RA patients. This can explain the upregulation of MMP12 in 
the DMM model, while on the other hand, no MMP12 upregulation was seen in the 
CIA model.
We previously have shown that CIA in mice is highly dependent on the cytokine IL-1 
and either treatment with neutralizing antibodies or with the IL-1 receptor antagonist 
can prevent onset and cure CIA in mice [19,20]. In the present study, IL-1 was used 
to investigate the sensitivity of the fluorescent probes to a treatment response. Both 
the ProSense and MMPSense signal was markedly lower in mice treated with anti-
IL-1 antibodies, reflecting lower cathepsin and MMP activity. As a consequence, 
effects of anti-IL-1 were also seen on histology; almost no inflammatory cell influx, no 
proteoglycan depletion as well as almost no chondrocyte death was present. Also, no 
DIPEN expression was seen. This is in line with the findings of van Meurs et al. [24]; 
they found that IL-1 is involved in DIPEN expression and therefore blocking IL-1 can 
prevent this neoepitope formation.  
We showed that NIR-fluorescent probes are useful tools to measure enzyme activity 
in the (osteo)arthritic joint in real-time and quantitatively. We demonstrated that the 
measured NIR-fluorescence signal intensity is correlated to pathological changes and 
can be used to monitor the anti-inflammatory effect of therapeutics as we showed for 
anti-IL-1 in this study. Furthermore, in experimental settings it can provide additional 
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information on the pathophysiology of arthritis, and in combination with histological 
evaluation of pathology and gene expression, it may provide new insight into the 
enzymes that are potentially involved in cartilage damage, as shown by DIPEN 
staining on histology.
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Abstract
Objective
To evaluate the applicability of a lentiviral (LV) Saa3-promoter luciferase (Luc) reporter 
for assessing inflammation in experimental arthritis, synovial fibroblasts (SF) from 
osteoarthritis (OA) and rheumatoid arthritis (RA) patients. 
Methods
In mice, synovium was transduced in vivo by cholesterol optimized LV and two flares 
of acute joint inflammation were induced by injection of streptococcal cell wall (SCW) 
material into the knee joint cavity. The time course of synovial inflammation was 
assessed using ex vivo luciferase assays, and histology. Uptake of 99mtechnetium 
(Tc) was used to assess edema. SF (n=12) of RA and OA patients were stratified by 
hierarchical clustering of whole genome expression profiles. Relative Saa3-promoter 
responses were determined in cytokine- or toll-like receptor-stimulated SF subgroups. 
Results
In vivo, the Saa3-promoter reporter activity was strongly upregulated at one and two 
days after the first and second SCW challenge. The Saa3-promoter activities during 
acute inflammation correlated with Tc uptake measurements, but was more sensitive 
and able to respond to the ongoing synovitis in the chronic phase of SCW arthritis. 
Molecular stratification defined two inflammatory SF subtypes, unrelated to disease 
classification. Relative Saa3-promoter responses to IL-1b, TNFa and TLR4 agonist 
were significantly increased in OA/RA SF with a high compared to a low inflammatory 
profile subtype. Serum stimulation of the Saa3-promoter reporter cell-line could 
discriminate between healthy and RA-patients. 
Conclusion
The Saa3-promoter reporter demonstrates a robust and feasible tool for assessing 
the course and severity of experimental arthritis and to distinguish molecularly distinct 
inflammatory SF subtypes from a heterogeneous patient population.
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Introduction
Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease that mainly 
affects the synovial joints that ultimately leads to joint destruction. Prior to and during 
joint inflammation the synovial lining tissue, consisting of synovial fibroblasts (SF) 
and macrophages, becomes activated. In both experimental and human arthritis, SF 
have been identified as cells that actively drive inflammation and joint destruction [1-
3]. Moreover, transmigration of activated RASFs has been implicated in mediating the 
spreading of destructive arthritis to unaffected joints[4]. Due to their key role in RA 
pathogenesis, SF are regarded not only as major target cells for treatment, but also for 
diagnostic assessment of disease activity or phenotype.
Non-invasive assessment of disease activity is frequently performed using 
radiographic agents such as 99mtechnetium pertechnetate (99mTc) [5]. Histological 
and immunohistochemical analyses of synovial tissue comprise the classic ex vivo 
methods for assessing the grade of inflammation and molecular pathology in human 
and experimental arthritis and have evidently pointed out that RA is a heterogeneous 
disease [6, 7]. Moreover, these have shown that disease heterogeneity is stably 
imprinted in SF and molecularly distinct inflammatory subtypes can be discerned. 
Gene expression is regulated at multiple levels including epigenetic, transcriptional and 
translational control. Transcriptional control is exerted by the differential activation of 
transcription factors (TF) and pivotal TFs implied in RA pathogenesis include nuclear 
factor-kB (NF-kB), activator protein-1 (AP-1) and CCAAT/Enhancer binding protein b 
(C/EBPb) [14-16].  Activity of TFs can be dynamically assessed using transcriptional 
assays based on expression of luminescent, fluorescent or enzymatic reporter genes 
driven by a promoter containing TF-response elements. Until now, the diagnostic 
potential of transcriptional reporters in RA has not been extensively investigated. 
Recently, we have designed a number of promoter-luciferase reporters, using gene 
expression profiling data of inflamed synovium in murine collagen-induced arthritis 
(CIA), that demonstrated responsive to experimental arthritis and inflammatory stimuli 
in human SF [17]. These reporters contained composite elements of AP-1, NF-kB 
and C/EBPb binding sites. Notably, we found an enrichment of C/EBPb-binding sites 
in the promoters of genes whose expression correlated with disease severity in CIA, 
in particular the promoter of serum amyloid A3 (Saa3). This led to the hypothesis 
that a Saa3-promoter reporter might serve as a novel diagnostic tool for assessing 
inflammatory subtypes in arthritis. 
Therefore, we performed kinetic analyses of Saa3-promoter activity in SCW arthritis 
and compared this novel method with 99mTc uptake and histological assessment of joint 
inflammation. In addition, we evaluated whether Saa3-promoter responses in SF would 
be able to discriminate between SF of low and high inflammatory expression profiles, 
as deduced by gene expression profiling. 
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Materials And Methods
Animals
C57Bl/6 mice were obtained from Janvier (le Genest-Saint-Isle, France). During viral 
experiments, mice were housed in HEPA filtered individually ventilated cages. The 
animals were fed a standard diet with food and water ad libitum. All in vivo studies 
complied with national legislation and were approved by the local authorities of the 
Care and Use of Animals.
SCW preparation and induction of SCW arthritis
Streptococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. 
Cell walls were prepared as described previously [18]. Uni- or bilateral arthritis was 
induced by intra-articular injection of 25 mg of streptococcal cell wall (SCW) fragments 
(rhamnose content) in 6 ml of phosphate buffered saline (PBS), respectively, into 
both or only the right knee joints of naive mice.
Assessment of joint inflammation by 99mTc-uptake
Joint inflammation was quantified by 99mTc uptake in knee joints as described previously 
[5]. Briefly, animals were sedated by intraperitoneal administration of chloral hydrate. 
Approximately 20 mCi 99mTc in 200 ml saline was injected subcutaneously and after 
15 minutes the accumulation of the isotope was determined by external gamma 
counting. The severity of inflammation is expressed as the ratio gamma counts of the 
inflamed (right) over the contralateral joint. Ratios larger than 1.1 are considered as 
inflammation.
Histology
Whole knee joints were isolated at day one or six after SCW challenge and fixed in 
4% paraformaldehyde for 4 days. After decalcification in 5% formic acid, specimens 
were processed for paraffin embedding. Tissue sections (7 mm) were stained with 
haematoxylin and eosin. Histological changes were scored in the patella/femur region 
on five semi-serial sections of the knee joint, spaced 70 mm apart. Scoring was 
performed by two observers without knowledge of the group. Infiltration of cells was 
scored on a scale of 0-3, depending on the amount of inflammatory cells in the joint 
cavity (exudate) or synovial tissue (infiltrate).
Patients and samples
Synovial tissue was obtained from RA and osteoarthritis (OA) patients undergoing 
open joint replacement surgery. Human sera was obtained from RA patients (Nijmegen 
Inception Cohort of Early Rheumatoid Arthritis) and age-matched (40-70 year) 
healthy blood donors (Sanquin Bloedbank, Nijmegen, The Netherlands) were used 
as controls. RA and OA patients were classified according to the ACR criteria[19]. 
Assessment of inflammation by the Saa3 promoter reporter ׀ 109
6
108 ׀ Chapter 6
The local Medical Ethics Committee and that of University Hospital Jena approved 
the study protocol. SF were purified from synovial tissue as previously published [20]. 
Briefly, the tissue samples were minced, digested with trypsin/collagenase p (Sigma, 
St. Louis, MO), and the resulting single cell suspension cultured for seven days. Non-
adherent cells were removed by medium exchange. SF were negatively purified using 
Dynabeads M-450 CD14 (Invitrogen, Carlsbad, CA). 
Oligonucleotide arrays and clusteranalyis
Second passage SF were used for oligonucleotide arrays as described in detail 
previously [9, 19].
Plasmids
For generation of recombinant lentiviral vectors we made use of the third-generation 
self-inactivating transfer vectors pRLL-cPPT-PGK-mcs-PRE-SIN containing the 
human phosphoglyceratekinase (PGK) promoter, pRLL-cPPT-PGK-GFP-PRE-SIN, 
and the promoterless pRLL-cPPT-mcs-PRE-SIN (kind gift from J. Seppen, AMC Liver 
Center, Amsterdam, The Netherlands). Construction of promoter-luciferase constructs 
is described in detail elsewhere [17].
Lentiviral vector production
VSV-G pseudotyped recombinant LV particles were produced as described previously 
[17] with following modifications: Preceding calcium phosphate-based co-transfection 
of packaging plasmids and during virus production, HEK293T cells were cultured 
in medium supplemented with 0.01, 0.03 or 0.1 mM water-soluble cholesterol 
(Sigma). Viral particles were purified from supernatant by ultracentrifugation. Viral 
particle titers were determined by assaying p24gag values with an enzyme-linked 
immunosorbent assay (ELISA) kit (Abbott, IL) and expressed as ng p24gag/µl. The 
transduction efficiency of these lentiviruses is highly reproducible and is approximately 
10 transduction units (TU) per pg of p24gag. In our in vitro experiments we used 50 ng 
per 5x104 cells, corresponding to a MOI of 10.
Production of NIH 3T3-Saa3-Luc reporter cell line
Saa3-reporter cell line was generated by limiting dilution after stable transduction with 
LV-Saa3-Luc. A clone strongly responsive to IL-1β, TNFα, LPS and serum from RA 
patients was used for further studies. Cells were stimulated with 10% RA or healthy 
control serum in a total volume of 100 µl DMEM medium for 6 hours. Luciferase was 
assayed as described below.
Luciferase measurements
For in vitro reporter studies, cells were seeded at 5 x 104 cells per well in a Krystal 
2000 96-wells plate (Thermo Labsystems, Brussels, Belgium). The day after, 
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cells were transduced with 50 ng p24gag equivalents of lentivirus in 50 µl medium 
supplemented with 8 µg/ml polybrene (Sigma) for 4 hours at 37 ºC. Cells were serum-
starved (1% FCS) for two days and subsequently stimulated with recombinant human 
IL-1β  (R&D Systems Europe, Oxford, UK), TNFα (Abcam, Cambridge,UK), E. Coli 
lipopolysaccharide (LPS, Sigma) or Pam3Cys (EMC Microcollections, Tübingen, 
Germany) for the indicated hours and subsequently lysed in ice-cold lysis buffer. 
Luciferase activity was quantified using the Bright-Glo luciferase assay system 
(Promega, Madison, WI, USA) by adding an equal volume of Bright-Glo to the cell 
lysate. Luminescence was quantified in a luminometer (Lumistar, BMG, Offenburg, 
Germany), expressed as relative light units (RLU) and normalized to the total protein 
content of the cell/tissue extracts. For in vivo studies, knee joints were injected with 
300 ng p24gag equivalents LV in a total volume of 6 µl. Four or seven days after 
transduction, knee joints were challenged with SCW fragments. At indicated time 
points, patellae with surrounding tissue were dissected, put in 250 µl cell culture lysis 
buffer (Promega) and snap frozen in liquid nitrogen. Supernatant was centrifuged at 
13.000 rpm for 5 minutes and luciferase activity assayed as described above.
Immunocytochemistry
SF were cultured in chamber slides (Nunc, Rochester, NY) and fixed in 100% methanol 
at -20 °C for 15 minutes. Cells were washed three times in PBS and subsequently 
incubated for 1 hour with mouse-anti-human Thy-1 (CD90) (AS02, Dianova, Hamburg, 
Germany) or mouse-IgG control (Dako, Glostrup, Denmark) diluted 1:50 and 1:250, 
respectively, in 5% normal rabbit serum. Consecutively, cells were incubated for 
1 hour with a peroxide-coupled rabbit-anti-mouse antibody (Dako) diluted 1:100 in 
5% normal rabbit serum and 1.5 hours with Vectastain ABC Kit Rabbit-IgG (Vector 
Laboratories, Peterborough, UK) according to the manufacturer’s instructions. The 
peroxidase was revealed by incubating cells for 5 minutes in DAB solution (1 mg/ml 
3,3’-diaminobenzamide (Sigma) in 50 mM Tris-HCl pH 7.6, 0.03% H2O2). 
FACS analysis
Cells transduced with LV PGK-GFP were harvested two days post-transduction 
by trypsinization, washed twice in FACS buffer (1% BSA/PBS) and fixed in 1% 
paraformaldehyde/PBS. Analyses were performed on a BD FACSCalibur (BD 
Biosciences, San Jose, CA). 
Statistics
Data are represented as means+SEM. and significant differences were calculated 
using one-way analysis of variance (ANOVA) followed by Bonferroni’s Multiple 
Comparison test (GraphPad Prism, San Diego, CA, USA). P-values of less than 0.05 
are regarded as significant.
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Results
Optimal transduction efficiency of synovial fibroblasts using cholesterol-optimized 
lentivirus
HIV-1 recombinant lentiviruses (LV) have been demonstrated to efficiently 
transduce murine SF in vivo [17, 22]. To establish a novel LV vector-based 
method for assessing synovial inflammation, we determined optimal transduction 
efficiency of murine synovium using cholesterol-optimized LV particles (figure 
1A).[23] Cholesterol addition during LV production resulted in maximally six-fold 
increased functional titers (P<0.001) at a cholesterol concentration of 0.01 mM. 
Figure 1. Enhanced transduction efficiency of murine synovium using cholesterol-optimized LV. A, 
5x104 NIH-3T3 fibroblast were transduced with 50 ng p24gag equivalents LV-PGK-Luc. Viral particles were 
produced in the presence of indicated amounts of water-soluble cholesterol. Two days post-transduction 
luciferase expression was quantified using a luciferase assay. Data are expressed as RLU/mg protein 
+SEM (n=3). B, C and D, Analysis of transduction efficiency of murine synovial tissue in vivo. Knee joints 
of naïve C57Bl/6 mice were transduced with 300 ng p24gag equivalents LV-PGK-Luc (B,C) or LV-PGK-
GFP (D) produced in absence (B) or presence (C, D) of cholesterol. Five days post-transduction joints 
were dissected and transgene expression was quantified using a luciferase assay (B,C) or fluorescence 
microscopy (D). Luciferase expression is expressed as RLU corrected for protein content of samples +SEM 
(n=3). D, Analysis of GFP expression in synovium using immunofluorescence microscopy of tissue sections. 
Statistical differences were determined using ANOVA with Bonferroni’s post-test. ** P<0.01, *** P<0.001.
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Using conventionally-produced LV, maximal transgene expression in vivo was reached 
at 300 ng of LV p24gag equivalents per joint (figure 1B).  In contrast, cholesterol-
optimized LV showed a four-fold increase in transgene expression at the same particle 
titer (figure 1C). Fluorescence microscopy of tissue sections demonstrated that 
increased transgene expression resulted from an enhanced transduction efficiency of 
the synovial lining layer (figure 1D).
Next, we determined optimal transduction efficiency of human SF isolated from tissue 
biopsies. The fibroblast phenotype of isolated cells was confirmed by the abundant 
surface expression of Thy-1 (figure 2A). Transduction efficiency reached approximately 
98% of the starting from 100 ng of p24gag LV per 1.6x105 cells and the optimum was 
reached at 200 ng, respectively. 
Figure 2. Transduction efficiency of 
human SF by cholesterol-optimized LV. 
Fibroblasts were isolated from the synovial 
tissue by consecutive digestion of the tissue 
with trypsin and collagenase p, followed 
by negative CD14 MACS isolation.[20] A, 
Strongly positive immunohistochemical 
staining of CD14 MACS negatively isolated 
RA SF for the surface marker Thy-1 (CD90) 
confirms a fibroblast phenotype. Insert 
shows the absence of  background staining 
with the isotype mouse IgG control antibody. 
B and C, 1.6x105 SF were transduced with 
the indicated p24gag equivalents LV-PGK-
GFP. After two days, GFP expression was 
evaluated using fluorescence microscopy, 
a representative picture is shown (B). 
The optimal transduction efficiency was 
deduced using FACS analysis of the 
percentage GFP-positive cells (% GFP+) 
and the protein expression level (MFI) (C).
Saa3-promoter activity correlates with histological assessment of joint inflammation 
in SCW arthritis
Using optimal transduction parameters described in the previous section, we 
investigated the kinetics of Saa3-promoter activity during two consecutive flares of 
SCW-induced arthritis. Histological analysis revealed a large inflammatory infiltrate at 
one day post-challenge, which was most prominently located in the joint cavity (exudate, 
score: 2.05±0.37) and marginally in the synovium (infiltrate, score 0.30±0.11) (figure 
3A). At six days after SCW challenge exudate was resolved (0.06±0.13), whereas 
the infiltrate remained and showed an increase compared to day one (1.19±0.37) 
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(figure 3B). In this study we used the promoter of PGK, a housekeeping gene, as the 
reference for Saa3 and Cxcl1. During the course of the disease the luciferase activity 
under control of the PGF-promoter gradually increased in time (figure 3C), probably 
as a result of LV amplification by the joint-inflammation as described by Gouze and 
colleagues [22]. In line with histology, the induction of Saa3-promoter activity peaked 
at day one after challenge (35.3±6.8-fold over PGK-promoter), declined significantly 
at 2,4 and 6 days (~12-fold over PGK), but did not return to basal levels (figure 3C). A 
second SCW injection strongly reactivated Saa3-promoter activity at one (23.3±6.8-
fold over PGK) and three days (40.3±8.7-fold over PGK) after challenge. To assess 
whether these results are specific for the Saa3-promoter, we performed the same 
experiment using a Cxcl1-promoter reporter. Our previous computational analyses 
demonstrated that, unlike Saa3, expression of Cxcl1 does not correlate with disease 
severity in CIA but its promoter contains two strong NF-kB motifs that react to 
inflammation[17]. Cxcl1-promoter activity showed peak induction (6.9±2.5-fold over 
PGK) at day one and returned to nearly basal levels (~2-fold over PGK) from day two 
through six. However, a second SCW challenge failed to induce reactivation of Cxcl1-
promoter reporter compared to the PGK-promoter. These results suggest a unique 
correlation between Saa3-promoter activity in synovium and joint inflammation.
Figure 3. Saa3 promoter activity correlates 
with histological assessment of joint 
inflammation. A,B Knee joints of naïve 
C57Bl/6 mice were challenged with 25 
mg SCW and mice were sacrificed at 
one (A) or six (B) days thereafter. Joint 
inflammation was assessed by evaluation 
of hematoxylin and eosin-stained tissue 
sections, representative pictures are 
shown. Filled and open arrowheads mark 
inflammatory infiltrate in the synovial 
cavity and synovial lining, respectively. 
Inlays show the synovial lining at a higher 
magnification. C, Knee joints of naïve 
C57Bl/6 mice were transduced with either 
300 ng p24gag LV-Saa3-Luc, LV-Cxcl1-Luc 
or constitutively-active LV-PGK-Luc. Four 
and ten days post-transduction (days 0 
and 6) acute arthritis was induced by intra-
articular injection of 25 mg SCW (arrows). 
Luciferase activities were evaluated ex vivo 
at indicated time points, and represented 
as fold-induction+SEM (n=5) over naïve 
conditions (day 0). 
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Figure 4. Comparison of Saa3-promoter reporter versus 99mTc uptake for assessment of joint 
inflammation. A, Both knee joints of naïve C57Bl/6 mice were transduced with 300 ng p24gag equivalents LV-
Saa3-Luc. Seven days post-transduction, unilateral arthritis was induced by intra-articular injection of 25 mg 
SCW fragments (right joint). 99mTc uptake was assessed at indicated days and immediately thereafter joints 
were dissected and luciferase activities assessed. Bars represent means+SEM (n=4) of luciferase (black) 
and 99mTc uptake (white) ratios (right/left joint). B, Correlation between Saa3-promoter reporter and 99mTc 
uptake ratios from non-inflamed and SCW-challenged knee joints. Data are collected from two independent 
experiments. C, Sensitivity of Saa3-promoter reporter versus 99mTc uptake. Right knee joints were transduced 
with LV-Saa3-Luc and after 6 days challenge with indicated amounts SCW fragments. Bars represent 
means+SEM (n=3) of luciferase activity (black, fold induction over naïve conditions) and 99mTc ratios (white). 
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Saa3-promoter reporter provides increased sensitivity for detecting joint inflammation 
compared to 99mTc uptake
Bioluminescent imaging has shown potential for non-invasive assessment of 
inflammation in arthritis [24]. Therefore, we compared the performance of Saa3-
promoter reporter with 99mTc uptake measurement, which is an well-established 
method for non-invasive quantification of joint inflammation [5]. Both Saa3-promoter 
activation (15.0±1.5-fold) and 99mTc uptake measurement (1.84 ±0.02), revealed 
strong joint inflammation at day one after SCW challenge (figure 4A). In addition, we 
observed a strong and significant correlation between both methods at this time point 
(P<0.0005, Pearson r 0.82) (figure 4B). At day seven, in line with the observations 
from the previous section, Saa3-promoter reporter remained significantly activated 
(6.3±2.4-fold) during relapse of joint inflammation. However, joint inflammation was 
not detectable at this time point using 99mTc uptake measurement (1.01±0.02). 
These results prompted us to investigate the sensitivity of both methods by measuring 
the dose-response to SCW fragments (1, 5 and 25 mg) (figure 4C). Whereas Saa3-
promoter reporter showed a clear response for all doses and a trend towards stronger 
responses at higher dose (5.5±0.8, 6.5±1.3, 7.9±1.6-fold), joint inflammation as 
measured by 99mTc uptake was only evident (1.62±0.17) at highest SCW-dose. 
These data suggest that Saa3-promoter reporter is a more sensitive read-out for joint 
inflammation than 99mTc uptake.
Molecular stratification of inflammatory subtypes in OA/RA SF using gene expression 
profiling
Since Saa3-promoter reporter in murine synovium could discriminate the grade 
of inflammation in experimental arthritis, we hypothesized that this method might 
discriminate between high and low inflammatory synovial tissues from arthritis 
patients. Molecular stratification of inflammatory subtypes was performed using 
complete-linkage hierarchical clustering of whole-genome expression profiles of RA 
and OA SF (n=6 for each) (figure 5A). Based on expression profiles, RA and OA SF 
were completely intermingled and three subgroups could be discerned. To define low 
and high inflammatory subtypes, we analyzed gene identities in the subclusters (A 
through E) displaying clearly differential gene expression between subgroups (figure 
5B). Consistent with prior studies, group III could be classified as a high inflammatory 
subtype based on significantly increased expression of genes involved in chemotaxis, 
angiogenesis and TGFb/activin A pathways [10, 25, 26] .
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Figure 5. Hierarchical clustering of RA and OA SF gene expression profiles. A and B, Hierarchical 
clustering of the expression of 7705 cDNAs in SF from patients with RA (n=6) or OA (n=6). Each row 
represents a single gene; each column represents an individual SF sample. Black, red and green bands 
indicate relative expression equal to, greater or lower than the median of all samples. Gray bands indicate 
the absence of expression of the corresponding cDNA. Color intensities indicate the magnitude of the 
deviation from the median (bottom, B). Subgroups are labeled I, II and III. Gene clusters with a related 
expression profile are labeled A through E (A). B, Detailed cluster diagram of subcluster A. Gene symbols 
are indicated.
Increased Saa3-promoter response in stimulated SF with high inflammation profile  
Next, we evaluated Saa3-promoter responses in SF from low and high inflammation 
synovial tissue. Irrespective of the subtype, Saa3-promoter activity could be significantly 
induced by TNFa, IL-1b, LPS, but not Pam3Cys (figure 6A). Whereas basal promoter 
activity was equal between groups (data not shown), we observed significant higher 
induction of Saa3-promoter reporter in high inflammatory SF stimulated with IL-1b 
(10.1±1.4 vs. 18.3±1.4, P<0.01), TNFa (5.5±1.0 vs. 11.8±1.1, P<0.01), or LPS (2.6±0.4 
vs. 7.1±0.7, P<0.05). Since IL-1b-induced Saa3-promoter response provided the largest 
readout window, we evaluated whether this response could discriminate inflammatory 
subtype in individual samples (figure 6B). Within subgroups, individual Saa3-promoter 
responses did not differ significantly. Two out of three high inflammatory SF showed 
significantly increased (P<0.05) responses over all low inflammatory SF, while the 
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third revealed a clear trend towards a higher response that failed to reach significance. 
These results suggest that Saa3-promoter reporter might have a diagnostic value for 
classification of molecularly distinct low and high inflammatory synovial tissues. 
A B
Figure 6. Saa3-promoter reporter distinguishes low and high inflammatory SF. A, Low (n=3) and 
high (n=3) inflammatory SF were transduced in quadriplicate with LV-Saa3-Luc and serum-starved for two 
days. Cells were stimulated for 6 hours with human IL-1b (1 ng/ml), TNFa (10 ng/ml), LPS or Pam3Cys 
(both 1 mg/ml). Luciferase activities are given as fold-induction and represented as box plots indicating the 
sample minimum, lower quartile, median, upper quartile and sample maximum of low and high subgroups. 
B, IL-1b-induced Saa3-promoter activation in individual SF of a healthy control, or SFs from low and high 
inflammatory subtypes. Data are represents as means+SEM. Statistical differences were determined using 
ANOVA with Bonferroni’s post-test. * P<0.05.
The Saa3-promoter responds to human RA sera
The diagnostic value of the Saa3-promoter in humans was further substantiated 
by exposing a stable Saa3-promoter-luciferase reporter cell-line to 10% serum of 
RA patients (n=71) or from healthy blood donors (n=82). The RA-sera induced a 
significant (p<0.0001, t-test) upregulation of the Saa3-promoter activity over control 
sera (figure 7). 
Figure 7. Enhanced Saa3-promoter response 
to human RA serum. A stable Saa3-luc promoter 
reporter NIH-3T3 cell-line was serum starved for 2 
days (1% FCS) and thereafter challenged for 6 hours 
with 10%  serum from healthy blood donors (n=82, 
40-70 years of age) or RA-patients (n=71). Luciferase 
activities are given as fold induction of 10% over 
0% serum and expressed as box plots. Statistical 
differences between RA and control (blood donors) 
were determined using students-t-test P<0.0001.
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Discussion
Regarding the significant role of activated SF in the local inflammatory processes 
within the arthritic joint, methods that allow quantitative measurement of inflammation 
through assessment of the degree of activation of these cells are of great value toward 
diagnostics of disease activity and treatment efficacy. In experimental arthritis, a number 
of methods has been developed for ex/in vivo assessment of synovial inflammation 
including histological analysis, 99mTc uptake, magnetic resonance imaging and ultrasound 
biomicroscopy [5, 27, 28]. In our study, we have introduced a lentiviral bioluminescent 
Saa3-promoter reporter as a novel, sensitive and feasible tool for discriminating between 
inflammatory subtypes in experimental arthritis and human SF. synovial inflammation 
via SF. A bioluminescent promoter-reporter has several prominent advantages over the 
aforementioned methods.                                 
First, the versatility of luciferase as a reporter gene enables quantitative analysis at 
several levels of resolution. We have assayed transgene expression in synovium ex vivo 
by performing a luciferase assay on a lysate from homogenized tissue. Alternatively, 
luciferase expression can be revealed and semi-quantitatively scored in histological tissue 
sections using standard immunohistochemical analysis. Most importantly, luciferase 
activity can readily be assessed non-invasively and in real-time using in vivo imaging 
systems. These offer high sensitivity and ease of use and have been successfully been 
applied for monitoring zymosan-induced arthritis [29, 30], angiogenesis [31], and stem 
cell transplantations [32]. In a pilot experiment we were able to monitor inflammation 
knee and ankle joints of collagen-induced arthritis (CIA) mice using real-time imaging 
(unpublished observations).
Second, using standard molecular cloning it is possible to generate a diverse range of 
promoter-luciferase reporters that allow imaging of the activity of individual transcription 
factors, genes-of-interest or the specific processes with which they correlate, e.g. 
chemotaxis, cartilage destruction, inflammatory infiltration. Zhang and co-workers utilized 
this approach to create a number of transgenic luciferase-reporter mice for monitoring 
diverse cellular processes including DNA damage (Gadd45 promoter), angiogenesis 
(Vegfr2 promoter), and NF-kB signaling (Ikba promoter) [31, 33, 34].
Gouze and co-workers have demonstrated that intra-articular injection of lentivirus 
leads to predominant transduction of synovial fibroblasts, but not macrophages. [35] 
This means that our findings with Saa3-promoter reporter have to be interpreted within 
a synovial fibroblast-specific context. Acute SCW arthritis is initiated via a TLR2- and 
MyD88-dependent macrophage-driven mechanism [36, 37], which suggests that 
activation of the promoter reporter most likely does not arise directly from SCW-induced 
TLR2 activation in synovial fibroblasts. In support of this hypothesis, we found only 
marginal induction of Saa3-promoter in human synovial fibroblasts upon TLR2 triggering. 
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Histological analyses of joint inflammation revealed a predominant exudate, consisting 
of polymorphonuclear neutrophils [38, 39], at the peak of promoter induction. An 
outstanding question remains therefore whether correlation of Saa3-promoter 
in synovium with joint inflammation arises from a response to neutrophil-secreted 
molecules, synovial-derived cytokines, or both. In favor of the latter, the cytokine profile 
of IL-1b in SCW arthritis appears to coincide with Saa3-promoter activity, showing a 
peak of induction within 24 hours and declining thereafter [40]. Notably, upon repeated 
SCW challenge IL-1b protein was present at an increased level compared to the first 
flare, which corresponds to our findings that Saa3-promoter reporter was stronger 
induced after SCW restimulation. In addition, we have shown that IL-1b is a potent 
inducer of Saa3-promoter reporter in human SF. Recent studies have shown that a 
Saa3-promoter can be induced by S100A8 in macrophages, mononuclear cells and a 
tumor cell line.[41] S100A8 is highly expressed and secreted by activated neutrophils 
[42] and has been shown regulate joint inflammation in antigen-induced arthritis [43]. 
This might represent a mechanism that specifically links neutrophil infiltration with 
Saa3-promoter activation, although it remains to be verified if S100A8 can induce 
pro-inflammatory signaling in SF.       
The observation that Saa3-promoter reporter in stimulated human SF could distinguish 
low and high inflammatory phenotypes, was our most clinically relevant finding. This 
phenomenon was observed for IL-1b, TNFa and TLR4 stimulation. Based on these 
findings it can be hypothesized that increased Saa3-promoter activation in SF results 
from differential receptor expression or a downstream protein that is common between 
pathways. However, in our gene expression profiling the respective receptors IL1R1, 
TNFR1 or TLR4 were absent from subclusters showing differential expression 
between low and high inflammatory groups. In contrast we did detect an increased 
expression of transcription factor CEBPB, which is a strong inducer of Saa3-promoter 
activity [44, 45]. Previous studies have demonstrated enhanced expression and DNA 
binding of C/EBPb in RA SF.[46] Additionally, Pope and co-workers have established 
a correlation between nuclear staining of C/EBPb in synovial lining and the grade of 
inflammation [16]. Moreover, the correlation was not a disease-specific since it could 
be observed both in RA and OA. This corresponds to our finding that RA and OA 
expression profiles were not distinct but intermingled.
A recent study by van Baarsen et al. has shown that high inflammatory synovial gene 
expression profile correlates with higher disease activity, C-reactive protein (CRP) 
levels, erythrocyte sedimentation rates (ESRs), increased platelet numbers and a 
shorter disease duration in RA patients [12].  This indicates that there is a diagnostic 
value of determining low and high inflammatory subtypes of synovial tissue. We failed 
to observe a correlation with these clinical parameters in our study (data not shown), 
which is most likely caused by the intermingling of RA with OA samples, since the 
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latter showed an overall shorter disease duration, lower CRP levels and ESRs. On 
the other hand, intermingling of RA and OA tissues corresponds with recent to recent 
findings of the involvement of synovial inflammation in the pathogenesis of OA and a 
change in the dogma that OA is not an inflammatory disease [47-49].
We demonstrated the versatility of the Saa3-promoter to detect inflammation by 
challenging  a stable Saa3-luciferase reporter NIH-3T3 cell-line to serum of RA 
patients. Blood is a highly dynamic environment, communicating with practically 
every tissue in the body, and is thus proposed as a ‘sentinel tissue’ that reflects 
disease activity. For instance, a known serological marker for RA disease activity 
is C-reactive protein, a liver derived protein inducible by cytokines as IL-1 and IL-6 
released in the inflamed joints. We found enhanced transcriptional activity of the 
Saa3-promoter was found in sera from RA-patients compared to controls (figure 7), 
showing disease-regulation of the Saa3-promoter. This corroborate the diagnostic 
value of the Saa3-promoters in RA to discriminate not only between the inflammatory 
profile of the synovial fibroblast but also that of blood in RA patients. 
Our findings have demonstrated that lentiviral Saa3-promoter reporter is a novel and 
feasible tool with a potential diagnostic value in experimental and human arthritis. 
In the future, it seems valuable to explore the potential of real-time bioluminescent 
imaging of Saa3-promoter activity in vivo as a non-invasive molecular imaging 
approach in animal models. Apart from its potential in identifying inflammatory 
subtypes, elucidation of the molecular mechanism causing differential induction of 
Saa3-promoter activity in SF could provide valuable insight into pathogenesis of 
arthritis.     
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Abstract
Objectives 
Rheumatoid arthritis (RA) is a chronic destructive autoimmune disease, but the 
course is unpredictable in individual patients. An attractive treatment would provide 
a disease-regulated therapy that offers personalized drug delivery. Therefore, we 
expressed the anti-inflammatory interleukin-10 (IL-10) gene under the control of 
inflammation-dependent promoters in a mouse model of arthritis.
Methods
Proximal promoters of S100a8, Cxcl1, Mmp13, Saa3, IL-1b, and Tsg6 were selected 
by whole genome expression analysis of inflamed synovial tissues from arthritic mice. 
Mice were injected intra-articularly in knee joints with lentiviral vectors expressing 
a luciferase reporter or the therapeutic protein IL-10 under control of the Saa3 or 
Mmp13 promoter. After 4 days, arthritis was induced by intra-articular injection of 
streptococcal cell walls (SCW). At different time points after arthritis induction, in vivo 
bioluminescent imaging was performed and knee joints were dissected for histological 
and RNA analysis.
Results
The disease-regulated promoter-luciferase reporter constructs showed different 
activation profiles during the course of the disease. The Saa3 and Mmp13 promoters 
were significantly induced at day 1 or day 4 after arthritis induction respectively and 
selected for further research. Overexpression of IL-10 using these two disease-
inducible promoters resulted in less synovitis  and markedly diminished cartilage 
proteoglycan depletion and in upregulation of IL-1Ra and SOCS3 gene expression.
Conclusions
Our study shows that promoters of genes that are expressed locally during arthritis 
can be  candidates for disease-regulated overexpression of biologics into arthritic 
joints, as shown for IL-10 in SCW arthritis. The disease-inducible approach might be 
promising for future tailor made local gene therapy in arthritis.
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Introduction
Arthritis is a debilitating disease which affects about 1% of the world population. The 
course of the disease can be intermittent, with episodes of inflammation and remission. 
Conventional treatments nowadays consist of repeated systemic administration 
of biological drugs, such as tumor necrosis factor alpha (TNF-α) blockers, which 
continuously suppress the immune system. This kind of treatment gives rise to 
different side effects, like infections and the formation of anti-drug antibodies [1]. Local 
gene therapy for arthritis, with the use of disease-regulated promoters, represents a 
promising alternative for coping with side effects of the conventional treatments. Using 
gene therapy via viral expression systems, the patient can be treated for a prolonged 
time, by only a single intra-articular injection. Nathwani and co-workers [2] already 
showed this by treating hemophilia B patients using viral overexpression of factor IX.
Previously, we constructed different disease-regulated promoters from genes 
differentially regulated during collagen-induced arthritis in mice, selected via 
a computational approach [3]. These disease-regulated promoters respond to 
transcription factors activated during inflammation, restricting the production of the 
transgene to episodes of inflammation. Several promoters showed an inducible profile 
in lentivirally transduced macrophage and fibroblast cell lines after in vitro stimulation 
with LPS. In addition, the Saa3 promoter was able to detect differences between 
high and low inflammatory profiles in synovial fibroblasts from rheumatoid arthritis 
(RA) and osteoarthritis patients [4]. This proved the inducibility and sensitivity of this 
promoter to disease activity. 
Interleukin-10 (IL-10) is a good candidate transgene to suppress arthritis using 
disease-regulated promoters. IL-10 is a broad spectrum anti-inflammatory cytokine 
and is produced by different immune cells, like Th1 and Th2 cells, B cells, monocytes 
and macrophages. Inhibition of several pro-inflammatory cytokines has been reported; 
effects were seen on interleukin-1 (IL-1) and TNF-α [5, 6]. IL-10 is also known to 
induce the production of interleukin-1 receptor antagonist (IL-1Ra) and suppressor 
of cytokine signaling-3 (SOCS3) [7, 8]. Nonetheless, several clinical studies showed 
lack of efficacy using IL-10 supplementation and even increased disease activity as 
compared to placebo treated RA patients has been reported [9]. Because the half-
life of IL-10 is short, around 1.1 to 2.6 hours[8], patients had to be injected either 
intravenously or subcutaneously 3 times a week.  Furthermore, in different cohorts, 
IL-10 treated patients were at risk of developing anemia. This paved the way for 
developing a more effective F8-IL-10 fusion protein, which targets the systemically 
delivered IL-10 to the fibronectin deposits in the arthritic joints [10]. 
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Unnecessary off-target effects can also be avoided by using disease-regulated gene 
therapy to limit the height and time of exposure to IL-10 as we previously have shown 
for IL-4, a cartilage protective cytokine that has proinflammatory properties in vivo 
[11]. We previously showed feasibility of the disease-regulated IL-10 therapy by 
transplantation of lentiviral transduced haematopoeitic stem cells [12]. This led to 
production of IL-10 in B and non-B APC cells in lymph nodes and clear-cut reduction 
of collagen-induced arthritis (CIA). An effect also shown by Tanaka et al. [13] where 
they found effects of IL-10 protein treatment on CIA. A reduction in the incidence 
and score of the arthritis was found, together with a significant reduction of IL-6 by 
macrophages. The effect of local IL-10 treatment using this disease-regulated gene 
therapy concept has not been explored and could be very promising. 
The SCW model was chosen, because repeated intraperitoneal IL-10 injections 
showed a significant reduction in joint pathology [14]. Also, different processes of 
influx of inflammatory cells in the joint cavity, synovitis and proteoglycan depletion 
occur sequentially at different time points, resulting in a predictable disease course. 
Because we expected the disease-regulated promoters to respond differently to 
the different events, this model was chosen to elucidate the different kinetics of the 
disease-regulated promoters.
Hence, in this study, we set out to select the suitable disease-regulated promoter 
according to the profiles of the different promoters during the SCW-induced arthritis 
model. We showed that local disease-dependent overexpression of IL-10 diminished 
proteoglycan depletion and synovitis and is therefore proven to be a suitable strategy 
to suppress disease activity.
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Material and Methods
Animals
Male 12 week old C57Bl/6N mice were obtained from Janvier (Le Genest Saint Isle, 
France). During virus experiments, mice were housed in HEPA filtered individually 
ventilated cages and were fed a standard diet with food and water ad libitum. All in vivo 
studies complied with national legislation and were approved by the local authorities of 
the Care and Use of Animals.
Plasmids
Recombinant lentiviral vectors were generated using the third-generation self-
inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN (PGK-empty) containing 
the human phosphoglycerate kinase (PGK) promoter (kind gift from J. Seppen, AMC 
Liver Center, Amsterdam, The Netherlands). Construction of promoter-luciferase 
constructs was done as described elsewhere.[3] For construction of pRLL-cPPT-
PGK-IL10-PRE-SIN, pRLL-cPPT-Saa3-IL10-PRE-SIN and pRLL-cPPT-MMP13 
-IL10-PRE-SIN, mIL-10 was amplified from pIG1-IL1e-IL6p-IL10, a construct used by 
Henningsson and collegues, [12] using primers FW 5’- tttgctagctccaccatgcctggctc-3’ 
and RV 5’-aaacatatgttagcttttcattttg-3’ introducing an NheI and NdeI site, and ligated into 
the promoter constructs.
Lentiviral vector production
Lentiviral vector production was performed as described previously [3] with co-
transfection of packaging and expression plasmids at half concentration. For the in vivo 
studies, knee joints were injected with 300 ng p24gag equivalents lentivirus in a total 
volume of 6 µl.
Cell culture
Mouse embryonic fibroblasts (NIH-3T3) and macrophages (RAW 264.7) were cultivated 
in DMEM with 1 mM pyruvate, 40 µg/ml gentamycin, and 5% or 10% fetal calf serum 
(FCS) respectively. Cells were kept at 37˚C in a humid atmosphere containing 5% CO2.
In vitro luciferase measurements
Cells were seeded at 3 x 104 cells per well in a white clear bottom Costar 96 wells 
plate (Corning, NY). After one day, cells were transduced with 50 ng p24gag equivalents 
lentivirus in 50 µl medium supplemented with 8 µg/ml polybrene (Sigma) for 4 hours 
at 37˚C. Two days after transduction, cells were serum starved (1% FCS) for one day 
and subsequently stimulated with 10 ng/ml recombinant mIL-10 (R&D systems) or a 
combination of 10 ng/ml Pam3Cys (EMC Microcollection) and 100 ng/ml E.Coli LPS 
(Sigma) for indicated hours. Thereafter, cells were lysed in water and luciferase activity 
was quantified using the Bright-Glo luciferase assay system (Promega, Madison, WI, 
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USA) by adding an equal volume of Bright-Glo to the cell lysate. Luminescence was 
quantified in a luminometer (Lumistar, BMG, Offenburg, Germany).
Preparation of streptococcal cell walls and induction of arthritis
Strepococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. 
Cell walls were prepared as described previously [15]. Uni- or bilateral arthritis was 
induced four days after transduction with the lentivirus by injection of 25µg SCW in 6µl 
of phosphate buffered saline (PBS) into the joint cavity of the knee. 
In vivo bioluminescence imaging
At indicated time points after SCW injection, in vivo bioluminescent imaging was 
performed (n=6 mice per inducible promoter) on an IVIS Lumina system (Caliper Life 
Sciences, Hopkinton, MA, USA), 10 minutes after intraperitoneal injection of 150 mg/
kg D-Luciferine (Caliper Life Sciences) dissolved in PBS. Mice were anesthetized with 
2.5% isoflurane/oxygen, shaved, placed on their back in the light tight chamber and 
imaged for 4 minutes with a sensitive CCD camera. Images were analyzed using the 
Living Image 3.0 software (Caliper Life Sciences). Two-dimensional regions of interest 
(ROIs) were drawn around the knee joints. Luciferase activity is presented in photons 
emitted per second per square cm.
Histology
In total, 9 knee joints per inducible promoter per time point were used. Histological 
sections of knee joints were analyzed for synovitis, and proteoglycan depletion as 
described earlier [16].
RNA isolation and quantitative PCR analysis
One synovial tissue sample from the lateral side and one from the medial side of the 
knee joint were isolated using a 3 mm biopsy punch (Stiefel, Wachtersbach, Germany) 
and pooled. In total, 9 knee joints per promoter per time point were analyzed. Total RNA 
was extracted from the tissue homogenates and from cells using TRI reagent (Sigma) 
according to manufacturer’s protocol. Isolated RNA was treated with DNAse followed 
by reverse transcription of 1µg RNA into cDNA using Moloney murine leukemia virus 
reverse transcriptase 0.5µg/µl oligo(dT) primers, and 12.5mM dNTPs (Invitrogen). 
Quantitative real-time PCR was performed using the StepOnePlus sequence detection 
system (Applied biosystems). PCR was performed in a total reaction volume of 12.5 
µl consisting of appropriate cDNA, 5 µM forward and reverse primer and SYBR green 
PCR master mix (Applied biosystems). The PCR protocol consisted of 2 min at 50°C 
and 10 min of 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. The 
cycle threshold value (Ct) of genes of interest were compared to the Ct of reference gene 
glyceraldehyde-3-phophate dehydrogenase (GAPDH) (delta Ct). Primer sequences are 
listed in table S1.
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Blood serum cytokine measurement
KC (the murine homologue of IL-8) levels in the blood serum, were determined on 
a Luminex-100 system (Luminex Corp) using a bead-based multiplex immunoassay 
(Milliplex, Merck Millipore). Data analysis was performed with Bio-Plex Manager 
software (Bio-Rad Laboratories).
Statistics
Statistical analysis was performed using students’ t-test, 1way ANOVA, Pearson 
correlation or Mann-Whitney U test (GraphPad Prism, V 4.0). A p-value of <0.05 was 
regarded as significant.
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Results
Selection of a promoter for local gene therapy
Luciferase reporter expression profiles of 6 different disease-regulated promoter 
reporters were made during SCW arthritis, using bioluminescence imaging (fig. 
1a,b). All 6 promoters showed different activation kinetics during the acute model of 
arthritis. The Saa3 promoter showed the highest fold increase (127-fold) with an early 
activation at day 1 after arthritis induction. The Mmp13 promoter response showed a 
delay and was activated at day 4 and stayed high up to 7 days. All other promoters 
peaked at day 4 or 7 after SCW injection. Because of these profiles, the Saa3 and 
Mmp13 promoters seemed interesting candidates for local gene therapy using the 
anti-inflammatory IL-10 transgene. To ascertain that both promoters responded only 
to the local arthritic process we first tested the Saa3 and Mmp13 promoter responses 
to IL-10, our transgene of choice. Mice were co-injected with PGK-IL10 and Saa3-
luciferase or Mmp13-luciferase and the luciferase signal was measured at the same 
time points of SCW-arthritis (fig. 2). The Saa3 and Mmp13 promoters were still 
activated at day 1 and 4 respectively, indicating that the inducible promoters are not 
responsive to IL-10 in vivo. Therefore, no positive feedback loop will be created by 
the promoters that might uncouple their regulation by the local inflammatory process. 
This finding was supported in vitro, where likewise no effects of IL-10 were found on 
the activation of the Saa3 promoter by SCW in fibroblasts and macrophages, both 
important cell types in the synovial lining (fig. S1). Our Mmp13 promoter construct 
is not responsive in both cell-types to the stimuli tested as we have shown before[3], 
therefore an IL-10 effect could not be demonstrated (data not shown).
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Figure 1. Profiling of the different disease-regulated promoters using bioluminescent imaging. 
a: Both knee joints of 6 C57Bl/6N mice per inducible promoter were transduced with 300 ng p24gag 
lentiviral vector containing either the Saa3, S100a8, Cxcl1, IL-1b, Tsg6 or Mmp13 proximal promoter 
with luciferase reporter gene. Four days after transduction, the knee joints were injected with 25 µg SCW 
to induce arthritis. At day 0, 1, 4, 7 and 9, mice were imaged in a light tight chamber 10 minutes after 
luciferin injection. Luciferase activity was quantified and plotted as fold induction compared to day 0. b: 
Representative images of the bioluminescent imaging of the Saa3 promoter in one mouse at day 0, 1, 4, 7 
and 9. Depicted as mean±SEM; n=12.
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Figure 2. Profiling of the disease-regulated Saa3 and Mmp13 promoter in SCW arthritis in the 
presence of local IL-10 expression. Both knee joints of 6 C57Bl/6N mice per inducible promoter were 
transduced with 300 ng p24gag lentiviral vector containing PGK-IL-10, cotransfected with either 300 ng 
p24gag lentiviral vector Saa3-luciferase (a) or Mmp13-luciferase (b). Four days after transduction, the 
knee joints were injected with 25 4g SCW to induce arthritis. At day 0, 1, 4, 7 and 9, mice were imaged in 
a light tight chamber 10 minutes after luciferin injection. Luciferase activity was quantified and plotted as 
fold induction compared to day 0. Depicted as mean±SEM; n=6.
Supplementary Figure S1: Luciferase signal in stimulated fibroblasts and macrophages in vitro 
after transduction with Saa3-luciferase. NIH-3T3 fibroblasts (a) or RAW264.7 macrophages (b) were 
transduced with 50 ng p24gag lentiviral vector containing the Saa3 proximal promoter and luciferase 
reporter gene. Subsequently, cells were stimulated with either IL-10, SCW or a combination IL-10 and 
SCW. 6 hours after stimulation, luciferase activity was quantified and plotted as relative light units.
IL-10 is upregulated by the Saa3 and Mmp13 promoters during arthritis
Next, the disease-regulated expression of the IL-10 transgene under the control of 
the inducible promoters was examined (fig. 1a). Mice were i.a. injected in both knee 
joints with the lentiviral construct expressing IL-10 under the control of the constitutive 
PGK or the inducible Saa3 or Mmp13 promoter. One knee joint was injected with 
25 µg SCW and the contralateral knee joint with PBS. Subsequently, IL-10 mRNA 
expression was measured in both knee joints at day 1 after the intra-articular injections. 
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The constitutive PGK promoter showed the same extent of IL-10 expression in both 
the PBS injected control joint as well as the SCW injected arthritic knee joint, while 
the inducible Saa3 promoter showed a significant inducible expression in the arthritic 
knee joint compared to the contralateral knee joint (fig. 3a,b). The Mmp13 promoter 
showed a slightly higher activity in the contralateral joint compared to Saa3 (fig. 3b,c). 
At day 4 and 7, IL-10 expression was upregulated by all three promoters, compared to 
the empty control treated animals (fig. 3d,e). This confirms that the Saa3 and Mmp13 
promoters are activated by inflammation after induction of arthritis.
Figure 3. IL-10 gene expression analysis of synovial tissue from knee joints after arthritis induction 
in joints with IL-10 overexpression. Both knee joints received intra-articular injections with lentiviral PGK-
IL10, Saa3-IL10 or Mmp13-IL10. Arthritis was induced in one knee joint 4 days after transduction. After 1 
day, gene expression analysis was performed for IL-10 in synovial tissue from both the arthritic and non-
arthritic contralateral knee joint (a-c). IL-10 expression was also measured in synovial tissue from PGK-
empy, PGK-IL10, Saa3-IL10 and Mmp13-IL10 injected arthritic knee joints at day 4 (d) and day 7 (e). Gene 
expression is shown as -delta Ct, corrected for GAPDH. Depicted as mean±SEM; n=9. * = p<0.05, *** = 
p<0.0001 versus control Group empty when using a paired t-test (a-c) or a 1way ANOVA (d,e).
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Disease-dependent IL-10 expression decreases synovitis and proteoglycan depletion
To test the therapeutic effects of disease-regulated IL-10 expression, mice were 
treated locally with IL-10 under control of the Saa3 or Mmp13 promoter. After 4 days, 
SCW arthritis was induced. Mice were sacrificed for histological- and gene expression 
analysis at 1, 4 or 7 days after arthritis induction. Synovitis was significantly reduced 
in IL-10 treated joints at day 4 after arthritis induction (table 1, fig. 4a-d). 
Figure 4. Histology of day 4 and 7 after arthritis induction in joints with IL-10 overexpression. 
Histology of knee joints using haematoxylin-eosin staining for analysis of inflammation and safranin-O 
staining for analysis of cartilage proteoglycan depletion. Knee joints were injected with PGK-empty (a,e), 
PGK-IL10 (b,f), Saa3-IL10 (c,g) or Mmp13-IL10 (d,h). Histology from day 4 (a-d) or day 7 (e-h) after 
arthritis induction is shown. Representative pictures from mice described in table 1 are depicted. p=patella, 
f=femur, s=synovium, c=cartilage. 
Table 1. Histological scoring after local inducible IL-10 gene therapy in SCW-induced joint pathology. 
Day 1 Day 4 Day 7
Exu Syn PG depl Exu Syn PG depl Exu Syn PG depl
PGK Empty
3.0
(2.6-3.0)
1.0
(0.6-1.0)
1.0
(0.1-1.5)
1.5
(1.0-1.5)
2.0
(2.0-2.5)
3.0
(2.0-3.0)
0.5
(0.5-0.5)
1.0
(1.0-1.8)
2.0 
(1.5-3.0)
PGK
IL10
2.3
(2.0-2.9)
1.0
(1.0-1.4)
0.8 
(0.1-1.0)
1.5
(1.0-1.8)
1.5**
(1.3-2.0)
2.0*
(1.5-2.0)
0.5
(0.5-0.5)
1.0
(1.0-1.5)
0.5**
(0.0-1.3)
Saa3
IL10
3.0
(2.3-3.0)
1.0
(0.6-1.0)
0.8
 (0.5-1.4)
1.0
(0.5-1.5)
1.5**
(1.0-2.0)
1.5***
(1.0-1.8)
0.5
(0.0-0.5)
1.0
(0.8-1.3)
0.0**
(0.0-1.8)
Mmp13
IL10
2.8
(2.5-3.0)
1.0
(0.6-1.4)
1.0
(0.6-1.4)
2.0
(0.8-2.0)
1.5**
(1.0-2.0)
1.5**
(0.5-2.3)
0.5
(0.3-0.5)
1.5
(1.0-1.8)
1.0*
(0.3-2.0)
Histological scoring of exudates (exu), synovitis (syn) and proteoglycan depletion (PG depl) at day 1, 4 
and 7 after arthritis induction showed a significant decrease in synovitis and proteoglycan depletion after 
IL-10 overexpression. Depicted as median±interquartile range. n=6 mice. * = p<0.05, ** = p<0.01, *** = 
p<0.0001 statistically significant as compared to control group PGK-Empty using a 1way ANOVA.
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Proteoglycan depletion was significantly lower in IL-10 treated animals at day 4 and 
7 after arthritis induction (fig. 4e-h). Because the extent of the therapeutic effect on 
SCW arthritis of the Saa3 and Mmp13 promoters were similar, the subsequent in vivo 
experiments were performed using the Saa3 promoter.
Disease-dependent IL-10 upregulation has an effect on protein and gene expression
Keratinocyte chemoattractant (KC) protein concentration was measured one day after 
arthritis induction in the serum of Saa3-IL-10 mice. KC is the murine homologue of IL-
8, a cytokine involved in recruiting inflammatory cells to invade the joint. A significant 
reduction in KC concentration from 359±84 pg/ml to 161±32 pg/ml using the PGK 
promoter and to 139±26 pg/ml using the Saa3 promoter was seen compared to the 
control group (fig. 5). In addition, IL-1Ra was upregulated in the synovium at the gene 
expression level at day 7 in the Saa3 group, compared to the empty control virus. This 
effect was also seen on Socs3 gene expression at day 4 and 7 (fig. 6a,b). At these 
time points, IL-1Ra and Socs3 expression was significantly correlated with IL-10 
expression (fig. 6c), indicating that the upregulation is the result of IL-10 expression.
Figure 5. Expression of KC at day 1 
after arthritis induction in knee joints 
with IL-10 overexpression. KC protein 
concentration (pg/ml) was measured 
in blood serum at day 1 after arthritis 
induction using a bead array. A significant 
(p<0.05) lower concentration was found in 
the blood serum of mice treated with Saa3-
IL10. Depicted as mean±SEM; n=9. * = 
p<0.05 versus control group empty using 
a 1way ANOVA.
Supplementary Table S1. Sequences of primers used for quantitative PCR measurements.
Primer FW RV
IL-10 ATTTGAATTCCCTGGGTGAGAA ACACCTTGGTCTTGGAGCTTATTAA
IL-1Ra CAAGATGCAAGCCTTCAGAATCT CACCATGTCTATCTTTTCTTCTAGTTTGA
SOCS3 TAGACTTCACGGCTGCCAAC CGGGGAGCTAGTCCCGAA
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Figure 6. IL1Ra and Socs3 mRNA expression after IL-10 overexpression. IL1Ra (a) and Socs3 (b) 
gene expression in synovial tissue from knee joints was measured by qPCR. Significant upregulation was 
seen in the PGK-IL10 and Saa3-IL10 treated groups, compared to the PGKempty group. Gene expression 
is shown as -delta Ct, corrected for GAPDH. Depicted as mean±SEM; n=9. * = p<0.05, ** = p<0.01, 
*** = p<0.0001 versus control group empty when using a 1way ANOVA. The expression levels at day 7 
were correlated with IL-10 overexpression for IL1Ra (c) and SOCS3 (d). Depicted as individual joints. * = 
p<0.05, *** = p<0.0005 using Pearson r correlation analysis.
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Discussion
In this study, we have shown that IL-10 under the control of the disease regulated 
promoters Saa3 and Mmp13 can diminish synovitis and cartilage proteoglycan 
depletion in experimental arthritis. Effects were seen on histology, protein- and gene 
expression levels.
SCW-induced arthritis is an acute and transient model, which triggers the alternative 
complement activation cascade to attract neutrophils to the joint, already at day 1 
after induction. A peak in synovitis is seen at day 4 after induction and proteoglycan 
depletion is most severe at day 7. During these stages of the disease, different 
transcription factors are activated, triggering the recombinant promoters at different 
time points, resulting in distinct profiles between the different promoters. The Saa3 
promoter contains multiple predicted binding sites for C/EBPβ [3], which is associated 
with the acute phase of inflammation [11]. Microarray analysis also revealed a high 
and quick upregulation of the Saa3 gene in the knee joints of mice with RA.[3] 
According to the in vivo profile of promoter activation, Saa3 is highly upregulated with 
a 127 fold increase one day after induction of arthritis, as expected for an acute phase 
protein.  In contrast, the Mmp13 promoter contains at least three functional binding 
sites for ETV4, which is associated with tissue remodeling and repair mechanisms 
taking place in the remission phase of arthritis [17]. This explains the observed delay 
in MMP13-luciferase expression in the short-lasting SCW-arthritis model.
The inducibility of the Saa3 and Mmp13 promoters was shown by upregulation of 
IL-10 in the arthritic knee, compared to the non-arthritic knee. The constitutive PGK 
promoter, on the other hand, did not show inducibility, but a continuous upregulation 
of IL-10 in both the arthritic and non-arthritic knee. No direct effects of IL-10 on Saa3 
promoter activation were found, indicating that the Saa3-IL-10 construct produces no 
positive feedback loop. Among others, the Mmp13 promoter was activated at from 
day 4. The Tsg6 promoter even showed strongest induction at day 7, indicating that 
the promoters are activated during different phases in disease by different triggers. 
This property might be useful for application of gene therapy in models with specific 
pathologies, e.g. sclerosis, osteophyte formation or arthritis with flare ups at later time 
points. Such further stratified approacheswarrants further investigation.
Upregulation of IL-10 was seen at all days after disease induction. The therapeutic 
effect of IL-10 overexpression was seen on histology: both proteoglycan depletion and 
synovitis were significantly decreased. This is in line with the results of Lubberts et 
al. [14] where likewise an effect of IL-10 on inflammatory cell influx and proteoglycan 
depletion was found after repeated injections of IL-10 during SCW arthritis in mice. 
In addition, both IL1Ra and SOCS3 were upregulated. These genes are known to be 
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induced by IL-10 [6, 7]. IL1Ra is known to counteract the detrimental IL-1-dependent 
production and activation of different MMPs and aggrecanases.[18] By blocking IL-1 
with IL-10 induced IL-1Ra, these effects might be inhibited. SOCS3 can inhibit the 
JAK/STAT pathway and therefore diminish synovitis by, for instance, downregulating 
IL-6 [7, 19]. 
The neutrophil attracting chemokine KC protein levels were also significantly lower 
at day 1 after disease induction, which can influence synovitis as well.[20] Arthritis 
activates the complement cascade, with subsequent release of C5a.[21] C5a can 
activate the p38 MAP kinase pathway [22] and as a consequence KC is upregulated 
[23]. The p38 pathway can be inhibited by IL-10 [24] and therefore influence the 
expression of KC. Alternatively, IL-10 can induce instability of KC mRNA by repressing 
the mRNA stabilizing protein HuR [24, 25].
We showed that treatment of an acute joint inflammation with local IL-10 overexpression 
under the control of disease-regulated promoters, is a promising concept to modulate 
arthritis progression. By precise timing and prolonged, restricted production at the site 
of inflammation we might limit adverse IL-10 side effects in RA patients, such as the 
risk of developing anemia. It has been shown that IL-10 can enhance the FcγRI and 
IIa expression on monocytes/macrophages resulting in enhanced TNF-α production 
in response to immune complexes [9]. Although we did not use an antibody-mediated 
arthritis model, IL-10 in our study did not enhance the expression of both receptors 
(data not shown).  Disease-inducible promoters might be applied for expression of a 
transgene as a quick response to inflammation, or for supplementing the endogenous 
production of anti-inflammatory mediators at later time points, as we showed for the 
Saa3 and Mmp13 promoters respectively. This study showed that our previously 
described computational approach for selecting disease-response promoters 
combined with thorough in vivo validation using bioluminescent imaging of transgene 
expression results in promising candidates for tailor made/personalized therapy using 
local delivery of biological genes in arthritis. 
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Abstract
Antigen presenting cells (APCs) play an important role in arthritis and APC specific 
gene therapeutic targeting will enable intracellular modulation of cell activity. Viral 
mediated overexpression is a potent approach to achieve adequate transgene 
expression levels and lentivirus (LV) is useful for sustained expression in target 
cells. Therefore, we studied the feasibility of lentiviral mediated targeting of APCs 
in experimental arthritis. Third generation VSV-G pseudotyped self-inactivating 
(SIN)-LV were injected intravenously and spleen cells were analyzed with flow 
cytometry for green fluorescent protein (GFP) transgene expression and cell surface 
markers. Collagen-induced arthritis (CIA) was induced by immunization with bovine 
collagen type II in complete Freund’s adjuvant. Effect on inflammation was monitored 
macroscopically and T-cell subsets in spleen were analyzed by flow cytometry. 
Synovium from arthritic knee joints were analyzed for proinflammatory cytokine 
expression. Lentiviruses injected via the tail vein preferentially infected the spleen 
and transduction peaks at day 10.  A dose escalating study showed that 8% of all 
spleen cells were targeted and further analysis showed that predominantly Ly6C+ 
and F4/80+ cells in spleen were targeted by the LV. To study the feasibility of blocking 
TAK1-dependent pathwhays by this approach, a catlytically inactive mutant of TAK1 
(TAK1-K63W) was overexpressed during CIA. LV-TAK1-K63W significantly reduced 
incidence and arthritis severity macroscopically. Further histological analysis showed 
a significant decrease in bone erosion in LV-TAK1-K63W treated animals. Moreover, 
systemic Th17 levels were decreased by LV-TAK1-K63W treatment in addition to 
diminished IL-6 and KC production in inflamed synovium. In conclusion, systemically 
delivered LV efficiently targets monocytes and macrophages in spleen that are 
involved in autoimmune arthritis. Moreover, this study confirms efficacy of TAK1 
targeting in arthritis. This approach may provide a valuable tool in targeting splenic 
APCs, to unravel their role in autoimmune arthritis and to identify and validate APC 
specific therapeutic targets.
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Introduction
Inflammatory diseases, such as rheumatoid arthritis, are characterized by infiltration 
of leukocytes into the inflamed tissue consisting of various immune cells from both the 
innate and adaptive immune system. Macrophages in arthritis have been extensively 
studied and play an important role in maintaining inflammation and joint destruction 
[1;2]. Moreover, a general approach of macrophage specific targeting with lipoplexes 
ameliorates experimental arthritis [3;4].
Specifically modulating macrophage activity during inflammatory conditions is a 
suitable approach to limit systemic side effects of treatment. In addition, gene therapy 
can be  a powerful  technique to achieve intracellular modulation of protein expression 
or signaling. Effective gene therapeutic treatment of collagen-induced arthritis has 
been achieved by ectopic overexpression of suppressor of cytokine signaling 3 
(SOCS3) in splenic antigen presenting cells (APCs) [5]. In addition, knock down of 
TNF receptor I by overexpression of a short hairpin was also effective in ameliorating 
experimental arthritis [6]. Both studies used adenoviral vectors, ensuring a high, but 
transient transgene overexpression. Over recent years, HIV based lentiviral vectors 
have been optimized regarding safety and production and proved to be a valuable 
tool in order to get long term transgene expression.
Multiple studies have evaluated the feasibility of intravenous injection of lentivirus. 
These studies shown that the spleen is one of the organs predominantly targeted by 
lentivirus injected intravenously [7]. Further analysis on localization on GFP expression 
in the spleen showed large fluorescent clusters overlapping the marginal zone [8]. 
Cell surface markers revealed that mostly MHC-II positive cells were targeted by 
lentivirus [8;9], indicating preferential targeting of APCs by lentivirus.
Specific targeting of APCs by lentivirus makes it possible to study the role of these APCs 
in inflammatory conditions. In addition, specific interference with gene expression can 
possibly identify new therapeutic targets in APCs. To validate macrophage targeting 
a known potent therapeutic target was used, TGF-beta activated kinase 1 (TAK1). 
This MAP kinase is a key signaling protein as it is used by many pro-inflammatory 
signals. Toll-Like receptor and cytokine receptor activates intracellular signaling 
which converges to TAK1 and subsequently activate AP-1 and NF-κB. Therefore, 
TAK1 poses a compelling target to block pro-inflammatory signaling. Moreover, TAK1 
has been shown to be important in autoimmune arthritis [3] and is a suitable target to 
validate macrophage specific targeting by lentiviral vectors.
In this study, we validated intravenous lentivirus injections into DBA1/J mice by 
determining expression kinetics, a dose escalating study, and analysis of targeted 
cells. This has shown that predominantly splenic F4/80+ and Ly-6C+ cells are targeted 
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by this approach. To evaluate the gene therapeutic potential of LV-mediated targeting 
of splenic APCs, a TAK1 kinase negative mutant (TAK1-K63W) was over expressed 
during collagen-induced arthritis. TAK1-K63W decreased knee joint inflammation 
macroscopically and systemic Th17 levels in the spleen were reduced. In addition, bone 
erosion was diminished by TAK1-K63W and pro-inflammatory cytokine expression in 
synovial tissue was decreased. This study shows that intravenous delivery of lentiviral 
vectors enables evaluation of therapeutic targets in splenic monocyte/macrophage-
like cells that are important cells in autoimmune diseases.
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Material and Methods
Ethics Statement
All in vivo studies complied with national legislation and were approved by local 
authorities (Animal Ethics Committee, Radboud University Nijmegen. Permit number: 
2009-177) for the care and use of animals with related codes of practice.
Mice
Male DBA/1 mice aged 10-12 weeks (Janvier, Elavage, France) were housed in top-
filter cages and fed a standard diet with freely available food and water. 
Induction and monitoring of collagen-induced arthritis
Bovine type II collagen was dissolved in 0.05M acetic acid to a concentration of 2 mg/
ml and was emulsified in equal volumes of Freund’s complete adjuvant (2mg/ml of 
Mycobacterium tuberculosis strain H37Ra) (Difco, Detroit, MI) Mice were immunized 
intradermally at the base of the tail with 100ul of emulsion (50ug of bovine type II 
collagen). Subsequently, mice were given an intra-peritoneal booster injection of 
100ug of type II collagen dissolved in phosphate buffered saline (PBS) on day 21. 
Two independent observers monitored clinical signs of arthritis in paws and ankle 
joints, macroscopically. Cumulative scoring based on redness, swelling, and, in later 
stages, ankylosis was as follows: 0=no changes; 0.25=1-2 toes red or swollen; 0.5=3-
5 toes red or swollen; 0.5= swollen ankle; 0.5=swollen footpad; 0.5=severe swelling 
and ankylosis, with a maximal score of 2 per paw.
Plasmids
For generation of recombinant lentiviral vectors we used of the third-generation 
self-inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN (PGK-empty) 
containing the human phosphoglyceratekinase (PGK) promoter (kind gift from 
J. Seppen, AMC Liver Center, Amsterdam, The Netherlands). For cloning we 
used cloned Pfu DNA polymerase (Stratagene, La Jolla, CA) and T4 DNA Ligase 
(New England Biolabs, Ipswich, MA). All generated constructs were verified by 
sequencing. The cDNA sequences of a kinase-inactive mutant of human TAK1 
(K63W) were PCR cloned from pEGFP-C1-TAK1-K63W into NheI/NsiI sites of PGK-
SIN using the following primers: RV 5’-ATGCATTCATGAAGTGCCTTGTCAG-3’, 
FW 5’-GCTAGCGCCACCATGTCGACA GCCTCCGCCGCC-3’ (non-tagged, Kozak 
sequence for enhanced translation introduced).
Lentiviral vector production
Packaging of VSV-G pseudotyped recombinant lentiviruses was performed by transient 
transfection of 293T cells. One day prior to transfection, 293T cells were seeded in a 
T75 flask at 1x105 cells/cm2 in DMEM supplemented with 10% FCS, 1 mM pyruvate, 
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40 µg/ml gentamicin and 0.01 mM water-soluble cholesterol (Sigma). Cells were 
co-transfected with 19 µg transfer vector, 14 µg gag/pol packaging plasmid (pMDL-
g/p-RRE), 4.7 µg rev expression plasmid (RSV-REV) and 6.7 µg VSV-G expression 
plasmid (pHIT-G) by calcium phosphate precipitation. Transfections were performed 
in 6 ml DMEM without antibiotics and cholesterol and cultured for 16 hours. Thereafter 
medium was replaced with fully supplemented DMEM and supernatant harvested 
after 24 and 48 hours. Cell debris was removed by centrifugation at 1500 rpm for 5 
minutes at 4 °C, followed by passage through a 0.45 µm pore polyvinylidene fluoride 
Durapore filter (Millipore, Bedford, MA, USA). For concentration by ultracentrifugation 
28 ml supernatant was overlaid on 4 ml 20% sucrose solution and centrifuged at 
25.000 rpm for four hours in a Surespin 630 rotor (Thermo Fisher Scientific, Waltham, 
MA). Pelleted viruses were resuspended in sterile PBS and stored at -80 °C. Viral 
titers were determined by assaying p24gag values with a commercial enzyme-linked 
immunosorbent assay (ELISA) kit (Abbott Diagnostics, Hoofddorp, the Netherlands) 
and expressed as ng p24gag/µl.
In vivo imaging
In vivo bioluminescent imaging was performed on an IVIS Lumina system (Caliper 
Life Sciences, Hopkinton, MA, USA), 10 minutes after intraperitonal injection of 150 
mg/kg D-Luciferine (Caliper Life Sciences) dissolved in PBS. Mice were anesthetized 
with isoflurane/oxygen, placed on their back into the light tight chamber and imaged 
for 4 minutes with a sensitive CCD camera. Images taken were quantified using the 
Living Image 3.0 software (Caliper Life Sciences). Luciferase activity is presented in 
photons emitted per second per square cm.
RNA isolation and quantitative PCR analysis
Spleen, synovium, and liver samples were disrupted using the MagNaLyser 
(Roche). Total RNA was extracted from the tissue homogenates and from cells 
using TRI reagent (Sigma) according to manufacturer’s protocol. Isolated RNA was 
treated with DNAse followed by reverse transcription of 1µg RNA into cDNA using 
Moloney  murine leukemia virus reverse transcriptase 0.5µg/µl oligo(dT) primers, and 
12.5mM dNTPSs (Invitrogen). Quantitative real-time PCR was performed using the 
StepOnePlus sequence detection system (Applied biosystems, Foster City, CA) PCR 
was performed in a total reaction volume of 12.5 µl consisting of appropriate cDNA. 
Five µM of forward and reverse primer and the sYBR green PCR  master mix (Applied 
biosystems). PCR protocol consisted of 2 min at 50°C and 10 min of 95°C, followed 
by 40 cycles of 15 sec at 95°C and 1 min at 60°C. Quantification of PCR signals was 
achieved by calculating the difference between the cycle threshold value (Ct) of the 
gene of interest with the Ct value of their reference gene glycerldehyde-3-phophate 
dehydrogenase (GAPDH) for each sample (delta Ct)
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Histology
Spleens were isolated and fixed in  in phosphate buffered 4% paraformaldehyde and 
embedded in in paraffin wax. Whole knee joints were dissected and fixed in phosphate 
buffered 4% paraformaldehyde followed by decalcification with 5% formic acid, and 
embedded in paraffin wax. Serial tissue sections (7µm) were stained with Safranin O 
(BDH chemicals, Poole, UK) and counterstained with fast green (BHD Chemicals) or 
with hematoxylin / eosin (Merck, Germany) and eosin (Merck, Germany) (H&E). Serial 
sections were scored for histopathologic changes on a 0-3 scale, by 2 independent 
observers in a blinded manner. Joint inflammation was determined by the presence of 
synovial cell infiltrates and inflammatory cell exudates. Connective tissue destruction 
was determined by cartilage and bone erosion.  
FACS analysis
Spleens from mice were mashed, filtered and erythrocytes were removed by osmotic 
shock and directly stained for GFP expression and CD3, CD19, F4/80, and Ly-6C cell 
surface markers. For T-cell subset analysis CD3+ cells were isolated using the Pan 
T cell Isolation Kit (Miltenyi Biotec, Germany) according to manufacturer instructions. 
Purified CD3+ cells were stimulated in RPMI 1640 (Invitrogen) supplemented with 
10% FCS penicillin/streptomycin and pyruvate with 50ng/ml PMA, 1ul/ml/10^6 cells 
Brefeldin A (BD Pharmingen) and 1ug/ml ionomycin. After 4 hours of stimulation cells 
were stained with anti-mouse CD4-APC (1:200) (BD pharmingen) or IgG2a-APC 
controle (BD pharmingen) for 30 minutes at 4°C. Subsequently, cells were stained 
intracellular with anti-IL17-FITC and anti-IFNg-PE or with their controls respectively 
IgG1-PE and IgG1-FITC according to instructions by manufacturer (BD Pharmingen). 
Stained cells were analyzed using FACScalibur (Becton Dickinson) and analyzed 
with FlowJow software.
Statistics
Statistical differences were determined by one-way ANVA or student’s T-test (two 
sided) and GraphPad 5.0 software. P values below 0.05 were considered significant.
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Results and Discussion
Expression kinetics is dependent on route of administration
Although previous studies have shown efficient transduction of spleen cells by 
intravenously delivered lentivirus, there are considerable differences between 
Balb/c and C57Bl/6 mice[10]. Therefore the kinetics of lentiviral mediated transgene 
expression needs to be  determined in DBA1/J mice, an autoimmune prone strain 
used for the CIA model. We injected 10 µg p24GAG equivalent (approximately 5x10^8 
viral particles) of lentivirus encoding luciferase intravenously via the retro orbital 
sinus and luciferase activity was determined by in vivo imaging. figure 1A shows 
that maximal luciferase activity was reached at day 7 after virus injection. Organ 
distribution of the luciferase activity is shown in figure 1B and strikingly a substantial 
level of luciferase activity was found around the throat of the animals. These are 
possibly the submandibular lymph nodes draining the eye, but the precise localization 
was not identified. To avoid targeting this particular site and achieve more efficient 
delivery of LV to the spleen the retro orbital sinus injection site was compared with 
tail vein injections. figure 1C shows that the expression kinetics of lentivirus injected 
via tail vein in spleen and liver are different from injection via retro orbital sinus. 
Maximal luciferase activity peaks at day 10 and expression levels of luciferase were 
elevated compared to retro orbital sinus injections. Tail vein injection also showed 
more luciferase activity in the liver and spleen area (figure 1B and 1D). Unexpectedly, 
luciferase activity was also detected around the knee joint. This is most likely to 
originate from the bone marrow, as these cells are also transduced by lentivirus 
injected intravenously [7;10;11]  It appears that injection of lentivirus via the tail vein 
favors transgene expression levels and location and all subsequent experiments were 
performed with tail vein injections. Injection directly into a vein is potentially preferable 
over retro orbital sinus as the distribution of the lentivirus throughout the body is better 
than into a sinus, which has a slow blood flow.
Dose escalating study of lentivirus
After establishing the delivery route and transgene expression kinetics the optimal 
dose was determined by injecting increasing doses of lentivirus encoding GFP.  Figure 
2A shows that increasing doses of lentivirus also resulted in increasing percentage 
of GFP positive cells in spleen with 7.4% of total spleen cells were GFP positive 
when injected with 40 µg of p24GAG equivalent of lentivirus. Further analysis showed 
a 12 fold increase in GFP mRNA expression in spleen compared to liver samples 
(figure 2B). Together with the luciferase activity measurements shown in figure 1D we 
concluded that lentivirus efficiently transduces cells in the spleen. Although maximal 
expression of GFP was not reached we used 40 µg of p24GAG LV per animal in 
subsequent as a safe dose showing no side effects. GFP is known to elicit a specific 
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immune response [12], but no increase in splenic cell number was observed in the 
dose escalating study (data not shown).
Figure 1. Transgene expression kinetics. 
Every animal received 10 µg of p24GAG equivalent of lentivirus encoding firefly luciferase intravenously. 
Luciferase activity was determined after injection of luciferine using biophotonic imaging with the IVIS 
Lumina. Region of interest was placed over abdomen of mice. Kinetics of transgene expression (A) 
and organ distribution of transduction (B) after  lentivirus injection via the retro orbital sinus, n=6. B). 
Comparison between retro orbital sinus and tail vein injection (n=2 in both groups) for splenic expression 
(C) and localization of transgene expression in tail vein injected animals (D).
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Figure 2. Dose finding of intravenous lentivirus injection. 
Increasing doses of lentivirus encoding GFP were injected via the tail vein and GFP expression was 
analyzed 10 days after injection. A) Total spleen cells were analyzed by flow cytometry for GFP expression. 
B) GFP mRNA expression in liver and spleen samples. Relative expression = 2-ΔCt. Data represented as 
mean±SEM. Statistics: one-way ANOVA with Bonferonni post test compared to LPS injected animals, n=4 
per group.  ** p<0.01, *** p<0.001.
Macrophages and monocytes are preferentially targeted by lentivirus
Immunohistochemistry was done to determine the location of GFP expression in the 
spleen. Figure 3A shows that with increasing dose of lentivirus also more GFP protein 
is detected. GFP expression was detected around the white pulpa near the marginal 
zone, in line with other reports [8;13]. In a separate experiment it was determined 
which cells are targeted by lentivirus in the spleen, leukocytes were isolated from 
spleen and GFP expression was determined in combination with cell surface markers 
(figure 3B). This confirmed that lentivirus only marginally targets T- and B-cells, 
since the IHC showed that there was no GFP expression in the white pulpa of the 
spleen. In contrast, it appears that lentivirus preferentially targets F4/80+ and Ly-
6C+ cells as 30-40% of cell populations were GFP positive. The GFP expression in 
F4/80+ cells remains stable for up to ten days after virus injection (data not shown). 
This preferential targeting of the APC population has also been described by others 
[8;9]. The monocyte population shows a sharp drop off in GFP expression between 
day 4 and 7 after virus injection. This probably reflects migration or differentiation of 
Ly-6C+ monocytes, whereas the F4/80 expressing macrophages present in the red 
pulpa reside in the spleen [14]. The antigen presenting cell (APC) population in the 
spleen consists of many different subtypes of dendritic cells and macrophages. Here, 
we show a preferential targeting of the macrophage and monocyte population, but 
identification of the exact APC subpopulation remains to be determined.
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Figure 3. Localization splenic GFP expression and identification of transduced cell types by cell 
surface marker analysis. 
A) Increasing doses of lentivirus encoding GFP were injected via the tail vein and GFP expression was 
analyzed by immunohistochemistry ten days after virus injection. Representative histological images of 
experiment (magnification 200x), dotted line outlines white pulpa. W = white pulpa, R = red pulpa. Arrow 
heads indicate GFP positive cells. B) Flow cytometric analysis of GFP expressing cells 4 and 7 days after 
virus injection. Data represented as average (±SEM) GFP positive cells in gate indicated on x-axis (n=4). 
C) Representative plots of cell marker and GFP FACS analysis.
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Lentivirus targets cells that play an important role during arthritis
Next, we evaluated if the targeted cells also play a functional role in inflammatory 
diseases. Therefore mice immunized with bovine collagen type II were injected with 
lentivirus encoding a kinase negative mutant of TAK1 (TAK1-K63W) to decrease 
inflammatory signaling by Toll-Like Receptors and cytokines. This target was identified 
as an important signaling molecule in experimental arthritis and provides a suitable 
target to study the efficacy of intravenous injection of lentivirus [3]. Figure 4A shows 
that disease incidence is decreased in animals injected with lentivirus overexpressing 
the negative TAK1 mutant. In addition, macroscopic swelling of the knee joints was 
significantly decreased at time of sacrifice (figure 4B). Further histological analysis 
(figure 4C-E) showed only a trend towards decreased inflammation and cartilage 
erosion. Bone erosion, however, was significantly decreased in mice treated with 
TAK1-K63W. This is in line with the altered Th17 population, which plays an 
important role in osteoclast activity and bone erosion [15]. In addition, Ly-6C positive 
cells are precursors of osteoclasts [16] and inhibition of pro-inflammatory signaling 
on these cells possibly also inhibits osteoclast formation. A strong trend is found 
towards decreased levels of cell influx into the joint and Swirski and colleagues have 
described a pool of cells in the spleen that migrate towards the site of inflammation 
[17]. These cells were CD11b and Ly-6C positive and we have found Ly-6C+ cells 
expressing GFP after lentivirus administration (figure 3B). Additionally, Ly6C-high 
expressing monocytes are attracted to the site of inflammation from the bone marrow 
in a kidney injury model [18]. Taken together, lentivirus injected intravenously could 
possibly target this pool of migrating monocytes in the spleen. 
Lentivirus targets cells controlling the adaptive immunity
To study if the targeted cells are involved in controlling the adaptive immunity, T-cell 
subsets were determined in the spleen. At a systemic level, the TAK1 mutant had only 
marginally effects on Th1 development in the spleen. However, Th17 cell population 
was significantly decreased in the spleen by overexpression of the TAK1 mutant 
(figure 5A). This suggests that lentivirus delivered intravenously also targets cells that 
are involved in controlling the adaptive immunity. This is in line with previous studies 
that showed transduction of MHC-II+ cells  in spleen [9] and targeting of dendritic 
cell precursors and influence T-cell proliferation [19]. In addition, systemic lentivirus 
delivery has been used to induce tolerance in collagen-induced arthritis and showed 
clear potential in affecting T-cell function, with decreased proliferation [11].
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Figure 4. Effect of splenic TAK1 targeting on arthritis incidence and knee joint swelling. 
A) Arthritis incidence was monitored over time macroscopically. B) Swelling of knee joints macroscopically 
at time of sacrifice (day 30 of CIA). Data represented as mean±SEM. Statistics macroscopic scoring: 
Student’s t-test, n=7 per group. ** p<0.01. C-E) Knee joints were isolated and evaluated for pathohistological 
features. C) Inflammation scores determined on HE stained sections. D) Cartilage erosion scores 
determined on safranin-O stained sections. E) Bone erosion scores determined on safranin-O stained 
sections. F-G) Representative histological images of knee joints. Original magnification 100x. Bone 
erosion indicated with arrow head. P=patella, F=femur. Statistics histology: Student’s t-test, n=8 for GFP, 
n=6 for TAK1-K63W. * p<0.05.
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Figure 5. T-cell subsets in spleen during arthritis after TAK1 targeting in splenic APCs. 
A) Spleen cells were isolated and stimulated with PMA and ionomycin for 4 hours and subsequently stained 
for CD4, IFNγ, and IL-17. Percent positive cells from CD4 gate is shown. B) Representative FACS analysis 
plots. IL-17 and IFNγ positive cells in CD4+ gate shown. Data represented as mean±SEM. Statistics: 
Student’s t-test, two tailed, n=7. * p<0.05. 
Local inflammation decreased upon lentiviral targeting of macrophages and monocytes
From the inflamed joints synovium was extracted and mRNA analysis showed that 
proinflammatory cytokine mRNA expression was decreased when mice were treated 
with lentivirus encoding the TAK1 mutant (figure 6). Although not significant, IL-1β 
production shows a trend towards diminished production in the inflamed synovium 
and might underly the trend in decreased cartilage erosion. The decrease in IL-6 
production also supports the diminished levels of Th17, as IL-6 is a crucial factor for 
Th17 development [20] . Moreover, RANK and RANK ligand, important for osteoclast 
formation and function are decreased in synovium of inflamed knee joints (figure 6B) 
[21]. Together with altered systemic Th17 levels, this possibly causes the decrease 
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in bone erosion. Additionally, production of the chemokine KC is significantly reduced 
and possibly explains the clear trend in reduced inflammation observed on histology. 
This shows that targeting the macrophages and monocytes in the spleen and liver 
can have distal effects on the inflamed tissue and shows the importance of this cell 
population in experimental arthritis.
A B
Figure 6. Proinflammatory cytokine expression in synovium of arthritic animals. 
Synovium was isolated from arthritic animals and disrupted. Total mRNA was isolated and analyzed for A) 
cytokines (IL-1β, IL-6, KC) and B) RANK, and RANKL mRNA expression. Data represented as mean±SEM. 
Relative expression = 2-ΔCt. Statistics: Student’s t-test, n=6. * p<0.05.
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TAK1 as therapeutic target in arthritis has been established by Courties and 
colleagues [3], in which TAK1 expression was knocked down using RNA interference 
and ameliorated collagen-induced arthritis. This study also showed altered T-cell 
subsets upon TAK1 targeting in APCs, but also showed a more efficacious therapy on 
arthritis severity. In the present study we overexpressed a negative mutant of TAK1 
which is a competitive mutant and complete blockade of TAK1 cannot be achieved. In 
addition, lentivirus tropism is possibly more selective than lipoplexes. Nevertheless, 
we find matching results with TAK1 targeting in collagen-induced arthritis. 
Interestingly, a novel role for TAK1 has been described recently [22;23]. Both studies 
have investigated the role of TAK1 in the production of pro-inflammatory cytokines 
and, remarkably, TAK1 negatively regulates cytokine production in myeloid cells. In 
these studies used lipopolysaccheridewas used as stimulus, which is a very potent 
activator of neutrophils and macrophages. In addition, cytokine production was only 
determined over 24 hours. In contrast, collagen-induced arthritis involves a more 
complex process than a single stimulation and the clinical features of collagen-
induced arthritis were studied for 12 days on our study.
In summary, this study shows an effective method to target a monocyte and macrophage 
population in spleen that is involved in inflammation and immunity. Blocking almost all 
pro-inflammatory signals, by overexpression of a TAK1 mutant, disrupts progression 
of experimental arthritis and impairs T-helper cell development. Injection of lentivirus 
intravenously provides a straightforward tool to study potential therapeutic targets in 
monocytes and macrophages during inflammatory conditions. Additionally, this study 
confirms the efficacy of TAK1 targeting in arthritis and emphasizes the role of this 
crucial MAP kinase in monocytes and macrophages during autoimmune arthritis.
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Imaging is a broad and versatile technique used nowadays in the clinics to diagnose 
and monitor arthritis patients. Imaging may also help on clinical decision making in 
the treatment of rheumatoid arthritis (RA) patients. Concomitantly, imaging is also 
used in  biomedical research. The beauty of these different tools and techniques is 
the possibility to combine them with personalized anti-rheumatic treatment. The aim 
of this thesis was therefore to explore some promising imaging tools and implement 
them into murine experimental arthritis models, while simultaneously using some of 
these techniques to optimize personalized (gene)therapy.
Imaging of inflammation in experimental arthritis by SPION
Joint inflammation is an important hallmark of RA and can lead to cartilage and bone 
damage. To be able to intervene in the process of cartilage damage, early detection 
of inflammation is important. Nanotechnology is an emerging field in life sciences and 
superparamagnetic iron oxide nanoparticles (SPION) can be an interesting tool to 
detect inflammation[1]. In chapter 2, an overview is given of the different applications 
of SPION in arthritis research, as well as in other inflammatory diseases. Due to its 
superparamagnetic properties, SPION can be visualized using magnetic resonance 
imaging (MRI). SPION are taken up easily by cells of the reticuloendothelial 
system, in particular by macrophages. Macrophages are abundantly present during 
inflammation and by labeling macrophages with SPION, inflammation can be detected 
using MRI. SPION can also be coupled to, for instance, a neutralizing antibody or a 
therapeutic protein. This can make the SPION a theranostic agent; the combination 
of a therapeutic drug and a diagnostic imaging entity into one drug delivery vehicle
SPION are large iron oxide nanoparticles and often coated with foreign material to 
enhance the circulation half life. To use SPION as an imaging tool, administration 
of the SPION during arthritis is required either locally or systemically. Important to 
know is if the body will give an adverse reaction to the SPION and if this response 
will aggravate arthritis. Hence, in chapter 3, we examined the reaction of the body to 
SPION administration and studied potential SPION effects on the course of antigen-
induced arthritis (AIA) in the mouse. A clinically relevant dose or an excess dose of 
SPION was administered either locally or systemically in healthy mice or in mice 
suffering from arthritis. No adverse reactions were seen after injection of the low 
dose. However, injection of the high dose into healthy knee joints immediately gave 
a short lasting inflammatory reaction of the soft tissue around the joint, called the 
synovium. On the other hand, no disease-aggravating effect on the synovium was 
seen after injection into an arthritic knee joint. We therefore concluded that injection 
of a high dose of SPION gave a limited, short-lasting inflammatory response, while 
the clinically relevant dose of SPION did not elicit a response altogether. Because of 
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this profile, we conclude that SPION can be applied safely to detect joint inflammation 
by MRI. In addition, SPION in future application may also be coupled to, for instance, 
antibodies or therapeutic agents. This next generation SPION could be used to target 
specific tissues or processes in the joint and to more effectively treat arthritis.
Imaging of destruction in experimental arthritis by fluorescent 
probes and antibodies
Cartilage damage can occur early in the arthritic disease process[2]. Because cartilage 
does not have regenerative capacities, early detection or prediction of cartilage 
damage is important to be able to intervene in this process as early as possible. 
Imaging can be a helpful tool to achieve this. Antibodies directed against cartilage 
components like collagen type II can be used to detect cartilage damage. Collagen 
type II is the basic structural component of articular cartilage and abundantly present. 
When the top layer of the cartilage is damaged mechanically or enzymatically, the 
collagen fibrils become exposed at the cartilage surface. In chapter 4 we selected an 
antibody directed against collagen type II. Selection and validation of the antibody 
was done using artificially damaged bovine cartilage explants and damaged human 
cartilage explants. Different degrees of cartilage damage were achieved using different 
concentration of the enzyme trypsin. Trypsin digests the cartilage proteoglycans 
which are the second most abundant cartilage component facilitating resistance to 
compressive forces. The amount of anti-collagen type II antibody binding correlated 
with the degrees of cartilage damage. We concluded that this anti-collagen type II 
antibody can be coupled to imaging modalities like SPION or radioactive tracers 
to specifically detect cartilage damage, and eventually can be used for targeted 
treatment into the arthritic joint by attachment of a therapeutic agent.
In addition to the anti-collagen type II antibodies, it is also possible to image and 
measure the processes that leads to cartilage damage before clinical signs 
are present, using activatable fluorescent probes. These probes are optically 
silent and become fluorescent after cleavage by a range of enzymes like matrix 
metalloproteinases (MMPs) or cathepsins. Real-time enzyme activity can then be 
measured in vivo by quantification of the fluorescent signal. MMPs and cathepsins 
are important proteases during the process of cartilage damage. In chapter 5, MMP 
and cathepsin activity was measured using these activatable fluorescent agents in 
two different mouse models, one representing RA and one representing osteoarthritis. 
Fluorescent signals were compared to and correlated with gene expression analysis 
and histological parameters, such as inflammation, cartilage erosions and DIPEN 
staining, a neoepitope of aggrecan cleaved by MMPs. By combining these datasets 
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we found that various MMPs are active during the process of irreversible cartilage 
damage in both mouse models, while cathepsin activity was only detectable in the 
murine RA model. We also showed that it is possible to monitor the efficacy of a 
therapeutic agent, in this case anti-IL-1, using these activatable probes.     
Overall, cartilage damage can be visualized and quantified using a variety of 
techniques. We used antibodies and activatable fluorescent probes to show the 
feasibility of these techniques to detect and monitor cartilage destruction and catabolic 
processes in cartilage explants and in RA and OA mouse models. 
Imaging of gene expression profiles and targeted gene therapy in 
experimental arthritis
Because RA is a highly heterogeneous disease, meaning that patients differ from 
each other regarding their symptoms and their responsiveness to treatment, patient-
tailored therapy is a widely discussed topic nowadays[3]. Concomitantly, side-effects 
caused by the therapeutic drugs raise another question; whether it is possible to only 
administer medication during an exacerbation of the disease? Gene therapy using 
disease-inducible promoters can be a way to achieve this: these promoters can drive 
the transcription of a therapeutic gene or a reporter gene only during exacerbation of 
the disease.
In chapter 6 a lentiviral vector based disease-inducible promoter reporter is evaluated. 
Optimal dose-finding was performed to efficiently transduce a murine knee joint. 
Using this information, expression profiles of the inducible Saa3 and Cxcl1 promoter 
were made in the streptococcal cell wall (SCW) mouse model. The Saa3 promoter, 
compared to the Cxcl1 promoter, was highly inducible and followed the course of 
inflammation during SCW arthritis. Therefore this inducible promoter was selected 
for further investigation. It was shown that the Saa3 promoter was a more sensitive 
read-out compared to an established method for detection of joint swelling, the 
Technetium-99m uptake, especially during mild joint inflammation. The Saa3 promoter 
was then used to investigate whether this promoter can detect a difference between 
synovial fibroblasts with a high or low inflammatory gene expression profile. Indeed, 
the promoter was able to distinguish between these two subtypes, showing higher 
activity in fibroblasts with a high inflammatory phenotype. Finally, the diagnostic value 
of the inducible promoter was evaluated by incubation of Saa3 reporter cells with 
serum of RA patients and healthy controls. Sera from RA patients gave a significant 
upregulation of the reporter compared to healthy control sera. We therefore concluded 
that the Saa3 promoter-reporter is a novel and feasible tool with a potential diagnostic 
value in experimental and human arthritis.
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Besides the Saa3 and Cxcl1 promoters, more disease-inducible promoter reporters 
were developed in our group. The potential for using these inducible promoters in 
personalized gene therapy has been investigated and described in chapter 7 of this 
thesis. Six different proximal promoters with a luciferase reporter gene were used to 
make local gene expression profiles in the murine SCW model. Profiling was performed 
using in vivo bioluminescence imaging of the knee joints. From these profiles two 
inducible promoters, the Saa3 and Mmp13 promoter, were selected for their high 
inducibility and differences in profile. These promoters were used to examine the 
therapeutic effects of disease-regulated IL-10 expression in the SCW mouse model. 
Histological analysis of the knee joints showed significantly lower proteoglycan 
depletion and synovitis using both inducible promoters. The Saa3 promoter was 
selected for further gene expression analysis. This showed an upregulation in synovial 
tissue of the SOCS3 and IL-1Ra gene, both negative regulators in inflammation known 
to be upregulated by IL-10. Expression levels of SOCS3 and IL-1Ra also correlated 
to the overexpression of IL-10. In conclusion, treatment of an acute joint inflammation 
by local overexpression of IL-10 under the control of a disease-inducible promoter is 
a promising concept for patient-tailored treatment of arthritis.
In chapter 7 local gene therapy in arthritis is explored, but because arthritis is a disease 
that is not only located in one joint, systemic gene therapy can also be an appealing 
option. This is investigated in chapter 8. Firstly, expression kinetics were made 
after intravenous injection of a lentivirus encoding a constitutively active promoter 
with a luciferase reporter gene. This was done using bioluminescence imaging and 
quantification of the whole mouse body. As concluded from the bioluminescence 
imaging, the lentivirus primarily targets the spleen. From a subsequent experiment 
we learned that especially the monocytes and macrophages in the spleen were 
targeted. The next step was to investigate whether these targeted cells that play a 
role in the arthritic process can be manipulated using gene therapy. We therefore 
intravenously injected mice with the lentiviral vector overexpressing TAK1-K63W, 
coding for an inactive mutant of a protein kinase, during an arthritis model. Disease 
incidence, macroscopic swelling of the knee joints and microscopic bone erosion 
were decreased by this gene therapeutic approch. We can therefore conclude that 
systemically administered lentivirus targets the monocytes and macrophages of the 
spleen and that these cells can successfully be used for targeted gene therapy to 
diminish experimental arthritis. Treatment by systemic gene therapy is a feasible and 
effective manner to abate experimental arthritis and can therefore be a promising tool 
for personalized treatment of RA.
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Future perspectives
Early diagnosis of RA, at the stage of subclinical joint inflammation and destruction, 
is a widely discussed topic and is essential to provide a window of therapeutic 
opportunities. If joint inflammation is detected as early as possible, effective disease-
suppressing therapies can be started before irreversible cartilage damage occurs. 
This can delay the course of the disease significantly. Imaging, in the broad sense 
of the word, already contributed to an earlier diagnosis, but there is always room for 
improvement. X-ray techniques are the ‘gold standard’ and are already in use for 
a long time to detect bone erosions. For early detection of inflammation or tissue 
damage more advanced techniques are needed, such as MRI, ultrasound, PET or 
SPECT imaging. 
Subclinical detection of joint inflammation can be done using MRI. It is also shown 
that signs of subclinical inflammation associates with radiographic progression[4, 
5]. Detection of inflammation by MRI is relatively easy, but detection of cartilage 
damage and especially early cartilage damage is much more difficult. The use of a 
targeted contrast agent in combination with MRI can be a solution[6]. Nanoparticles 
such as SPION have been used already in a wide range of diseases[7, 8] and may 
also be useful in early detection of joint inflammation or cartilage damage in RA 
patients. Functionalization of SPION by attachment of an antibody can bring plenty 
of opportunities to target damaged cartilage or specific disease processes during 
arthritis. Attachment of a therapeutic agent can even further expand the opportunities, 
in that way targeting can be combined with a personalized disease-suppressing 
therapy, bringing the therapeutic agent to the place of inflammation or damage. 
But with these opportunities also come more difficulties. Toxicity, biodistribution, 
but also stability of these functionalized nanoparticles are big issues that need to 
be addressed before going into patients[9, 10]. However, SPION are very versatile 
and can be used in multiple imaging modalities, such as MRI, SPECT or for optical 
imaging[11]. Therefore, after solid research, there can be a great future for targeted 
SPION in the clinics.
Fluorescence imaging is already used in patients, but is still relatively new. 
Fluorescence guided surgery to remove malignant tumors using 5-Aminolevulic acid 
(5-ALA) is carried out. 5-ALA causes overproduction of cellular protoporphyrin IX, 
which can emit a red fluorescence signal after excitation with a blue-violet laser[12]. 
Using this technique, certain brain, bladder and gastrointestinal tumors can be 
resected very precisely with minimal damage to healthy tissues. Detection of joint 
inflammation using ICG can be done and monitoring of therapeutic interventions is now 
being investigated[13]. The future here lies in the possible application of activatable 
fluorescent probes in the clinics. The ability to image enzyme activities in vivo in real 
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time by optical imaging can provide more information about the disease activity in 
a non-invasive manner. For instance, this information can be utilized in making a 
decision about which therapeutic strategy to use. However, fluorescence imaging can 
still be complicated because of auto-fluorescence, low resolution and the relatively 
low tissue penetration[14]. Different techniques are investigated to overcome these 
issues, such as photoswitchable fluorescent probes[15], the use of near-infrared 
wavelengths[16], or multimodality imaging[17]. For now, activatable fluorescent 
probes like the ones used in this thesis, are mainly applied pre-clinically to gain more 
insight into disease processes and to study potential therapeutic interventions[18].
Bioluminescence imaging to follow gene expression profiles can be carried out using 
disease-regulated promoter reporter constructs[19]. In the future there should be an 
opportunity for clinical imaging of regulated promoters, with for instance the promising 
Saa3 promoter, using a variety of different reporter genes in various imaging modalities. 
Currently, reporter genes that can be used for multimodal imaging are explored. 
For instance, superpositively charged mutants of GFP are used to investigate the 
possibilities for MR-imaging in combination with fluorescence imaging[20]. But also an 
artificial gene, the lysine-rich protein (LRP), is used as a reporter gene for detection of 
tumor tissue using MR-imaging[21]. Ex vivo use of disease-regulated promoters can 
be another, maybe more likely approach in diagnosing arthritis or other inflammatory 
diseases. Tests using disease-regulated promoter-reporters based on blood or serum 
from the patient can be a non-invasive method to diagnose an inflammatory disease 
or to monitor treatment efficacy. On top of that, this method can provide valuable 
insights into the pathogenesis of arthritis on gene expression level. As demonstrated 
in this thesis, the Saa3 promoter-reporter can be used for this purpose.
Disease-regulated promoters can, together with bioluminescence imaging, also be 
used in a gene therapeutic approach. Gene therapy is a thoroughly investigated 
topic nowadays. Although lots of positive results are gained in experimental animal 
models[22, 23], the way into the clinic is not easy. Strict rules are needed before using 
gene therapy in patients. On the other hand, the challenge is to inform researchers, 
patients and general public about gene therapy to reduce their fear of the unknown. 
Only a couple of clinical trials have been performed regarding gene therapy in 
arthritis[24]. The use of regulated promoters can be a very promising concept to 
take a step closer to personalized medicine. Different regulated promoters are under 
investigation: cell or tissue-specific promoters[25], promoters that are artificially 
regulated, such as the Tet-On/Off systems[26, 27], or disease-regulated promoters 
that react to transcription factors activated during a disease, such as arthritis[28]. 
The concept of disease-regulated promoters is yet only investigated in experimental 
models[28-30] and therefore still in its infancy, but holds great promise. Hence, an 
important question is which regulated promoter to choose and what the transgene of 
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choice will be. This can of course vary between patients, but in the end will meet the 
requirements of personalized therapy.
In summary, the imaging tools and techniques presented in this thesis all show 
promising results towards personalized therapy in arthritis. With this thesis a solid 
base is build for further research towards application of these tools and techniques in 
the patient. With more characterization and safety studies this can be feasible. Hence, 
the results discussed in this thesis will help to put emphasis on the added value of 
using SPION, antibodies, fluorescent probes and gene therapy in the treatment and 
imaging of arthritic diseases. 
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Reumatoïde artritis (RA) is een chronische auto-immuun ziekte, voornamelijk gekenmerkt 
door ontsteking en schade in een of meerdere gewrichten. Ongeveer 0,5-1,0% van de 
westerse bevolking lijdt aan deze invaliderende ziekte. De oorzaak is nog niet geheel 
bekend, maar meerdere factoren spelen samen een rol, zoals onder andere genetische 
aanleg of roken.
Het gewricht is omgeven door een dunne laag cellen, het synovium genaamd. Dit 
synovium vormt een barrière rond het gewricht en een belangrijke functie is de aanmaak 
van synoviale vloeistof. Het synovium bestaat voornamelijk uit twee soorten cellen: de 
fibroblasten en de macrofagen. Het kraakbeen aan de uiteinden van de botten zorgt voor 
schokdemping tijdens het bewegen.
Een algemeen geaccepteerde behandeling voor RA is het gebruik van biologicals; 
antilichamen of peptiden geïsoleerd uit natuurlijke bronnen. Een bekende biological is 
anti-TNF. Alhoewel deze biologicals over het algemeen goed werken is bekend dat het 
ziekteverloop en de effectiviteit van de medicijnen per behandelde patiënt verschillend 
is. Sommige patiënten reageren ook niet op anti-TNF behandeling en vele medicijnen 
geven ongewilde bijeffecten. 
In sommige gevallen verloopt de ziekte zeer grillig, met uitbraken van ontsteking, maar 
ook met tijden van remissie. Een oplossing zou zijn om de patiënt alleen te behandelen 
met medicatie als deze in een periode van opvlamming van de ziekte zit, maar ook om 
de patiënt dus niet te behandelen ten tijde van remissie. Om erachter te komen hoe 
actief de ziekte is bij de patiënt kunnen niet-invasieve methodes zoals imaging (beeld 
vormende technieken) gebruikt worden. 
Imaging is op dit moment al een veel gebruikte methode in de kliniek. Bekende imaging 
methodes zijn, onder andere, magnetische resonantie imaging (MRI-scan), echo 
apparatuur of computertomografie (CT-scan). Ziekte activiteit of schade aan bot en 
kraakbeen kan zichtbaar gemaakt worden met gebruik van contrast vloeistoffen. Optische 
imaging technologie kan ook gebruikt worden om ziekte activiteit vast te stellen. Hierbij 
wordt gebruik gemaakt van bioluminescentie of fluorescentie, zoals bijvoorbeeld een 
antilichaam gekoppeld aan een fluorescerend label. Het voordeel van optische imaging 
is de korte tijd die nodig is om een beeld te vormen.
Om gedegen onderzoek te kunnen doen in een laboratorium, zijn er verschillende 
muismodellen beschikbaar. Alhoewel het moeilijk is om RA precies na te bootsen 
in een model, zijn er wel verschillende modellen beschikbaar die elk gefocust zijn 
op verschillende aspecten van RA, zoals ontsteking of kraakbeenschade. Deze 
muismodellen worden gebruikt om het ziekteproces verder te ontrafelen. Dit wordt ook 
op laboratoriumschaal steeds meer gedaan met behulp van imaging technieken.
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Alhoewel er al goede imaging technieken en behandelingen bestaan voor RA patiënten, 
is er nog ruimte voor verbetering. Het is nog steeds een uitdaging om een patiënt 
adequaat te diagnosticeren en te behandelen met zo min mogelijk bijeffecten. Het 
doel van dit proefschrift is dan ook het onderzoeken en nagaan van nieuwe imaging 
technieken, imaging hulpmiddelen en therapeutische toepassingen hiervan en het 
implementeren van deze technieken in verschillende muismodellen voor artritis.
Imaging van ontsteking in experimentele artritis met behulp van SPIONs.
Nanotechnologie kan ook gebruikt worden in de medische wereld, voornamelijk voor 
imaging en medicatie doeleinden. Super paramagnetische ijzeroxide nanodeeltjes 
(SPIONs) kunnen worden opgenomen door macrofagen, die een grote rol spelen bij 
ontstekingen tijdens RA. Deze SPIONs kunnen daarna weer zichtbaar gemaakt worden 
met behulp van MRI. SPIONs kunnen ook gekoppeld worden aan bepaalde antilichamen 
of medicijnen, hierdoor hebben de SPIONs een dubbel doel: het zichtbaar maken van 
ontstekingshaarden of schade en tegelijkertijd het behandelen van het ziekteproces 
wat gaande is. In hoofdstuk 2 van dit proefschrift is een overzicht gegeven van de 
verschillende toepassingen van SPIONs in onderzoek naar ontstekingsziekten. SPIONs 
kunnen lokaal maar ook systemisch, via de bloedbaan, geïnjecteerd worden. Het is 
daarom belangrijk om te weten of het lichaam een reactie geeft op deze SPIONs en 
wat voor effect het heeft op het verloop van de ziekte. In hoofdstuk 3 van dit proefschrift 
is onderzocht wat voor reactie het lichaam geeft na injectie van SPIONs en of dit een 
effect heeft op het verloop van het antigeen geïnduceerde muismodel. Een hoge dosis 
SPIONs gaf een acute kortdurende reactie, maar een lage, meer klinisch relevante dosis 
gaf geen reactie. Het verloop van de artritis werd ook niet beïnvloed door de injectie van 
SPIONs. Daarom hebben wij geconcludeerd dat SPIONs gebruikt kunnen worden om 
gewrichtsontstekingen te kunnen diagnosticeren met behulp van MRI. In de toekomst 
kunnen deze SPIONs gekoppeld worden aan antilichamen of medicatie, zodat ze nog 
gerichter en effectiever ingezet kunnen worden voor de diagnose en behandeling van 
RA. 
Imaging van gewrichtsschade in experimentele artritis door middel van fluorescerende 
probes en antilichamen.
Kraakbeenschade is een irreversibel proces, waardoor vroege diagnose en een adequate 
behandeling van groot belang is. Antilichamen gericht tegen kraakbeen componenten, 
zoals collageen type II, kunnen gebruikt worden voor de diagnose van kraakbeenschade. 
In hoofdstuk 4 van dit proefschrift hebben we een antilichaam gericht tegen collageen type 
II geselecteerd uit een groep van 9 antilichamen. Selectie was gedaan met behulp van 
kraakbeen geïsoleerd uit het gewricht van een koe waarbij kraakbeenschade kunstmatig 
was aangebracht door incubatie met trypsine. Trypsine breekt de proteoglycanen die in 
het kraakbeen zitten af, waardoor er schade ontstaat. Door het gebruik van verschillende 
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concentraties trypsine is het mogelijk om het kraakbeen in verschillende mate kapot te 
maken. De binding van het geselecteerde antilichaam correleerde met de mate van 
kraakbeenschade. We kunnen concluderen dat dit antilichaam geschikt zou kunnen 
zijn om kraakbeenschade te detecteren met behulp van imaging, door middel van het 
koppelen van het antilichaam aan bijvoorbeeld een fluorescente marker of een SPION. 
In de toekomst zou er ook medicatie aan gekoppeld kunnen worden, waardoor deze 
precies op de plek van de kraakbeenschade gebracht zou kunnen worden. 
In tegenstelling tot het direct meten van kraakbeenschade, is het ook mogelijk om de 
processen die leiden tot kraakbeenschade te imagen. Hiervoor kunnen fluorescerende 
probes gebruikt worden. Deze probes worden fluorescent nadat specifieke enzymen, 
zoals matrix metalloproteinases (MMPs) of cathepsines, de probes geknipt hebben. 
Hierdoor is het mogelijk om de actuele enzym activiteit te meten. In hoofdstuk 5 zijn deze 
probes gebruikt om enzym activiteiten te meten in twee verschillende muismodellen, 
een voor RA en een voor osteoartritis (OA). Door het fluorescente signaal te correleren 
aan gen expressies en histologische parameters, hebben we kunnen concluderen dat er 
verschillende MMPs actief zijn tijdens het proces van onherstelbare kraakbeenschade 
in zowel het RA als het OA muismodel. Cathepsine activiteit daarentegen was alleen te 
vinden in het RA muismodel. Ook hebben we aangetoond dat het mogelijk is met behulp 
van de fluorescerende probes het effect van een behandeling te monitoren, in dit geval 
een anti-IL-1 behandeling.
Imaging van gen expressie profielen en doelgerichte gentherapie in experimentele artritis
RA verloopt bij elke patiënt anders en sommige patiënten kennen zelfs tijden van 
opvlamming of remissie van de ziekte. Om iedereen gericht te kunnen behandelen 
en bijeffecten van medicatie te verminderen is er een op maat gemaakte therapie 
nodig. Gentherapie met behulp van een ziekte induceerbare promotor kan hierbij de 
oplossing zijn. In hoofdstuk 6 wordt de ziekte induceerbare promotor reporter Saa3-Luc 
geëvalueerd. Het streptococcal cell wall muismodel wordt hierbij gebruikt om te bepalen 
wanneer en met welke mate de Saa3 promotor geactiveerd wordt tijdens het verloop van 
de experimentele artritis. De uitlees hierbij is imaging met behulp van bioluminescentie. 
Ook wordt aangetoond dat Saa3-Luc een gevoeligere uitlees is vergeleken met de 
veelgebruikte technetium-99m methode. Vervolgens is er aangetoond dat de Saa3 
promotor reporter een verschil kan detecteren tussen synoviale fibroblasten met een 
hoog of laag inflammatoir gen expressie profiel. Als laatste is gekeken of Saa3-Luc 
eventueel gebruikt kan worden in de diagnose van RA patiënten. Hierbij werd een Saa3-
Luc reporter cellijn geïncubeerd met serum van RA patiënten of gezonde controles, 
waarbij bleek dat de Saa3 promotor meer geactiveerd werd door serum van RA 
patiënten. Daarom is geconcludeerd dat de Saa3-Luc promotor reporter een mogelijk 
nieuw hulpmiddel is in het diagnosticeren van experimentele artritis en RA.
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Naast de Saa3 promotor reporter zijn er nog meer promotor reporters ontwikkeld 
binnen onze groep. De mogelijkheid voor het gebruik van deze promotor reporters in 
gepersonaliseerde lokale gentherapie is onderzocht en beschreven in hoofdstuk 7. 
Van elke promotor is een profiel gemaakt die de lokale up- en downregulatie in het 
kniegewricht tijdens experimentele artritis weergeeft. Uiteindelijk zijn de Saa3 en 
MMP13 promotor geselecteerd voor verder onderzoek, vanwege de hoge upregulatie 
en verschillen in profielen. De Saa3 en MMP13 promotor zijn vervolgens gebruikt om 
het effect van ziekte gereguleerde expressie van IL-10 te bestuderen. Zowel de Saa3 
als de MMP13 promotor zorgde voor een upregulatie van SOCS3 en IL-1Ra genen 
in synoviaal weefsel en proteoglycaan depletie en synoviale ontsteking waren op 
histologisch niveau verminderd. We hebben geconcludeerd dat de behandeling van 
acute gewrichtsontstekingen te behandelen is met behulp van overexpressie van IL-10 
onder de controle van een ziekte gereguleerde promotor.
In hoofdstuk 7 hebben we lokale overexpressie onderzocht, echter omdat RA zich niet 
beperkt tot één enkel gewricht, kan systemische gentherapie ook een interessante 
methode zijn. Dit is onderzocht in hoofdstuk 8. Luciferase expressie kinetieken zijn 
gemaakt met behulp van imaging na systemische injectie van een constitutieve promotor 
in een lentivirale vector. Er is gebleken dat vooral de monocyten en macrofagen in de 
milt geraakt werden. Vervolgens is onderzocht of deze cellen gemanipuleerd kunnen 
worden met behulp van gentherapie door overexpressie van TAK1-K63W gedurende 
experimentele artritis. Ziekte incidentie, macroscopische score van zwelling van 
de gewrichten en histologisch zichtbare boterosie waren verminderd door deze 
gentherapeutische aanpak. We kunnen hierdoor concluderen dat monocyten en 
macrofagen van de milt succesvol geraakt kunnen worden door lentivirus en dat deze 
cellen gebruikt kunnen worden voor gerichte gentherapie.
Conclusies
Een vroege diagnose van RA, op het moment dat er nog weinig tot geen schade zichtbaar 
is, is een onderwerp dat vaak aan bod komt. Een vroege diagnose is essentieel in een 
goed behandelproces, waarbij wordt geprobeerd onherstelbare kraakbeenschade te 
voorkomen en het ziekteproces te vertragen. Imaging, in de meest brede zin van het 
woord, heeft al veel bijgedragen aan het vervroegen van een diagnose, maar er is altijd 
nog ruimte voor verbetering. De imaging methodes en technieken die gebruikt zijn in 
dit proefschrift tonen veelbelovende resultaten in de richting van gepersonaliseerde 
behandeling van artritis. Met dit proefschrift is een solide basis gebouwd voor verder 
onderzoek naar de toepassingen van deze methodes en technieken in de patiënt. Met 
meer karakterisering en veiligheid studies moet dit zeker mogelijk zijn. De resultaten 
in dit proefschrift zullen helpen om nadruk te leggen op de toegevoegde waarde van 
het gebruikt van SPIONs, antilichamen, fluorescerende probes en gentherapie in de 
behandeling en beeldvorming van reumatoïde artritis.
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Marije, jij ook bedankt voor al je advies en commentaar! En natuurlijk bedankt voor je 
steun en gezelligheid tijdens alle NanoDiaRA meetings. Het waren soms lange dagen 
in het buitenland, maar ons vervelen deden we niet!
Wim, bedankt voor je vertrouwen in mij! Je altijd kritische commentaren tijdens de 
werkbesprekingen zorgde ervoor dat ik nog een keer extra naar de opzet van mijn 
experimenten ging kijken of toch mijn conclusie nog iets aanpaste.
Mijn paranimfen wil ik natuurlijk ook graag bedanken voor hun inzet voor en tijdens 
mijn promotie.
Miranda, mijn partner-in-crime in Utje 3 en tijdens de lange dagen in het dierenlab: 
Bedankt voor alle qPCRs, histo’s, luminexen etc. die je voor mij gedaan hebt. Ook 
bedankt voor al die jaren gezelligheid in Utje 3 en het dierenlab, waar wij toch heel wat 
kuddes muizen geïnjecteerd hebben samen. Je stond altijd klaar om proefopzetten, 
resultaten of ons privé leven te bespreken, waardoor ik toch heel wat nieuwe inzichten 
heb gekregen. Fijn ook dat je mijn paranimf wilt zijn!
Caroline, mijn vriendinnetje vanaf dat ik 3 dagen oud was. Het waren 3 rustige dagen 
in mijn leven, daarna begon de gezelligheid. Van scoutingkampen tot logeerpartijtjes 
tot vele avondjes in het tapas restaurant, wij vermaakten ons wel! Ik hoop dat er nog 
vele jaren van leuke uitstapjes in het verschiet liggen. Jij ook bedankt dat je mijn 
paranimf wilt zijn!
Dan komen we aan bij groepje 2. Onno, jij hebt mij wegwijs gemaakt op het lab, 
waar ik als groentje binnen kwam. Je enthousiasme werkte aanstekelijk en de wilde 
ideeën voor originele experimenten waar je ’s ochtends mee op het lab aankwam 
waren altijd voer voor discussie. Bedankt voor al je hulp! Mathijs, jij ook bedankt voor 
je hulp, vooral tijdens mijn zwangerschapsverlof heb jij hard doorgewerkt aan onze 
masterpiece; het IL-10 artikel! Marieke, Shahla, Silke, Bartijn, Claire, Sharon, jullie 
ook bedankt voor alle tips tijdens de maandagochtend werkbesprekingen en voor de 
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gezellige tijd op het lab. Ben, je bent al een tijdje weg bij lab reuma, maar bedankt 
voor de fijne samenwerking aan o.a. hoofdstuk 8 in dit boekje. Jeroen, je bent ook al 
een tijdje ex-lid van groepje 2, maar toch bedankt voor je kritische blik op mijn werk, 
wat gedeeltelijk voortgekomen is uit jouw werk. 
De werkgroepleiders: Peter van Lent en Peter van de Kraan, jullie ook bedankt 
voor alle wijze woorden en leerzame discussies tijdens de lijndiscussies en 
donderdagochtend besprekingen over mijn onderzoek.
De analisten: Annet, Monique, Birgitte, Liduine, Elly, Richard. Zonder jullie hulp 
was ik nu nog steeds bezig met het verwerken van mijn dierexperimenten. Enorm 
bedankt voor al jullie hulp, jullie zijn onmisbaar! Annet, jij ook nog bedankt voor de 
gezellige lunches in de kantine en natuurlijk voor alle kinderkleding waar Tess nog 
steeds in rondloopt!
Alle AIOs, oud-AIOs en post-docs van lab reuma: Laurie, Arjan, Esmeralda, Arjen, 
Dennis, Martijn, Rik, Wouter H., Wouter de M., Stephanie, Rebecca, Debbie, 
Irene, Lilyanne, Bas, Menno, Wojciech, Tom, Lenny, Kim, Marta, Tamara, Mark, 
Renoud, Alsya, Henk, Edwin: Bedankt voor jullie hulp en alle gezelligheid tijdens de 
koffie- en lunchpauzes, de kerst spellen, borrels en pubquizzen.
Marianne, bedankt dat je alle administratieve zaken goed en snel geregeld hebt en 
natuurlijk was het altijd gezellig om tijdens de pauzes weg te kunnen dromen bij onze 
verhalen over ski-vakanties en andere mooie plekken.
Mijn studenten, Diana en Maciek: bedankt voor jullie hulp met het uitvoeren van de 
experimenten!
CDL medewerkers, jullie ook bedankt voor alle hulp en de goede zorgen voor mijn 
muisjes!
I also would like to thank the NanoDiaRA project, and all the people involved in it, 
thanks for your support, cooperation and the nice meetings!
Vrienden uit alle uithoeken van het land, jullie zullen het vast niet altijd gesnapt 
hebben waar ik mee bezig was, maar bedankt voor jullie steun en interesse in mijn 
onderzoek en voor de broodnodige ontspanning tussendoor.
Eveline, Arno, Wendy: hopelijk komen er nog vele gezellige Wii-dates! 
Liesbeth, Woest, Anne, Broodje, GJ: met jullie is het altijd gezellig in het Wageningse, 
hopelijk blijven jullie ook nog lange tijd hangen voor o.a. de zomerse BBQs en de 
meiden thee-avondjes. Celia, jij bent al weg uit Wageningen, maar bedankt voor de 
gezellig tijd en veel succes in Brussel. Mark en Teunke, ook (nog) in Wageningen: 
hopelijk kunnen we nog veel BBQs houden met hier en daar een speciaal biertje voor 
de mannen. 
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De dames van mijn CP groepje: Monique, Hadewijch, Els, Sabine, Marjolein, 
Ciska, altijd gezellig om met jullie een bakkie te doen of met de kindjes ergens heen 
te gaan!
Mijn oud huisgenootjes (en ook de aanhang) van 13B: Brenda, Kirsten, Dennis, 
Nicole, Patrick, Jan, Ingrid, Henk, Renée, Paul: de sauna uitjes met de meiden 
waren altijd heerlijk ontspannend, hopelijk kunnen we deze, ondanks onze drukke 
agenda’s, nog vaker doen. En natuurlijk onze onvergetelijke skivakanties, van Rosa 
tot Ohoh Cherso, wat heb ik een lol gehad! 
Mijn schoonouders en Gerard: Ook voor jullie zal het niet altijd duidelijk zijn geweest 
waar ik mee bezig was, maar bedankt dat jullie altijd interesse hebben gehouden in 
mijn onderzoek en de voortgang van mijn proefschrift!
Mijn ouders, pap en mam: Altijd hebben jullie achter mij gestaan in mijn lange traject 
van basisschool naar promotie. En nog steeds helpen jullie mij, ondanks de moeilijke 
situatie, met alles: van oppassen tot eten koken tot advies over ons nieuwe huis. 
Bedankt voor alles wat jullie hebben gedaan en wat nog gaat komen!
En dan natuurlijk nog mijn eigen gezinnetje! Wat ben ik trots op jullie. Tess, mijn kleine 
meisje, jij krijgt nog niet veel mee van wat mama allemaal aan het doen is/was op haar 
werk, maar wat geniet ik van jou als ik ’s avonds thuis kom en je vrolijke koppie zie! 
Baby in mijn buik: ik ben nu al trots dat jij samen met mij voor de promotiecommissie 
komt te staan, alhoewel ik me waarschijnlijk wel moet verontschuldigen voor alle 
promotie-stress die jij dus ook automatisch meekrijgt. Ik kijk uit naar jouw komst! 
John, mijn lieve man en rots in de branding: Bedankt voor je steun en geduld tijdens 
mijn promotie-traject en daarbuiten. Tijdens jouw promoveren stonden we op het punt 
om te gaan trouwen en nu staan we alweer op het punt om een tweede kindje te 
krijgen! Ik ben benieuwd wat voor mooie dingen de toekomst ons nog meer gaat 
brengen!

